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INTRODUCTION 
Siddha  system is a unique system of medicine because it is both spiritually and mentally 
enriched. Siddha system is one of the ancient system of Indian medicine. It evolved in south 
india and siddha medicine was developed by siddhars. 
         Our human body consist of 96 thathuvam,72000 nadi narampugal, 7 udal thathukkal, 3 uyir 
thathukkal and impalance in these constituents leads to rogum. 
The normal functioning of human body is based on homeostasis of 3 forces or 3 humors 
called VATHAM, PITHAM and KABAM. 
Any derangements in this homeostasis lead to pathological condition called PINI or NOI 
Siddhars classified the diseases in to 4448 types. Among that vadha disease are classified 
in to 84 types mentioned in yugi vadhiya cinthamani.In which uthira vatha suronidham is one 
among them and signs and symptoms of this disease is correlated with Rheumatoid arthritis in 
morden science. 
                Siddhars diagnosing the diseases by means of envagai thervu, nadi, and neerkuri, 
neikuri are the Precise diagnostic stool of siddhars. The treatment aspect involve the 
neutralization of affected humour. 
               BY  giving purgatives, vatha kutram is neutralized. By giving emetics, pitha kutram is 
neutralized. By giving nasiyam kapha kutram is neutralized  
RHEUMATOID ARTHRITIS is an autoimmune disorder which is world wide in 
distribution. About 0.5 - 3% seems to be affected. Womens are affected 3 times more than men. 
It is present from early childhood (when it is rare) to late old age, most common in 30-50 y 
It is the disease which causes much distress to the humanity at large. Till now there is no definite 
cure for this disease. Due to the prolonged and uncertain course of the disease and its prevalance 
the author planned to be conduct the study  on UTHIRAVATHA SURONITHAM. 
The author’s choice of drug for clinical study were, 
1. Mthiyoosna rasayanam- 6 gm twise a day internally 
                                           [yugimuni Vaithiya Kaviyam. Page no: 283] 
2.Nympathy thylam             - externally [sarabenthirar vaithiya muraigal] 
Siddha drug formulations has not undergone any clinical trial so 
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.AIM AND OBJECTIVES 
AIM 
 The principal aim of the present study is to evaluate the therapeutic efficacy of the siddha 
formulations “Mathiyooshna Rasayanam” (Internal) and “Nympathy thylam” (External ) in the 
treatment of “Uthiravatha suronitham” (Rheumatoid arthritis). 
PRIMARY OBJECTIVE:   
To Evaluate the Safety and Therapeutic efficacy of the siddha drugs “Mathiyooshna 
Rasayanam” (Internal) and “Nympathy thylam” (External) in reducing the pain in the 
treatment and restricted joint movements “Uthiravatha Suronitham (Rheumatoid Arthritis).” 
 
SECONDARY OBJECTIVES:  
 To conduct a clinical trail with a well defined proforma on identified patients with 
“UTHIRAVATHA SURONITHAM”. 
 To correlate the etiology, clinical features, signs and symptoms of 
“UTHIRAVATHA SURONITHAM” in siddha system to Rheumatoid Arthritis in 
modern science. 
 To study “UTHIRAVATHA SURONITHAM” on the basis of Mukkutram, 
poripulangal, udalkattugal, envagai thervugal in order to evaluate the pathology.  
 To access the biochemical constituents of the drug. 
 To perform the pharmacological analysis to evaluate the ANTI 
INFLAMMATORY, ACUTE TOXICITY  AND ANALGESIC effect on internal 
medicine and ANTI INFLAMMATORY on external medicine. 
 To conduct clinical study on “UTHIRAVATHA SURONITHAM” in both in 
patients and out patient department with reference to Age, Sex, Socio economic 
status, habits, family history etc on the disease. 
 To access the effect of steam bath in Uthira vatha suronitham patients. To find out 
whether there are any side effects / adverse effects produced by the trial drugs 
Mathiyooshna Rasayanam (Internal) and Nympathy thylam (External) if any. 
 To apply the modern parameters on investigation side and also NEIKURI on 
siddha aspect to confirm and follow the prognosis  
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SIDDHA ASPECT 
PRINCIPLES OF SIDDHA 
            Siddhars have recommended certain basic guidelines to be followed for healthy living 
which includes following certain regimen as mentioned in” PINI ANUGA VIDHI”  that help 
prevent disease. The rules are given below 
1.Drinking boiled water 
2.Take meals twise a day 
3.Take diluted buttermilk and melted ghee 
4.Take sufficient quantity of milk and milk products 
5. Never eat root tubers except yam 
6.Never consume food that was prepared the previous day 
7.Always have food after feeling hungry 
8.Always consume sour curd 
9.Drink water at the end of meals 
10.Practice walking after a good diet 
11.Use hot water while taking oil bath 
12. Take snuff medications eight times in a year 
13. Take purgative medication every four months in a year 
14. Take emetic medication once in six months  
15.Never sleep during day time  
16. Never suppress any natural urge 
17.Always indulge in healthy sexual acts 
18.Never sleep under a tree shade  
19. Never smell fragrance during midnight 
20. Never resides close to the dust 
21.Apply eye medications once in three days 
22.Shave weekly once  
23. Take oil bath once in every 4 days 
The siddha system is said to be the human body is composed of 5 elements such as : 
EARTH- gives shape to the body and release site energy.Bones, muscle,and tissues if in the body 
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WATER-Makes earth supple and transmission of energy.Serum, lymph,saliva,etc., represent in 
the body. 
3.FIRE- Makes the form of the body steady and gives vigour and stimulation. Digestion and 
circulation represent in the body. 
4. AIR- Ignites the fire works as a life carrier and is the support of all contact and exchange 
respiration and Nervous system represent in the body 
5. ETHER- It is the creator of life itself in the body. 
A harmonious combination and function of these five elements in the body produce a healthy 
and beautiful life. 
Characteristic features of Vatha diseases 
1. Body ache 
2. Nerve weakness 
3. Dryness 
4. Joint pain 
5. Bony pricking pain 
6. Constipation 
7. Darkness of eyes,skin and urine 
8. Mental distress 
9. Difficulty  to movement of limbs 
10. Polydypsia 
QUALITIES OF VATHAM 
The normal qualities are 
1.Rough  
2.Dry 
3.Light 
4.Cold 
5.Movable 
6.Subtle 
Opposite qualities of vatham 
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1.Soft 
2. Untuous 
3.Heavy 
4.Hot 
5.Stable 
6.Solid 
Relation with taste 
 
    CAUSES OF VATHA DISEASES 
“hgvOu!uiklK!Ogihqk<!kh<Ohi< << << < !
! h{<hig!oh{<Ohig!lKkie<!osb<bqz<< < < < << < < < << < < < <!
! fgvOu!ouGK~vupq!fmg<gqz<< << << <!
! ftqvie!gix<XOl!heqOlx<!hm<miz<< < < << < < << < < <!
! lqgvOu!gib<gt<!geqgqpr<G!ke<je< < < << < < << < < < !
! lqguVf<kq!lQxqOb!kbqi<kie<!ogi{<miz<< Q < < < << Q < < < << Q < < < <!
! LgvOu!LKogZl<jh!LXg<gq!ofif<K< < << < << < < !
! Lpr<giZl<!gjeg<giZl<!gMh<H< < < < << < < < << < < < < !d{<miOli<<< ”!
. B,gq!juk<kqb!sqf<kil{q!himz<!< < << < << < < .!39!
Walking for long distance and harmful combinations like fruits, vegetables and tubers 
causes toxic factors which affects bones and joints.!
According of Agathiar kanma kandam – 300 
 “F~oze<x!uikl<!uf<kujg!kiOe< < << < << < < !
K{<jlbib<g<!ge<lk<kqe<!ujgjbg<!OgT< < < < < < << < < < < < << < < < < < < !
! gizqOz!Okie<xqbK!gMh<h!OkK< << << < !
! jggizqz<!Lmg<gqbK!uQg<gOlK< < Q << < Q << < Q < !
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! OgizqOz!hMgqe<x!uqVm<s!lie< << << < !
! Gpf<jk!lvf<ke<je!oum<mz<Olz<!Okiz<!sQuz<< < < < < < < Q << < < < < < < Q << < < < < < < Q <!
! fizqOz!sQuosf<K!giz<!Lxqk<kz<Q < < < <Q < < < <Q < < < <!
! fz<z!ogi{<H!kjp!Lxqk<kz<fzqk<kz<!kiOe< < < < < << < < < < << < < < < < !
. ng^<kqbi<!ge<l!gi{<ml<!< < < < << < < < << < < < < .!411!himz<!67<<< !
Agathiar kanma kandam -300 attributes the following psychological factors such as, 
breaking the animal legs, removing the bark of living trees. Cutting the trees in the living 
branches and removing leaves to be the cause for vatha diseases. 
UTHIRA VATHA SURONITHAM 
Definition 
Uthira Vatha Suronitham is a condition which deals with the involvement of joints which 
comprises the symptoms of pain and swelling mainly in the small joints and also in large joints 
with lassitude and anorexia 
dkqvl<?!SOvi{qkl<!.!GVkq!
uikl<!.!uiB!+ Ngibl<!
! -kje!utq?!Sx<X?!gix<X?!Djk?!giz<!we<Xl<!%Xui</!
utq! )uikl<*! ke<! ntuqz<! lqGf<kqVg<Gl<! OhiK! dmzqz<! uikOfib<gt<!
Okie<Xgqe<xe/!!“B,gq!juk<kqb!sqf<kil{q”!F~zqe<!hc!
! “we<eOu! uiklK! w{<hkiGl<”! we<X! hiceiZl<! njugtqe<! ohbi<gjtBl<?!
G{r<gjtBl<! %Xl<OhiK! w{<hk<jkf<K! ujggjtg<! %xqBt<tiI! nux<xqz<! ye<X!
“dkqvuik!SOvi{qkl<”/!
! !
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Clinical features of uthira vatha suronitham 
In Yugi Vaidhiya cinthamany 
                “jugqklib<g<!g[g<giZ!Lpr<giz<!kiEl<< < < < < << < < < < << < < < < <!
! !lx<gmR<!sf<KHx!ucBl<!uQr<gqs<< < < < Q < << < < < Q < << < < < Q < <!
! !osb<gqkliR<!sqXuqvz<gt<!lqgUl<!ofif<K< < < < < << < < < < << < < < < < !
! !sqf<jkkV!lixqOb!szqh<H{<!miGl<< < < << < < << < < <”!
! !jhgqklil<!jhk<kqbk<kqz<!uik!lqR<sqh<< < < < < << < < < < << < < < < <!
! !hivlib<!dx<huqk<K!npZ{<miGl<< < < < << < < < << < < < <!
! !db<gqklib<!nselK!kiEl<!Ou{<mi< < < << < < << < < < !
! !dkqvuik!SOvi{qkk<!K{Is<sq!biOL< << << < !
ohiVt<<<<!
 g[g<giz<?! Lpr<giz<?! sf<Kgt<! -jugtqz<! uQr<Gl/ Swelling in ankle joint, knee 
joint, dorsum of foot and other joints!
 npz<!d{<miGl<!)Increased pitham)!
 hsqbqe<jl!d{<miGl<!)Loss of appetite)!
 sqXuqvz<gt<!lqgUl<!Ofijb!)Pain) hqxh<hqg<Gl</!)Pain in fingers that is interphalangeal 
joints)!
 sqf<jk!kMliXl<!)Mental confusion)!
 szqh<H{<miGl<!)Easy fatiguability!
In Pararasasegaram, 
 “ohiIsQOk!Ukqv!uik!SOvi{qk!Lpr<giz<!kiEl<!
! ohix<gj{g<!giZl<!sf<Kl<!Hxuc!kiEl<!uQr<gq!
! fx<g[!uqvz<g!oeif<K!fMh<!hbqk<kqb!uikk<kqz<!
! dx<hug<!G{LL{<mi!LXF~zqx<!osie<e!kiOl”!
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dkqvuik!SOvi{qkk<kqz<< << << <!
2/ Lpr<giz<?!g[g<giz<?!sf<Kgt<?!Hxuc!)Dorsum of foot) Ngqb!-mr<gtqz<!uQr<Gl<!
3/ g[g<gitqz<! dt<t! uqvz<gt<! OkiXl<! uzqB{<miGl<! )Pain in metacarpophlangeal 
and interphalangeal joints)!
4/ hbqk<kqb!uikk<kqz<!gi[l<!G{r<gt<!d{<miGl<!)Osteoporosis)!
 
factors stimulating vatha disease 
“okipqz<!ohXjgh<Hg<!giIk<kz<!kui<k<kz<!uqSgqE!OsiXl<< < < < < < < < << < < < < < < < << < < < < < < < <! !
hjpb!kil<uvG!lx<jxh<!jhf<kqjebVf<kqeiZl<< < < < < << < < < < << < < < < <!
! wpqz<!ohxh<!hgZxr<gq!-vuqeqZxr<!gikziZl<< < < < << < < < << < < < <!!
hqjp!fqgi<!GvzqeiOz!uikr<!Ogihqg<Gr<!giO{< < < << < < << < < < ”  
 Intake of items excessive in bitter and astringent taste. 
 Intake of old cooked food items 
 Sleeping in the day time and awakening at night. 
“gi{Ou!lqgU{<miZl<!gVKhm<ceq!uqm<miZl<< < < < << < < < << < < < <!
lije!biIg{<!Oliglxg<gqE!lqGf<kqm<miZl<< < < < << < < < << < < < <!
N{u!lzgml<!jlbOe!uqmikziZl<< << << <!
uiEke<!lmfz<ziOt!< << << < uikr<!Ogihqg<Gl<!giOe< < << < << < < ”!
 Excessive intake of food!
 Starvation!
 Excessive sexual desire!
“hiiqeqx<!hbh<hm<miZl<!hzVme<!Ogihqk<kiZl<< < < < < < << < < < < < << < < < < < <!
gioveg<!gVkqObicg<!gPlvk<Kvk<kqeiZl<< < < < << < < < << < < < <!
WIohX!keK!ovsqe<!lqgk<Kg<g!ljmf<kqm<miZl<< < < < < << < < < < << < < < < <!
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hiiqb!gix<xqeiZl<!hmiqEl<!uikr<!gi[l<< < < < << < < < << < < < <”/!
 Fear!
 Anger!
 Excessive running!
 Stress!
 Exposure to wind daily!
“gizr<g{<!lixqB{<[l<!giiqbg<!kiZf<k{<{QI< < < < < < < Q< < < < < < < Q< < < < < < < Q !
sizOu!bVf<kqeiZl<!sf<kqbqZm<!giIf<kiZl<< < < < < << < < < < << < < < < <!
Ogizlil<!Htqh<H!ofb<jl!Gjxux!uVf<kqeiZl<< < < < << < < < << < < < <!
uizuiI!Ljzfz<ziOe!uikLx<!hzqg<Gr<!giO{< < < << < < << < < < ” 
. B,gq!juk<kqb!sqf<kil{q< << << < !
Gtqi<! gix<xqz<! dm<giIf<kqVk<kz<?! Htqh<H?! ofb<! d{uqz<! lqGkqbig! Osi<k<K!
ogit<tz<?!gizl<!kuxq!d{<{z<!Ngqb!giv{r<gtqeiz<!uikl<!Okie<Xl</!
“gi{Ou!lqgU{<miZr<!gVKhm<ceq!uqm<mZl<< < < < << < < < << < < < <!
! lieje!biIg{<!Oliglqxg<gqE!lqGf<kqm<miZl<< < < < << < < < << < < < <!
! N{u!lzr<gmjl!br<rOe!uqmikkiZl<< < << < << < <!
uiEke<!lmfz<ziOt!uikr<Ogi< < << < << < < !hqg<Gr<giO{< << << < ”!
! nkqg! ntU! d{<{z<?! hm<ceq! gqmk<kz<?! N{ul<! nkqgiqk<kz<! Ngqbux<xiz<!
uikOfib<gt<!Okie<Xl</!
“utq!kV!gib<gqpr<G!ujvuqzi!kbqzz<!Ogijp!< < << < << < < !
! Ltq!kbqi<!Ohie<lqGg<G!Ljxbqzi!U{<c!Ogimz<< < < < << < < < << < < < <!
! Gtqi<kV!utqbqx<!Oxgr<!Geqh<Hx!Uzuz<!oh{<cI< < < < < << < < < < << < < < < < !
! Gtqk<kV!Lbg<gl<!ohx<OxiI!g< < < << < < << < < < c!osbz<!gVuqbiliz<< << << <”!
. shihkq!jgObM!
10 
 
!
EXTRINSIC FACTOR 
 Exposure to dampness and cold 
 Sleeping during day time 
 Month from aani to karthigai 
INTRINSIC FACTOR 
 Intake of old cooked food 
 Drinking rain water 
 Intake of food items which excess in bitter,astringent,and pungent taste 
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SIDDHA PATHOLOGY 
 Siddha system of medicine is based on Thirithodam theory.  They are vatham, pitham and 
kapham the manifestation of all diseases are result of derangement of these uyir thathus 
(Thirithodam) 
           When the seven thathu and mukkutram are in equilibrium, a normal structural and 
physiological state of body is ensured.As the thathu are affected by the extrinsic and intrinsic 
causative factors there will be distortion in the structural and functional state of the body. 
            ; In Uthiravatha suronitham 
1. Vatham – increased 
“uiklziK!OleqogmiK” 
Different kinds of vatham 
1. Uyir kaal – Praanan (Respiratory functions) 
“////////!fzlie!G{olz<zil<!hqvi{!uiB< << << < !
he<eOu!fQzu{<{l<!okb<ul<!sf<kqve<< Q < < < < < << Q < < < < < << Q < < < < < <!
hzh<hzuil<!ohisqh<ohz<zil<!< < < < << < < < << < < < < sQv{liGl</Q <Q <Q < !
. B,gq!Lequi<< <<!
This is the force of vital airs.  According to Yugi muni, pranan starts from Moolatharam and 
comes through the nostril and dose inspiration and expiration.  The inspiration and expiration is 
not uniform as the ratio is 8:12 there by the process of respiration is not complete.  The praana 
helps in the digestion of ingested food. 
2. Keel Nokku Kaal – Abanan (Excretory funtion) 
“///////!lVg<gOu!gQp<Ofig<gq!lzszf<kt<Tl<< Q < < < < << Q < < < < << Q < < < < <!
uigig!fqxf<kiEl<!hs<js!bigl<< < < << < < << < < <!
nVg<gOu!bisek<jks<!SVg<gq!jug<G/////< < < < << < < < << < < < < ”!
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Abanan, the downward air, starts from swathittanam and descends down and is 
responsible for excretion of urine and faeces.  It contracts the anus.  It helps to take the essence 
of the digested food to the different parts of the body. 
3. Vyaanan (Perfusion of oxygen nutrients) 
“kXh<hie!svusvf<!keqOz!fqe<X< < << < << < < !
kieQm<miz<!Lmg<gz<!h{<{qh<!hiqslxqBl<Q < < < < < < <Q < < < < < < <Q < < < < < < <!
nXh<hie!ue<esi!vf<ke<!jek<kie<!/////< < < < < << < < < < << < < < < < ”!
Vyaanan arises from the shoulders and go through all the 72,000 nerves and thus activate 
voluntary and involuntary movements of the body and thus make them to extend or contract.  
This appreciates the sense of touch, helps to take the essence of the food to the strategic points of 
the body and guards the body. 
4. Udhaanan (Reverse peristalsis) 
 It is responsible for the physiological reflex actions like vomiting , hiccup, cough etc., 
5. Samaanan (Homestatic functions) 
 “/////uiole<x!uiBuqe<!lqR<osim<milz<< < < < << < < < << < < < <!
! lmg<gqOb!sle<osb<K!lVuh<!h{<[l<< < < < < << < < < < << < < < < <!
! kiole<x!nXSjujbk<!k{<{QI!ve<el<< < < Q < << < < Q < << < < Q < <!
! sle<!osb<K!siQvolziR<!sivh<h[l</////< < Q < < << < Q < < << < Q < < < ”!
Samaanan starts from the umblical cord and spread out upto the lower limb.  This is 
responsible for the balance of the other four vathas.  It equalises the six tastes, water, food etc. 
and helps in assimilation. 
6. Naakan (higher intellectual functions) 
 It is responsible for the intelligence of an individual waking, singing and pilo erection. 
7. Koorman (Constrictory functions) 
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 It is responsible for yawning, closing of mouth winking, shedding of tears, vision and 
opening of the eyes. 
8. Kirukaran (secretory functions) 
 “....... gsqU{<mir<!gMl<hsqbqx<!ge<lR<!osz<Zl<< < < < < < < << < < < < < < << < < < < < < <!
! g{<{qOb!bqVk<koziM!Ohik!ziGl<< < << < << < <!
! KsqU{<mib<k<!Kl<lOzi!cVl!Z{<mil<< < < < < << < < < < << < < < < <...” 
 Kirukaran lies in the tongue and causes nasal and salivary secretions.  It induces hunger, 
it makes to concentrate one thing, sneezing and cough are attributed to kirukaran. 
9. Devathatan (Mental and physical sluggishness) 
 It is responsible for laziness, quarrelling, arguing. 
10. Dhananjayan (Bloater of the body) 
 It leaves the body by blowing up the cranium only on the third day after death. 
In case of Uthiravatha suronitham 
 
S.No. Vatham Affected 
1. Abanan Constipation 
2. Vyaanan Restricted joint movements 
3. Samaanan Due to derangement of other vayus 
4. Kirukaran Loss of appetite 
5. Dhevathatan Insomnia 
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II. PITHAM 
Types of Pitham 
1. Anar pitham 
 Its action is characteristic of theyu.  This is responsible for dryness and digestion of food. 
2. Ranjaga pitham 
 It is responsible for the colour and contents of the blood. 
3. Saathagam 
 It controls the whole body.  It is responsible for the action what we think. 
4. Aalosagam 
 It is responsible for the vision. 
5. Prasagam 
 It is responsible for the vision. 
In case of Uthiravatha suronitham 
S.No. Pitham Affected 
1. Anal pitham Loss of appetite 
2. Ranjaga pitham Pallor due to low Hb 
3. Saathaga pitham Difficulty in walking, climbing upstairs, squatting etc. 
4. Prasaka pitham Skin pallor 
 
III. KABHAM 
 Kapha has been further divided into five as follows. 
1. Avalambagam 
 Lies in lungs, controls the heart and other kabhas. 
2. Kilethegam 
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 Lies in stomach, makes food soft and helps in digestion. 
3.Pothagam 
 Responsible for identifying tastes. 
4. Tharpagam 
 Present in the head and responsible for the coolness of both eyes. 
5. Santhigam 
 It lies in the joints and responsible for the action of joints.  The above function may be 
altered whatever the mukkutram is altered. 
In case of uthiravatha suronitham 
S.No. Kabam Affected 
1. Klethagam Loss of appetite 
2. Santhigam Restricted movements of joints. 
 
PINIYARI MURAIGAL (METHOD OF DIAGNOSIS): 
It is based upon three main principles. 
i) Poriyal Arithal (Inspection) 
ii) Pulanal Arithal (Palpation) 
iii) Vinaathal Arithal (Interrogation) 
i) Poriyal Arithal  
Pori means “Five Sense Organs”  
1. Mei (Skin) 
2. Vai (Tongue) 
3. Kan (Eye) 
4. Mookku (Nose) 
5. Sevi (Ear) 
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ii) Pulanal Arithal 
Pulan are five senses. They are, 
1. Smell 
2. Taste 
3. Vision 
4. Sensation of touch (palpation) 
5. Hearing 
 
 “Pulanal Arithal” means examining the “Pulan” of the patient by the “Pulan” physician to 
diagnose a disease. 
 
iii) Vinaathal Arithal 
Vinaathal is collect the  information  the history of disease, its clinical features etc, from 
the patient or his / her close relatives useful when the patient is unable to speak or in the case of a 
child.  
 
DIAGNOSTIC METHODOLOGY IN SIDDHA SYSTEM OF MEDICINE 
ENVAGAI THERVUGAL (EIGHT DIAGNOSTIC TOOLS) 
These Tools not only help in the diagnosis but also helps to observe the prognosis of the 
diseases and for reassuring the patient and to be informed about the nature of diseases, they are 
1. Naadi (Pulse)     
2. Sparisam (Sensation to Touch)   
3. Naa (Tongue)                 
4. Niram (Colour) 
5. Mozhi (Voice) 
6. Vizhi (Eyes) 
7. Malam (Faeces) 
8. Moothiram (Urine) 
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Naadi (Pulse) 
 The study of ‘Naadi’ is the important diagnostic stool in Envagai thervugal which gives 
almost the correct diagnosis.  This  method developed by siddhars to extend our sensual 
perceptions to the interior of our body to diagnose and confirm illnesses. The study of naadi at 
hand is the best because the radial artery is located superficially, the unique factor which 
pertaining the soul in the body is known as “Naadi”.  Naadi is felt in right hand for males and left 
hand for females.  It is usually felt using 3 fingers (viz index, middle and ring fingers) in view of 
assessing the states of vatham, pitham, kabham in the ratio of 1: ½ : ¼ normally.  Derangement 
of this ratio leads to various disease. 
 “giq!Lgecjb!uip<k<kq!< << << < !
jgkeqz<!fic!hiIg<gqz<< < << < << < <!
ohVuqvzr<!Gzk<kqz<< < << < << < <!
hqck<kc!fMOu!okim<miz<< < << < << < <!
yV!uqvOzicz<!uikl<< << << <!
dbi<!fM!uqvzqz<!hqk<kl<< < < << < < << < < <! !
kqV!uqvz<!&e<xq< << << < Ozicz<<<<!
kqV!uqvz<!&e<xqOzicz<< < << < << < <!
! sqOzk<Kl!fic!kiOe<<< ”!
. ngk<kqbi<!< << << < .3111!
In Uthira vatha Suronitham, vatha kalappu Naadi will be felt. 
Vadha Naadi 
 “uikolEl<!ficbK!Okie<xqz<< < << < << < <!
! sQklf<koliM!ubqX!ohiVlz<!kqvm<squib<UQ < < < <Q < < < <Q < < < < !
! sQkLXr<!gqvi{q!lOgikvl<!fQvijlQ < < QQ < < QQ < < Q !
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! kqvt<uib<U!$jz!< << << < uzqgMh<Hk<!kQv< < Q< < Q< < Q !
! fQvLXr<!gqVlqGe<ll<!n{<muikl<Q < < < < <Q < < < < <Q < < < < <!
! fqjzBl<!fQIg<gqiqs<svr<gt<!kf<K!Olgl<< Q < < < < < << Q < < < < < << Q < < < < < <!
! Ohkgli!Lkvh<hq{q!&z!Ovigl<< << << <!
! OhsouG!hq{qgTOl!ohiVt!kiOl”!
. skg!fic!
Vatha Pitha Naadi 
 “ohiVtie!uikk<kqz<!hqk<kR<!Osi<f<K< < < < < << < < < < << < < < < < !
! ohiVf<K!G{r<gti!L< << << < ]<{uiB!sg<kq< << << < !
! osiqbijl!Htqk<Okh<hl<!ohiVlz<!fqiqx<< < < < << < < < << < < < <!
! squh<Hlzl<!hqck<kZVf<!kiK!fm<ml<< < < < < << < < < < << < < < < <!
! gVuie!Okglkq!Zjts<sz<!Osil<hz<< < < << < < << < < <!
! jggiz<!kxqh<Hfig<!gsg<G!le<el<< < < < < << < < < < << < < < < <!
! hiquie!D{<Gjxkz<!VsqOg!mikz<< < << < << < <!
! hzOfiBl<!uVk<kqjug<Gl<!hir<G!kiOe< < < < << < < < << < < < < ”!
. skgfic!
3/!Sparism (Palpation) 
 Skin examination reveals about the warmthness/chillness , dry/weeping skin, 
rough/smooth, soft/hard, tenderness, presence of ulcers, fissures, swelling, wrinkle, hair 
pigmentation etc. 
 In Udhira vatha suronitham the affected part may feel warm with swelling and 
tenderness. 
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3. Naa (Tongue) 
 The colour changes according to changes in Mukkuttram, coated tongue, dryness, 
Jaundice, cyanosis, paleness, ulcer, peeling of skin, fissures, teeth marks in the border, tumours, 
taste, deviation of the tongue and excessive salivation should be noted.  
 In Udhira vatha suronitham the tongue may be dry and coated.  If anamia is present, the 
tongue may be pale. 
4. Niram (colour) 
 By the examination of niram, the type of dhegam (body) cyanosis, redness, pallor, yellow 
discolouration can be noted. 
 Vatha Dhegi  - Dark colour 
 Pitha Dhegi - Yellow or red colour 
 Kabha Dhegi - White or yellow colour 
5. Mozhi (Speach or voice) 
 In the examination of mozhi, the pitch of voice (low or high) action of laughing, crying, 
slurring and speech in hallucination can be noted. 
6. Vizhi (Eye) 
 Changes according to mukkutram, redness of eyes, ulcers, other diseased conditions 
should be noted. 
7. Malam (Stools) 
Vatha type : Black colour, stools with constipation. 
Pitha type : Loose stools with yellowish red colour 
Kapha type : White coloured stools with muccus 
Thontha type : Stools possess some of the features of two doshas. 
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 Other examinations like diarrhoea, presence of blood, ova, cyst odour should be noted. 
In uthira vatha suronitham constipation may be present. 
8. Moothiram (Urine) 
 The examination of urine is classified into two types 
1. Neer kuri 
2. Nei kuri 
1. Neerkuri 
 Niram indicates the colour of the urine 
 Edai indicates the specific gravity of urine 
 Manam indicates the smell of the urine 
 Nurai indicates the frothy nature of the urine 
 Enjal indicates the quantity (increasd or decreased) and deposits of urine voided. 
In addition, frequency of micturition and sediments are noted. 
2. Neikuri 
 “nVf<K!lixqvkLl<!nuqOvik!lkib<< < << < << < <!
! n0gz<!nzi<kz<!ngiz!U,{<!kuqi<f<kpx<< < < < < < << < < < < < << < < < < < <!
! Gx<xt!uVf<kq< << << < !dxr<gq!jugjx<<< !
! Ncg<!gzsk<!kiuqOb!giKohb<< < << < << < <!
! okiV!L%Ik<k!gjzg<Gm<!hMfQiqe<< < < Q << < < Q << < < Q <!
! fqxg<Gxq!ofb<g<Gxq!fqVhqk<kz<!gmOe< < < < << < < < << < < < < ”!
. Okjvbi<<<<!
Procedure 
 Prior to the day of urine examination for neikuri, the patient is advised to take a balanced 
diet and the quantity of food must be proportionate to his appetite.  The patient should have a 
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good sleep.  After waking up in the morning the first voided urine is collected in a glass 
container and is subjected to analysis withing one and half hours. 
 A drop of gingelly oil is dropped over urine without disturbing the nature of the neikuri 
should be noticed in direct sunlight.  The spreading pattern exhibited by the oil droplet over the 
surface of urine gives a confirmatory clue that helps in the disease.!
SEVEN UDAL THATHUKKAL 
1. Saaram Strengths the body and mind. 
2. Senneer Gives power, knowledge and boldness to the mankind. 
3. Oon It strengthens the body. 
4. Kozhuppu It lubricates the joints. 
5. Enbu It protects all the internal organs and gives the 
structure to the body. 
6. Moolai It is present in the bone marrow 
7. Sukkilam and Suronitam Reproduction 
 
S.No. Udal 
kattukal 
Decreased features Increased features 
1. Saaram Loss of weight,  lassitude,  Dryness 
of the skin,  Diminished activity of 
sense organs 
Leads to disease identical to 
increased kabham, like loss of 
appetite, profuse salivation, 
depression etc. 
2. Senneer Tiredness, Lassitude, Anaemia, 
Dryness 
Increased blood pressure Reddish 
eye and skin jaundice, 
Haematuria, Boils and tumors in 
different parts of the body. 
3. Oon Muscle wasting,  lethargic sense 
organs 
Extra growth around neck, face, 
abdomen, thigh, genitalia etc. 
4. Kozhuppu Joint pain,  Emaciation, It leads to identical features of 
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Splenomegaly. increase oon associated with 
dyspnoea on exertion 
5. Enbu Joint pain, falling of teeth, splitting 
and falling of hair and nails. 
Excessive ossification and 
dentition. 
6. Moolai Osteoporosis of the bone,  blurred 
vision. 
Obesity,  swelling of 
interphalangeal joints, oliguria, 
Non-healing ulcers. 
7. Sukkilam 
(or) 
Suronitham 
Pain in the genitalia failure to 
reproduce 
Increased sexual activity , 
Increased formation of urinary 
calculi. 
 In uthiravatha suronitham saaram, seneer, oon, kozhuppu, enbu are commonly affected. 
 TYPES OF VATHA SURONITHAM IN YUGI CYINTHAMANI 
• Vadha Suronitham 
• Sithuvatha Suronitham 
• Vaithiya Vatha Suronitham 
• Paithiya Vatha Suronitham 
• Slethumavatha Suronitham 
• Utharavatha Suronitham 
• Uthiravatha Suronitham 
sqk<KuikSOvi{qkl<<< ;; ;; 
“uixie!siQvolz<zi!Fjpf<K!Dkz<!
! ! lisx<x!Okiz<kiEf<!kqjvf<K!OhiGl<!
! fixie!fiXOhiz<f!vl<H!Sg<Gl<!
! ! fig<Gk<kie<!upupk<Kg<!Ogijp!biGl<!
! Fixie!ofVh<Hk<kie<!hm<mix<!Ohiz!
  ofif<KOl!smolz<zil<!ogih<h!tqg<Gl<!
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! uQxie!Uiqf<Khqe<je!ouKl<hq!uQr<Gl<!
! ! lqg<gsqk<!KuikSOvi!{qkl!kiOl”. 
SITHUVATHA SURONITHAM 
 Anasarca. 
 Wrinkles. 
 Neural pain. 
 Glossy tongue. 
 Sialorrhoea. 
 Bullous eruption as in burn. 
 Exfoliation, swelling  and Warmthness. 
Osk<KluikSOvi{ql<< << << <!
“h{<hig!Umz<GtqIf<K!WX!uQr<gqh<!
! hjkh<hie!uqmf<okim<mix<!hiv!Ofiuil<!
kq{<hie!sqvSofx<xq!Ofig<gi!M{<mil<!
! sqOzm<M!llib<g<Ogijp!obiMS!uisliGl<!
l{<hig!lbg<g!oliM!geU!L{<mil<!
! uib<uv{<M!Vsqbqz<zi!uVk<k!liGl<!
f{<hig!ficBOl!hm!hmg<Gl<!
! fx<Osm<h!SOvi{qklil<!fiMr<!giOz”/!
SLETHUMAVATHA SURONITHAM 
 Chillness with abdominal distension. 
 Severe pain and Head ache. 
 Syncope and Hallucination. 
 Dryness of mouth and Anorexia. 
 Tachycardia. 
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dkvuikSOvi{qkl<<<<!
 “fiMOl!Svl<uf<K!fMg<g!Z{<mil<!
! ! fiuv{<M!kjzofif<K!dml<h!Pk<kq!
! uiMOl!Okgolz<zi!leqs<sh<!H,h<Ohiz<!
! ! lgiuVk<k!L{<migq!lbg<g!liGl<!
! siMOl!bcg<gckie<!Ohkq!kiEl<!
! ! kuqg<GOl!k{<{QIki!eim<m!ligqk<!
! OkMOl!Osix<xqe<Olz<!fqjeU!kiEl<!
! ! osbUkv!uikSOvi{q!kf<ki!oee<Oe”/!
UTHARAVATHA SURONITHAM 
  Fever with rigor. 
 Dryness of mouth. 
 Pain in all over the joints. 
 Headache. 
 Diarrhoea. 
 Excessive thirst. 
 Hunger. 
jugqkuikl<<<<!
 “Nole<x!uQr<gqeOkiI!uqmk<kqz<!vk<kl<!
! ! nPk<klib<k<!kqv{<MOl!wr<Gl<!hib<f<K!
! Yole<X!Ym<cObkq!v{<c!Vg<Gl<!
! ! dXkqbib<k<!okim<MmOe!olk<oke<!xiGl<!
! Okole<x!Okgolr<g![L!Sg<Gl<!
! ! sQxqb!OkiiqVloziM!gis<s!Z{<mil<!
 hiole<x!hmf<keqOz!kqlqV{<!miGl<!
! ! hivlib<!jugqklil<!uikf<!kiOe”/!
.!!B,gq!juk<kqb!sqf<kil{q!
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Uthiravatha Suronitham is differentiated from other types of Vatha Suronitham as 
follows: 
VAIKITHA VATHA SURONITHAM 
 Swelling with hyperaemia. 
 Soft on touch. 
 Cough with pyrexia. 
Irritability. 
jugqkuikl<<<<!
 “Nole<x!uQr<gqeOkiI!uqmk<kqz<!vk<kl<!
! ! nPk<klib<k<!kqv{<MOl!wr<Gl<!hib<f<K!
! Yole<X!Ym<cObkq!v{<c!Vg<Gl<!
! ! dXkqbib<k<!okim<MmOe!olk<oke<!xiGl<!
! Okole<x!Okgolr<g![L!Sg<Gl<!
! ! sQxqb!OkiiqVloziM!gis<s!Z{<mil<!
 hiole<x!hmf<keqOz!kqlqV{<!miGl<!
! ! hivlib<!jugqklil<!uikf<!kiOe”/!
.!!B,gq!juk<kqb!sqf<kil{q!
Uthiravatha Suronitham is differentiated from other types of Vatha Suronitham as 
follows: 
VAIKITHA VATHA SURONITHAM 
 Swelling with hyperaemia. 
 Soft on touch. 
 Cough with pyrexia. 
 Irritability. 
SIRAPPU MARUTHUVAM FOR VATHA DISEASE 
2/ yx<xml<!
3/ OuK!
4/ okig<g{l<!
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5/ Nsel<!
6/ hqvi{ibill<!
7/ kqbiel<!
SPESIFIC TREATMENT FOR UTHIRA VATHA SURONITHAM 
OuK (STEAM BATH) : 
 dmzqVf<K!uqbIju!ohVGl<hc!osb<ukx<G!Wx<xLjxgtqz<!ye<X!OuK/!
 fQjvs<! sqz! &zqjggTme<! OsIk<K! ogikqg<g! juk<K! nkeqe<X! wPl<!
Nuqjb!hqck<kz</!
A steam room is an enclosed space with large amounts of high temperature steam, 
creating a high humidity environment. People sit in this room in a similar way to a sauna 
(conversely a hot, but dry atmosphere), for relaxation and purported benefits to health and well 
being. Steam rooms are commonly maintained at a temperature of 41 degrees Celsius or above, 
with a high humidity of around 100% adding to the sensation. 
The benefits of a steam bath are numerous. Some of the benefits include: 
 The most common and obvious reason is to relieve tension buildup and various forms of 
stress. 
 Various ailments such as arthritis, muscle pains and the like can be relieved because of its 
warm effect to the body. 
 Old people will surely benefit from this since joint pains and other body pains can be relieve. 
 Steam rooms due to its heat effect make you sweat a lot thus your body will eventually 
release toxins and other negative energies. 
 It will also regulate and stimulate the flow of your blood and make your metabolism works 
faster. 
 It also makes your skin looks fresh, young looking and truly healthy. 
 It can give you a lot of self-confidence due to the good effects it will cause to your personal 
appearance. 
 Increases circulation for healthier skin & more energy. 
 Relaxes stiff muscles & ceases swelling or tension in joints associated with arthirits. 
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 As well as nutrients also gets pushed to the surface of the skin, which may have a positive 
effect on collagen production. Collagen makes bones stronger and helps cell regeneration. 
That part about cell regeneration makes it partially accountable for firmer skin. 
Anyone suffering from sleeping disorders, poor skin circulation & Muscular tension & 
Weakness will benefit from taking a steam bath. 
hqvi{ibill ; ; ;; (BREATHING EXERCISE)  
hqvi{!uiBuqe<!njsU!wKOui!nKOu?!sqk<kk<kqe<!njsoue<Xl<!hqvi{!uiBuqe<!
szek<jk!oue<xiz<!sqk<kk<jk!ubh<hMk<kzil<!weUl<?!%xh<hMgqxK!
Benefits of Pranayamam 
 hqvi{ibilk<kqeiz<! sv! Ym<ml<! sQvig<gh<hm<M! nke<! &zl<! utq?! npz<?! Jbl<!
Ngqb!&e<X!dbqIk<kiKg<gTl<!slfqjzbqz<!fmg<Gl</!&e<X!dbqIkiKg<gTl<!
sQvjmBl<! OhiK! Ofib<gTl<! gm<Mh<hMl</! nOkOhiz<! dkqvuik! SOvi{qkk<kqz<!
hikqh<hjmf<k!utq?!npz<!slh<hMk<kh<hMgqxK/!
 Suisk<kqx<Gl<?! lekqx<Gl<! ofVr<gqb! okimIH! -Vh<hkiz<! dkqvuik!
SOvi{qkk<kqz<! Okie<Xl<! leszqh<H! )Depression*! fQr<gq?! leuzqjlBl<! )Self 
Confidence),!fz<z!Kig<gLl<!(Quite sleep*!d{<migqxK/!
 Improve health and heal diseases 
 Improve concentration and mental focus 
 Bestow joy, peace and happiness 
 Bestow psychic powers and yoga siddhis 
 Awaken, balance and heal the chakras 
 Increase energy, vitality and awareness 
 Cure insomnia and help break bad habits 
 Help manifest desires and intentions 
 Self-Realization. 
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kqbiel<<<< (MEDITATION)  
-K!n]<mir<g!Obigl<!)n*!ngk<kk<Kul<!wm<M!we<heux<Xt<!ye<xiGl</!kqbiel<!
&zl<!Nkivr<gt<!sQIhm<M!Ofib<!fQg<gk<kqx<G!lm<Mlqe<xq!Ofib<!uvilZl<!kMg<gzil</!
dkqvuik! SOvi{qkk<kqz<! ohVl<hizie! Ofibitqgt<! uVk<kl<?! szqh<Hme<!
gi{h<hMgqe<xeI/!
fe<jlgt<< << << <!
 kqbiek<kqe<! OhiK! osvOmieqe ; (Seratonin) Svh<H! nkqgliukiz; lek<oktqU!
d{<miGl</!
  Endorphin, Encephalin Ohie<x Svh<Hgt<!nkqgliukiz<!uzqgtqzqVf<K!fquiv{l<!
gqjmg<gqxK/ 
 
 It lowers oxygen consumption. 
 It decreases respiratory rate. 
 It increases blood flow and slows the heart rate. 
 Leads to a deeper level of relaxation. 
 Good for people with high blood pressure as it brings the B.P. to normal 
 Reduces anxiety attacks by lowering the levels of blood lactate. 
 Decreases muscle tension (any pain due to tension) and headaches. 
 Builds self-confidence. 
 It increases serotonin production which influences mood and behaviour. Low levels of 
serotonin are associated with depression, obesity, insomnia and headaches. 
 Helps in chronic diseases like allergies, arthritis etc. 
 Reduces Pre-menstrual Syndrome. 
 Enhances the immune system. Research has revealed that meditation increases activity of 
‘natural-killer cells’, which kill bacteria and cancer cells. 
 
! !
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Nser<gt<<< ; ; ;; (YOGASANAM)  
 dkqvuik! SOvi{qkk<kqz<! ohiKuig! Olx<ogit<th<hMl<! Nser<gt<! gcelqe<xq!
-Vk<kz<!Ou{<Ml</!
Yogasanam 
 Several clinic and university studies have shown that yoga is an excellent and effective 
way to relieve arthritis symptoms. The British Journal of Rheumatology published a study in 
1994 which showed arthritis symptoms improving in patients who practiced yoga. The 
Rheumatic Diseases Clinics of North America published two studies in 2002 which detailed the 
relief of joint stiffness and pain for those who regularly practice yoga. 
 Since rheumatoid arthritis is the result of the immune system damaging the joints, yoga 
provides even further benefits for those suffering from this type of arthritis. Practicing yoga 
helps balance all the body’s systems, including its immune defences. Correcting immune system 
problems can greatly reduce the instance of pain related to rheumatoid arthritis. 
 Scientific studies in major medical journals have found that yoga can help arthritis 
patients by 
 Building muscle strength 
 Increasing flexibility 
 Promoting better balance 
 Reducing body aches and pains 
 Creating a better sense of well-being 
 Reducing feelings of anxiety and depression 
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MODERN ASPECT 
Joints 
The place of union or junction between two or more bones is called joint 
Joints classified by 
 Fibrous joints 
 Cartilaginous joint 
 Synoviyal joint 
 General Classification of synovial joints 
 Plane joint 
 Hinge joint  
 Pivot joint 
 Bicondylor joint 
 Saddle joint 
 Elipsoid joint 
 Saddle joint 
 Ball and socket joints 
JOINT    POSSIBLE MOVEMENTS 
1. SHOULDER  Flexion & extension, adduction & 
abduction, circumduction, rotation 
2. ELBOW                            Flexion & Extension  
3. RADIO-ULNAR  Pronation & Supination  
4. WRIST   Flexion & extension, adduction & abduction,  
circumduction 
5. SPINE   Flexion & extension, lateral extension, rotation. 
6. HIP   Flexion & extension, adduction & abduction,  
circumduction. 
7. KNEE   Flexion & Extension 
8. ANKLE   Dorsi flexion & Plantar flexion 
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Features of a synovial joint 
 
RHEUMATOID ARTHRITIS 
Definition 
        Rheumatoid arthritis is a  chronic inflammatory autoimmune diaorder of human body. Its 
characterised by affecting the connective tissue of whole body with specific involvement of 
major and minor joints. that results in inflammation of joints, proliferative and destructive 
changes in synovial membrane, peri-articular structures, skeletal muscles and perineural sheaths. 
EPIDEMIOLOGY  
Eighty percent affected are women. 
 Male: Female ratio is 1:3  
RA affects 0.5 to 1% of adults in the developed world 
Aetiology 
 The cause remains unknown. 
 There is evidence of immune overactivity. 
FEATURE STRUCTURE FUNCTION 
Hyaline/articular 
cartilage 
Smooth& spongy covers ends of 
bones 
 Prevents friction between 
articulating bones 
Two layered joint 
capsule 
 
Outer layer – Tough & Fibrous 
Inner – Synovial membrane 
covers all internal surfaces 
 To strengthen joint 
 To secrete synovial fluid 
Synovial fluid Slippery fluid like egg white 
which fills joint capsule 
 Reduce friction 
 Nourish cartilage 
 To get rid of waste from 
joint 
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1. The presence in the serum of abnormal immuno globulin-rhematoid factors –IgG and 
IgM. 
2. The infiltration of the synovial tissue by immunologically competent cells, lymphocytes, 
and plasma cells, which are responsible for the local production of immunoglobulins 
including rheumatoid factor. 
3. The presence of immune antigen antibody complexes within leucocytes in synovial fluid 
and peripheral blood. 
4. The finding of lowered complement levels in synovial fluid. 
It has been suggested that the basic mechanism in the production of the inflammation is 
the combination of rheumatoid factor and an altered immunoglobulin with the utilization 
of complement.  The ingestion of the resulting immune complexes by neutrophils causes 
the release of lysosomal enzymes which act as a mediators of the synovitis (Weissmann, 
1972).  The alteration or production of the immunoglobulin with which rheumatoid factor 
combines is a vital step.  If the alteration appears de novo, rheumatoid arthritis can be 
called an autoimmune disease. 
Other aetiological factors 
1. A genetic influence (DR4): 
There is a tendency for the disease to be aggregated in families 
2. Trauma 
 Many patients have mentioned traumatic incidents as a precipitating cause. 
3. Psychological stress: 
 The study of identical twins in one of whom rheumatoid arthritis developed tends to 
support this concept (Meyerowitz et.al, 1968). 
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4. Infectious agents 
Renewed interest in this subject has resulted in is isolation of a variety of organisms from 
synovial tissue, synovial fluid and blood.  These include diphtheroid bacilli, mycoplasma and 
viruses. 
5.  Vascular changes 
Alteration of the normal peripheral vascular bed, perhaps by autonomic influence, has 
been suggested as the primary abnormality.  This has been implicated to explain the striking 
symmetry of the arthritis in many patients 
AUTOIMMUNITY 
 Rheumatoid arthritis was classified as an autoimmune disease, cheifly following the 
discovery of IgM rheumatoid factor in the blood of the patients.  The rheumatoid factor – 
secreting plasma cells have been demonstrated in the rheumatoid synovium, thus implicating 
them at the site of the disease 
PATHOLOGY 
 The condition is widespread, but the brunt of the attack falls on synovium.  The constant 
and characteristic feature is a chronic inflammation, an inconstant but pathognomonic lesion is 
the rheumatoid nodule. 
Joints and tendons 
 The pathological changes, if unchecked, proceed in three stages.  
Stage 1 Synovitis 
 Early changes are vascular congestion, proliferation of synoviocytes and infiltration of 
the subsynovial layers by polymorphs, lymphocytes and plasma cells.  There is thickening of the 
capsular structure, villous formation of the synovium and a cell-rich effusion into the joints and 
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tendon sheaths.  Though painful, swollen and tender these structures are still intact and mobile 
and the disorder is potentially reversible. 
Stage 2: Destruction 
 Persistent inflammation causes joint and tendon destruction.  Articular cartilage is 
eroded, partly by proteolytic enzymes, partly by vascular tissue in the folds of the synovial 
reflections and partly due to direct invasion of the cartilage by a pannus of granulation tissue 
creeping over the articular surface.  At the margins of the joints, bone is eroded by granulation 
tissue invasion and osteoclastic resorption. 
 Similar changes occur in tendon sheaths, causing tenosynovitis, invasion of the collagen 
bundles and eventually, partial or complete rupture of tendons. 
 A synovial effusion, often containing copious amounts of fibrinoid material, produces 
swelling of the joints, tendons and bursae. 
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Stage 3: Deformity 
 The combination of articular destruction, capsular stretching and tendon rupture leads to 
progressive instability and deformity of the joints.  By this times the inflammatory process may 
have subsided, the emphasis is now on the mechanical and functional effects of joint and tendon 
disruption. 
True Rhematoid Nodule 
 Theses are occasionally formed in synoivial tissue and are diagnostic.  They are more 
common in seropositive patients.  The nodules may also be found in bursal and tendon sheaths.  
An arteritis is often found close to the nodule the center of the nodule shows fibrinoid necrosis, 
which is rimmed by palisading macrophages.  The rheumatoid nodules develop and regress 
slowly and are less rich in hydroxyproline than the nodules of rheumatic fever. 
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CLINICAL FEATURES 
Onset 
 Insidious onset with fatigue, malaise, anorexia, weakness and vague musculoskeletal 
symptoms, which are perhaps caused by cytokine such as interleukin-1 and tumor 
necrosis factor. 
 Acute onset with rapid development of polyarthritis accompanied by constitutional 
symptoms including fever, lymphadenopathy and splenomegaly. 
 Palindromic onset where recurrent  acute episodes of joint pain and stiffness occur in 
individual joints lasting only a few hours or days. 
Articular manifestations 
 Joint involvement is usually symmetric.  It is characterized by pain, swelling, tenderness 
and painful limitation of movements.  The metacarpophalangeal and proximal 
interphalangeal joints of the hands, wrists, knees and the metatarsophalangeal and 
proximal interphalangeal joints of the feet are the most common joints involved. 
 Generalised stiffness may occur but “morning stiffness” lasting more than 1 hour is a 
characteristic features.  the intensity and duration of morning stiffnes is a measure of 
disease activity. 
 Morning stiffness which is a reasonably specific symptoms of Rheumatoid arthritis is 
probably due to increase fluid in and around the joint.  The proliferated and dilated 
synovial vessels cause the joint to feel warm and in fair skinned individuals a reddish 
discoloration of overlying skin may be observed. 
39 
 
 
 
 
 
 
 
40 
 
 
41 
 
Hand and wrist 
 Swelling of the proximal but not the distal interphalangeal joints, results in 
“spindling” of the fingers. 
 Hyperextension of the proximal interphalangeal joints with flexion of the distal 
interphalangeal joints results in “swan-neck” deformity. 
 Flexion of the proximal interphalangeal joint and extension of the distal 
interphalangeal joints result in “boutonniere” or “button hole” deformity. 
 Hyper extension of the first interphalangeal joint and flexion of the first 
metacarpophalangeal joint with a consequent loss of thumb mobility and pinch can 
occur. 
 Extensor tendon rheumatoid granulomata and tendon rupture result in “dropped 
finger”. 
 Radial deviation of the wrist with ulnar deviation of the digits often with palmar 
subluxation of the proximal phalanges results in the “z” deformity. 
 Wrist synovitis with median nerve entrapment can result in carpal tunnel syndrome. 
 In the hand, the small joints are swollen and the fingers assume a position of “ulnar 
deviation”. 
 The fingers assume an “intrinsic plus deformity” which consists of flexion at the 
metacarpo phalangeal joints and extension at the interphalangeal joints. 
Foot an ankle 
 Swelling of the metatarso-phalangeal joints results in “broadening” of the forefoot. 
 Lateral deviation and dorsal sub luxation of the toes. 
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EXTRA ARTICULAR MANIFESTATIONS. 
Rheumatoid nodules 
 These develop in 25% of persons with RA.  They are firm, round masses felt in the 
subcutaneous tissues-eg: the olecranon bursa, the proximal ulna, the Achilles tendon and the 
occiput.  Visceral structure like heart, lungs and pleura may also be involved. 
 Rheumatoid nodules are clinical predictors of more severe arthritis, sero-positivity, joint 
erosions and rheumatoid vasculitis. 
Pleuropulmonary manifestation 
 Pleural involvement results in effusion with low levels of pleural fluid glucose (less than 
10mg/dl) 
 Pulmonary involvement resulting in interstitial fibrosis. 
 Caplan’s syndrome: multiple nodules and interstitial lung disease due to pneumoconiosis. 
Cardiovascular manifestations 
 Pericarditis and chronic  constrictive pericarditis. 
 Premature atherosclerosis (an important cause of increased morbidity and mortality) 
 Valvular involvement 
 Conduction defects 
Neurological manifestations 
 Nerve entrapement syndromes.  Eg: carpal and tarsal tunnel syndrome. 
 Spinal compression due to atlanto-axial subluxation. 
 Peripheral neuropathies  
Ophthalmological manifestations 
 Scleritis, episclerits and scleromalacia perforans. 
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 Sicca complex. comprising keratoconjunctivits sicca, xerostomia and salivary gland 
enlargement. 
 Glaucoma 
 
Haematological manifestations. 
 Normocytic normochromic anemia. 
 Thrombocytosis 
 Eosinophilia and mild leucocytosis. 
 Osteoporosis 
Osteoporosis secondary to rheumatoid involvement is very common.  It may be 
aggravated by corticosteroid theraphy and immobilization 
 
Felty’s syndrome 
 This is the association of splenomegaly and neutropenia with RA 
Management 
 There is no cure for RA, but treatments can improve symptoms and slow the progress of 
the disease.  Disease-modifying treatment has the best results when it is started early and 
aggressively. 
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 The goals of treatment are to minimize symptoms such as pain and swelling, to prevent 
bone deformity and to maintain day to day functioning. 
 Need to make frequent assessments for the persons functional ability as the disease 
progress in order to provide realistic goals and support. 
Dietary supplements 
 Turmeric 
 Cherries (6-8 cherries every day) 
o High is magnesium natural pain killer 
o Potassium – diuretic to reduce inflammation 
 Omega – 3 polyunsaturated fatty acids (found in fish oil) is an effective treatment for RA. 
 Two garlic pearls with 2 ounces of buttermilk is an excellent daily drink and home 
remedy for rheumatoid arthritis. 
 Gamma-linolenic acid, which may reduce pain, tender joint count and stiffness is 
generally safe. 
Prognosis 
 The course of the disease varies greatly. 
 Some people have mild short-term symptoms, but in most the disease is progresive 
for life. 
 Around 20% - 30% will have subcutaneous nodules known as rheumatoid nodules.  
This is associated with a poor prognosis. 
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Classification criteria for Rheumatoid Arthritis (2010) 
Features 
A. Joint involvement *                Score 
• One large joint **       - 0 
• 2-10 large joints       - 1 
• 1-3 small joints *** (with or without involvement of large joints) -  2 
• 4-10 small joints (with or without involvement of large joints) -  3 
• >10 joints (at least 1 small joint) ****    - 5 
B. Serology (at least one test result in needed for classification) 
• Negative RF negative anticitrullinated protein antibodies (ACPA)  -  0 
• Low- positive RF or low-positive ACPA    -  2 
• High – positive RF or high-positive ACPA    -  3 
C.Acute – phase reactants (at least one test result is needed for classification) 
• Normal CRP and normal ESR     - 0 
• Abnormal CRP or abnormal ESR     - 1 
D. Duration of symptoms 
• < 6 weeks        - 0 
• ≥ 6 weeks        - 1 
 Add score of categories A-D, a score of ≥ 6/10 is needed for classification of a patient 
as having definite RA. 
DIFFERENTIAL DIAGNOSIS 
 Rheumatic Arthritis 
 Psoriatic Arthritis 
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 Gouty Arthritis 
 Osteo Arthritis 
 Syphilitic Arthritis 
 Ankylosing spondylosis 
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MATERIALS AND METHODS 
 
 The Study on Uthiravatha Suronitham was carried out in the OPD and IPD of the Sirappu 
Maruthuvam department, Govt. Siddha Medical College, Palayamkottai.  
 The trial drugs used are Mathiyooshna Rasayanam (Internal) indicated in the authorised 
Siddha text  Yugimuni Vithyakaviyam (Page No.283)  and Nympathy thylam (External) 
indicated in Sarabenthirar vaithiya Muraigal for Uthiravatha Suronitham. 
Objectives: 
Primary objective: 
To evaluate the clinical efficacy of “MATHIYOOSHNA RASAYANAM” (internal) & 
“NYMPATHY THAILAM” (external) in reducing the pain and restricted joint movements in 
the treatment of ‘Uthiravatha suronitham” (rheumatoid arthritis).  
Secondary objective: 
 To study the effect of Vedhu (steam bath) in reducing the pain towards the efficacy of 
medicine.  
Study design & conduct of study: 
Study type : Phase II Criteria based open clinical trial 
Study place : OPD & IPD of Govt Siddha Medical College & Hospital, Palayamkottai 
Study period : 24 months 
Sample size : 40 patients (20 OP +20 IP). Out of 20 IP patients, 10 IP patients will be  
given Vedhu (steam bath) in addition to internal and external medicine 
and the remaining 10 IP patients will be given internal and external 
medicine. 
Treatment: 
Internal medicine: MATHIYOOSHNA RASAYANAM 
Reference :  Yoogimuni Vaithya Kaaviyam. Pg No: 283 
Dose  :  Kottai paakku alavu(6.022 gm), twice a day. 
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Vehicle :  Jaggery 
Duration :  40 days  
 
EXTERNAL MEDICINE: NYMPATHY THAILAM 
Subject selections: 
 Patients reporting with symptoms of inclusion criteria in P.G. Dept of 
Sirappumaruthuvam, GSMC, Palayamkottai will be subjected to screening test and documented 
using screening proforma. 
Inclusion criteria: 
• Age : 18-60 years 
• Sex : both male and female 
• Symmetrical joint involvement 
• Arthritis of 3 or more joints 
• Rheumatoid factor positive or negative 
• Morning stiffness 
• Swelling especially in the inter phalangeal joint. 
• Patients who are willing for admission and stay in IPD for 40 days or willing to attend 
OPD 
• Patient who is willing to undergo radiological investigation and give blood and urine 
samples for laboratory investigation. 
• Patient willing to sign the informed consent stating that he/she will consciously stick to 
the treatment during 40 days but can OPD out of the trial of his/her own conscious 
discretion. 
Exclusion criteria: 
• Systemic illness. 
• Pregnancy and lactation 
• History of trauma 
• Neurological disorder 
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• Tubercular arthritis 
• Any other serious illness 
• Psoriatic arthritis 
• Gouty arthritis 
Withdrawal criteria: 
• Intolerance to the drug and development of adverse reactions during drug trial. 
• Poor patient compliance and defaulters. 
• Patient turned unwilling to continue in the course of clinical trial. 
• Occurrence of any adverse reactions.  
Tests and assessment: 
A. Clinical assessment 
B. Routine investigations 
C. Specific investigations 
D. Radiological  investigations 
E. Siddha investigations  
A. Clinical assessment: 
• Arthritis involving three or more joints. 
• Symmetrical joint involvement 
• Morning stiffness 
• Anorexia 
• Spindle shaped appearance of fingers 
• Rheumatoid nodules 
• Depression 
• Distaste to food 
• Swelling of small joints of hands and foot. 
B. Routine investigation: 
Blood 
 Hb 
 Total WBC count 
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 DC – 
1. Polymorphs 
1. Lymphocytes 
2. Eosinophils 
3. Monocytes 
4. Basophils 
Total RBC count 
ESR 
 ½ hr 
 1 hr 
Blood sugar  
 r: 
 f: 
 pp: 
Serum cholesterol. 
Urine 
 Albumin  
Sugar  
Deposit 
C. Specific investigations 
 CRP 
 RA factor 
 ASO titer 
D. Radiological investigations: 
 X ray of affected joints (AP and lateral view) 
E. Investigation based on siddha system: 
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1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Naadi 
6. Sparisam 
7. Malam 
8. Moothiram 
 
Conduct of the study: 
 15ml of moolakudori ennai is given in early morning, on the very first day of treatment 
for purgation. This will help to bring the vitiated mukkutram back to normal. From the next day, 
the trial drug is given for treatment.  
Then the trial drug MATHIYOOSHNA RASAYANAM (internal), NYMPATHY 
THAILAM (external) is given continuously for 40 days. OP patients should visit the hospital 
once in days.  At each clinical visit clinical assessment is done and prognosis is noted.  For IP 
patients the drug is given for 40 days and the clinical assessment is done daily. 10 IP patients 
will be given Vedhu (steam bath) treatment along with their internal medicine. The remaining 10 
IP patients will not be given Vedhu (steam bath). The results will be compared at the end of the 
study. Laboratory investigations & radiological investigation are done 0 day, 20th day, 40th day 
of the trial. For IP patients, who are not in a situation to stay in the hospital for a long time 
(minimum 15 days in IPD remaining days are followed in OPD)  is advised to attend the OPD 
for further follow-up. After the end of the treatment, the patient is advised to visit the OPD for 
another 2 months for follow-up. If any trial patient who fails to collect the trial drug on the 
prescribed day but wants to continue in the trial from the next day , he/she will be allowed, but 
defaulters of one week and more will not be allowed to continue and be withdrawn from the 
study with a fresh case being included. 
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Outcome:  
 
 The outcome is aimed at reducing the pain and weakness. 
Universal pain assessment scale 
A.   0      : no pain 
B. 1 -3 : mild pain 
C.4-6  :moderatepain 
D.7-10 :severepain 
 
Reference: clinical manual for nursing practice. (National institute of health warren grant 
magnuson clinical center) 
Restricted movements is assessed by  
Gradation of restricted movements: 
• G i – able to perform normal duties 
• G ii – moderate restriction – self care is possible. 
• G iii – marked restriction – limited self care / some assistance required. 
• G iv – confined to bed or wheel chair.  
Adverse effect/serious effect management 
     If the trial patient develops any adverse reaction, he/she would be immediately withdrawn 
from the trial and proper management will be given in OPD of Govt. Siddha medical college and 
hospital, Palayamkottai. 
 
53 
 
 
RESULTS AND OBSERVATION 
Results and observation are tabulated under the following headings, 
1. Age distribution 
2. Sex distribution 
3. Religion 
4. Body constitution 
5. Paruva kaalam 
6. Nilam 
7. Diet 
8. Occupational Distribution  
9. Duration of Illness 
10. Onset of symptoms 
a. Derangement in vatham 
b. Derangement in Pitham 
c. Derangement in kabam 
11. Gnanenthiriyam 
12. Udal thathukkal 
13. Envagai thervugal 
A. Naadi 
B. Neikuri 
14. Clinical features 
15. Deformities 
16. Involvement of joints 
17. Results. 
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1. AGE DISTRIBUTION 
Table  1 
S.No Age(years) No of Cases Percentage 
1 21-30 4 10 
2. 31-40 5 12.5 
3 41-50 17 42.5 
4. 51-60 13 32.5 
5. 61-70 1 2.5 
 Total 40 100 
 
 
Inference 
The percentage of age group is 41-50 years was 42.5%, 51-60 years was 32.5%, 31-40 
years was 12.5%, 61-70 years was 2.5%, 21-30 years was 10%. 
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2. SEX DISTRIBUTION 
Table 2 
S.No Sex No of Cases Percentage 
1 Male 9 22.5 
2. Female 31 77.5 
 Total 40 100 
 
 
Inference 
 Among the patient selected 77.5% female were affected.  22.5% male were affected. 
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3. RELIGION DISTRIBUTION 
Table 3 
S.No Reliion No of Cases Percentage 
1 Hindu 30 75 
2. Christian 2 5 
3. Muslim 8 20 
 Total 40 100 
 
 
 
Inference 
 Among the 40 cases, 75% of cases belongs to hindhu and 20% cases belong to muslim 
and 5% cases belongs to christian. 
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4. BODY CONSTITUTION 
Table : 4 
S.No Constitution of the Body No of Cases Percentage 
1 Vadha Thegi  0 0 
2. Pitha Thegi  0 0 
3. Kabha Thegi 0 0 
4. Thontha thegi 40 100 
 Total 20 100 
 
 
 
Inference 
All cases were Thontha thegam. 
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5.  PARUVAKAALAM 
Table : 5 
S.No Paruvakaalam No of Cases Percentage (%) 
1 Kaarkaalam   
(Aug 15- Oct 14) 
2 5 
2. Koothirkaalam  
(Oct 15- Dec 14) 
0 0 
3. Munpanikaalam 
(Dec 15 – Feb 14) 
20 50 
4. Pinpani kaalam  
(Feb 15 – Apr 14) 
10 25 
5. Ilavenirkaalam   
(Apr 15-Jun 14) 
7 17.5 
6. Muthuvenilkaalam – 
(Jun 15 – Aug 14) 
1 2.5 
 Total 40 100 
 
 
 
Inference 
 Among the 50% cases were admitted to the trial in munpanikaalam 25% cases in 
pinpanikaalam 25% cases in koothirkaalam 17.5% cases in Ilavenirkaalam and remaining 5% 
cases in kaarkaalam. 
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6. NILAM 
Table 6 
S.No Nilam No of Cases Percentage 
1 Kurinji 0 0 
2. Mullai 0 0 
3. Marutham 28 70 
4. Neithal 12 30 
5. Palai 0 0 
 Total 40 100  
 
 
 
Inference 
 Among the 40 cases 70% cases were from marutham nilam and the remaining 30% were 
from Neithal nilam. 
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7. DIET 
Table 7 
S.No Diet No of Cases Percentage (%) 
1 Vegeratian 4 10 
2. Non vegetarian 36 90 
 Total 40 100 
 
 
 
Inference 
  Among the cases 90% of cases were non vegetarian and 10% of cases were vegetarian. 
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8. OCCUPATIONAL DISTRIBUTION 
Table :8 
S.No Occupation No of Cases Percentage (%) 
1 House wife 28 70 
2. House maid 2 5 
3 Clerical 4 10 
4. Farmer 3 7.5 
5. Teacher 1 2.5 
6. Tailor 2 5 
 Total 40 100 
 
 
Inference 
 Among the 40 cases 70% cases were housewife, 5% cases were housemaid, 5% cases 
were tailor, 2.5% cases were teacher, 10% cases were clerical. 
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9.  DURATION OF ILLNESS 
Table : 9 
S.No  Duration of illness  No of Cases Percentage (%) 
1 3 Months -6 Months 5 15 
2. 6 Months -1 year 10 25 
3 1 year – 2 years 9 22.5 
4. 2 – 5 years 10 25 
5. 5-10 years 5 15 
6. More than 10 years 1 2.5 
 Total 40 100 
 
 
Inference 
 Among the 40 cases the duration of the illness at the time of study 25% were 6 month – 1 
year, 25% were in 2-5 years, 15% were in 5-10 years, 2.5% were in morethan 10 years. 
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10. ONSET OF  THE DISEASE 
Table 10 
S.No Mode of onset No of Cases Percentage (%) 
1 Sudden 5 12.5 
2. Gradual 35 87.5 
 Total 40 100 
 
 
 
Inference 
 According to the study 87.5% of cases had gradual onset and 12.5% had sudden onset.  
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10.A. DISTURBANCES IN VATHAM  
Table: 11  
S.No Vatham Number of cases Percentage 
1. Praanan 22 55 
2. Abaanan 10 25 
3. Samaanan 40 100 
4. Viyaanan  40 100 
5. Udhaanan 23 57.5 
6. Naagan 10 25 
7. Koorman 11 27.5 
8. Kirukaran 11 27.5 
9. Dhevathathan 33 82.5 
10. Dhananjeyan 0 0 
 
 
Inference 
 Among the 40 cases Samanan and viyanan was affected in 100%, Devathathan was 
affected in 82.5% cases, Udhanan was affected in 57.5% cases, Pranan was affected in 55% of 
cases koorman and kirukaran was affected in 27.5% cases, abanan was affected 25% cases. 
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10.B. DISTURBANCES IN PITHAM  
Table: 12  
S.no Pitham Number of cases Percentage 
1. Analam 15 37.5 
2. Ranjagam 20 50 
3. Saathagam  40 100 
4. Alosagam 11 27.5 
5. Prasagam 1 2.5 
 
 
 
Inference 
 Among the 40 cases 100% Saathagam affected, 50% ranjagam affected,  37.5% analam 
affected, 27.5% alosagam affected. 
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10.C. DISTURBANCES IN KABHAM  
Table 13.  
S.No Kabham Number of cases Percentage 
1. Avalambagam 20 50 
2. Kilethagam 15 37.5 
3. Pothagam 1 2.5 
4. Tharpagam 12 30 
5. Santhigam 40 100 
 
 
 
Inference 
 Among the 40 cases 100% santhigam affected, 30% tharpagam affected, 2.5% pothagam 
affected, 37.5 kilethagam affected, 50% avalambagam affected. 
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11. DISTURBANCES IN GNANENTHIRIYAM 
Table 14 
S.No. Gnanenthiriyam Number of cases Percentage (%) 
1. Mei 40 100 
2. Vai 4 7.5 
3. Kan 12 25 
4. Mooku 0 0 
5. Sevi 0 0 
 
 
Inference 
 Among the 40 cases, 100% mei is affected, 7.5% vai is affected, 25% kan is affected. 
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12. UDAL THATHUKKAL 
Table: 15 
S.No Udal thathukkal NUMBER OF CASES PERCENTAGE 
1. Saaram 40 100 
2. Senner 40 100 
3. Oon 40 100 
4. Kozhuppu 40 100 
5. Enbu 40 100 
6. Moolai 0 100 
7. Sukkilam/Suronitham 0 0 
 
 
 
Inference 
 Among the 40 cases All Udal thathukkal were affected in 100% . 
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13. ENVAGAITHERVUGAL 
Table : 16 
S.No. Envagai thervugal Number of cases Percentage 
1. Naadi (Thontham) 40 100 
2. Naa (Pallor)  14 35 
3. Niram  (Pallor of skin)  1 2.5 
4. Mozhi  0 0 
5. Vizhi (Pallor) 20 50 
6. Sparisam (Warmth) 28 70 
7. Malam (constipation) 10 25 
8. Moothiram 0 0 
 
 
Observation 
 In all the cases examination of Naadi, Naadi revealed thontham of vatham.  Sparisam was 
affected in 70% cases due warmth felt in the affected joints.  Vizhi was affected in 50% cases 
Naa was affected in 35% cases and malam was affected in 25% cases, Niram was affected in 
2.5% cases. 
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A.  NAADI 
Table 17 
S.No. Parameters Number of cases Percentage 
1. Vathapitham 30 75 
2. Pitha vatham 10 25 
 Total 40 100 
 
 
 
Observation 
 Among the 40 cases 75% of the cases revealed vatha pitha naadi,  25% of the cases 
revealed pitha vatham 
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B. NEIKURI 
Table 18: Neikuri Analysis 
S.No. Inference Number of cases Percentage (%) 
1. Spreading like snake 29 72.5 
2. Spreading like a ring 9 22.5 
3. Stands like a pearl 2 5 
 
 
 
Inference 
 Among the 40 cases 72.5% was spreading like snake, 22.5% was spreading like a ring, 
5% was stands like a pearl. 
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14. CLINICAL SYMPTOMS (BEFORE AND AFTER TREATMENT) 
Table 19 
S. 
No 
Clinical 
features 
Before treatment After treatment 
No. of cases 
40 
% Releived % Reduced % No improvement % 
1. Pain  40 100 8 20 30 75 2 5 
2. Swelling of 
joints 
40 100 8 20 32 80 0 0 
3. Morning 
stiffness 
40 100 8 20 30 75 2 5 
4. Tenderness 40 100 4 10 36 90 0 0 
5. Restricted 
movements 
40 100 2 5 38 95 0 0 
6. Warmth 40 100 2 5 38 95 0 0 
7. Low grade 
fever 
15 40 15 100 0 0 0 0 
8. Sleeplessness 30 75 30 100 0 0 0 0 
9. Loss of appetite 15 37.5 15 100 0 0 0 0 
 
 
Inference Pain, swelling of joints,  morning stiffness, tenderness, restricted movement and 
warmth were found in all the 40 patients before treatment. 
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 After treatment there was a considerable reduction in all symptoms particularly in pain, 
morning stiffness, swelling of joints, tenderness, restricted movements and warmth. 
 After treatment there was a complete relief in the symptoms like low grade fever, 
sleeplessness and loss of appetite. 
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15. DEFORMITIES 
Table:20 
S.No. Deformity Number of cases Percentage 
1. Spindle shaped fingers 7 17.5 
2. Swan neck 2 5 
3. Z shaped  0 0 
4. Ulnar deviation of hand 7 17.5 
5. Hallus valgus 2 5 
 
 
Observation 
 Among the 40 patients, 17. 5% cases hand spindle shaped fingers, 17.5% cases had ulnar 
deviation of hand, 5% cases had hallus valgus and 5% cases had swan neck deformity. 
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16. INVOLVEMENT OF JOINTS 
Table :21 
S.No. Joints involved Number of cases Percentage 
1. Proximal interphalangeal joints of hand 35 87.5 
2. Metacarphphalangeal joints 35 87.5 
3. Wrist joints 30 75 
4. Elbow joints 13 32.5 
5. Shoulder joints 10 25 
6. Cervical spine 26 65 
7. Hip joints 10 25 
8. Knee joints 40 100 
9. Ankle joints 35 87.5 
10. Metatarsophalangeal joints 8 20 
 
 
Among the 40 cases 100% had knee joints, 87.5% of the cases had proximal interphalangeal 
joint, ankle joints and 20% metacarpophalangeal joints, 75% had wrist joints, 65% had cervical 
spine, 32.5% had elbows, 25% had hip joints, shoulder joints and 20% had meta tarsophalangeal 
joints 
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EFFECT OF TRIAL DRUG ALONG WITH COMPLEMENTARY THERAPY 
Table - 22 
S.No. EFFECT OF TRIAL 
DRUG WITH STEAM 
Number of cases Percentage 
1. Marked effect 6 60 
2. Moderate effect 2 20 
3. Mild effect 1 10 
4. No effect 1 10 
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EFFECT OF TRIAL DRUG ALONE  
Table - 23 
S.No. EFFECT OF TRIAL 
DRUG ALONE 
Number of cases Percentage 
1. Marked effect 17 56.7 
2. Moderate effect 7 23.3 
3. Mild effect 5 16.7 
4. No effect 1 3.3 
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COMPARISION BETWEEN THE EFFECT OF TRIAL DRUG AND TRIAL DRUG  
ALONG WITH COMPLIMENTARY THERAPY 
Table - 24 
 
S.No. EFFECT OF 
THERAPY 
Trial drug alone 
(%) 
Trial drug with 
steam 
1. Marked effect 56.7 60 
2. Moderate effect 23.3 20 
3. Mild effect 16.7 10 
4. No effect 3.3 10 
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18. OVERALL REUSLT AFTER TREATMENT 
Table : 25 
S.No. Result Number of cases Percentage 
1. Good improvement 23 57.5 
2. Moderate improvement 9 22.5 
3. Mild improvement 6 15 
4. No improvement 2 5 
 
 
Observation 
 Out of the 40 patients 57.5% of the patients had good improvement, 22.5% had moderate 
improvement, 15% had mild improvement and 5% had no improvement 
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Table: 25.(a) List of  Out Patients of PG-III Sirappu Maruthuvam Department Given 
1. Mathiyoosna rasayanam- Internal 2. Nympathi thylam - External 
 
S.NO OP.NO NAME AGE/SEX 
Date of 
Registration 
on 
Date of 
Discharge 
Total 
No.of 
days 
treated 
Symptoms 
RESULTS 
P 
S MS MR 
1 73823 lakshmi 48/F 28.8.17 28.10.17 60 + + + + Good 
2 13009 perratchi 63/F 21.12.17 13.2.18 53 + + + + Moderate 
3 620 Meeral 45/F 2.1.18 16.2.18 44 + + + + Moderate 
4 1558 Kanagavathi  60/F 4.1.18 16.2.18 42 + + + + Fair 
5 1174 Kanagalakshmi  40/F 4.1.18 18.2.18 45 + + + + Good 
6 3330 Sahulhameed  36/M 8.1.18 28.2.18 52 + + + + Good 
7 3545 Revathi  50/F 9.1.18 23.8.18 45 + + + + Good 
8 6228 Rani  45/F 18.1.18 28.2.18 42 + + + + Moderate 
9 9768 Lakshmanan  42/M 30.1.18 16.3.18 46 + + + + Mild 
10 8994 Shanthi  40/F 2.2.18 20.3.18 47 + + + + Moderate 
11 10367 mumtaj 30/F 30.1.18 30.3.18 60 + + + + Good 
12 12563 Mukkammal 52/F 6.2.18 22.3.18 45 + + + + Moderate 
13 13534 Pushapavalli 29/F 8.2.18 22.3.18 42 + + + + Moderate 
14 15850  Rajammal  57/F 8.2.18 24.3.18 45 + + + + Good 
15 17570 Pechimuthu  54/M 20.2.18 10.4.18 49 + + + + Good 
16 18323 Syed ibrahamin  45/M 22.2.18 12.4.18 49 + + + + Mild 
17 22359 Mohideen  43/M 6.3.18 20.4.18 45 + + + + Moderate 
18 22335 Faritha  45/F 6.3.18 24.4.18 49 + + + + Good 
19 22173 Pitchaimari  29/F 7.3.18 5.5.18 61 + + + + Moderate 
20 40846 Raihana  60/F 8.3.18 5.5.18 61 + + + + Moderte 
 
P- Pain, S – Swelling, MS – Morning stiffness, MR – Movement Restricted 
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Table 25 (b)  Investigation for OP Patients 
S.No IP.No 
Haemotological Investigation     Urine Analysis 
WBC Total 
WBC Differential Count 
(%) E.S.R. mm/hr 
HB 
(gms%) 
BT AT RA 
FACTOR BT AT mgs% mgs% 
BT AT 
BT AT BT AT 
BT AT BS BU BC BS BU BC BT AT Alb Sug Dep Alb Sug Dep P L E P L E 
1/2 
hr 
1 
hr 
1/2 
hr 
1 
hr 
1 73823 6000 6200 64 34 2 66 32 2 15 30 15 28 11 12 80 31 102 90 23 106  +  + Nil Nil 1-2 PC Nil Nil NAD 
2 13009 8200 8600 72 24 4 72 26 2 27 45 20 42 10.5 11 90 19 162 90 19 158  +  + Nil Nil 1-2 PC Nil Nil NAD 
3 620 9500 9400 62 34 4 63 34 3 26 40 25 38 9.8 10.5 80 28 199 80 22 195  +  + Nil Nil 1-2 PC Nil Nil NAD 
4 1558 8000 8100 61 33 6 61 34 5 13 44 12 42 9 10.5 109 20 141 105 17 150  +  + Nil Nil 1-2 PC Nil Nil NAD 
5 1174 10000 9900 65 34 1 67 33 - 18 40 22 58 9.9 10.5 90 25 126 90 19 120  +  + Nil Nil 1-2 PC Nil Nil NAD 
6 3330 8100 8300 73 20 7 74 22 4 80 120 65 90 9.9 11 88 17 198 92 16 194  +  + Nil Nil 1-2 PC Nil Nil NAD 
7 3545 11000 11000 50 36 4 60 37 3 20  44 16 38 11.2 11.4 100 12 121 96 15 121  +  + Nil Nil 1-2 PC Nil Nil NAD 
8 6228 8800 8400 66 29 5 65 30 5 25 41 24 35 10.4 11.5 108 28 132 108 27 133  +  + Nil Nil 1-2 PC Nil Nil NAD 
9 9768 8700 8700 76 23 1 76 23 1 28 45 18 40 8.9 10.6 90 13 137 92 14 135  +  + Nil Nil 1-2 PC Nil Nil NAD 
10 8994 7000 7200 68 30 2 67 30 3 45 76 42 72 9.3 10.4 106 21 144 102 19 145  +  + Nil Nil 1-2 PC Nil Nil NAD 
11 10367 7500 7800 70 30 - 66 33 1 10 20 6 14 11.5 11.5 112 19 168 110 17 162  +  + Nil Nil 1-2 PC Nil Nil NAD 
12 12563 9500 9600 62 36 2 63 34 3 8 10 10 20 12 12.5 80 26 164 82 24 156  +  + Nil Nil 1-2 PC Nil Nil NAD 
13 13534 7000 7100 69 28 3 72 27 1 20 38 18 38 11 11.4 82 18 130 90 20 128  +  + Nil Nil 1-2 PC Nil Nil NAD 
14 15854 9000 9200 65 30 5 64 31 5 30 54 28 48 11.5 12 109 16 150 107 17 157  +  + Nil Nil 1-2 PC Nil Nil NAD 
15 17570 7800 8000 70 26 4 72 25 3 20 60 18 55 9.9 11 96 26 152 88 18 145  +  + Nil Nil 1-2 PC Nil Nil NAD 
16 18323 8600 8400 73 25 2 70 24 6 33 40 31 38 11 11.5 110 20 160 109 22 140  +  + Nil Nil 1-2 PC Nil Nil NAD 
17 22359 7000 7200 65 32 3 68 28 4 22 41 20 40 12 13 86 28 152 90 25 138  +  + Nil Nil 1-2 PC Nil Nil NAD 
18 22335 8100 8200 70 26 4 68 26 6 30 60 26 59 12.5 13 94 24 152 100 22 150  +  + Nil Nil 1-2 PC Nil Nil NAD 
19 22173 9100 9000 63 35 2 70 30 - 17 40 13 35 11.8 12.2 101 21 160 105 22 160  +  + Nil Nil 1-2 PC Nil Nil NAD 
20 40846 8900 8800 63 30 7 62 36 2 18 42 16 36 10.8 11.5 100 14 187 95 20 160  +  + Nil Nil 1-2 PC Nil Nil NAD 
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Table: 26 (a)  List of  IN Patients of PG-III Sirappu Maruthuvam Department Given 
1. Mathiyoosna rasayanam- Internal 2. Nympathi thylam - External 
 
S.NO IP.NO NAME AGE/SEX D.O.A D.O.D NO.OF. DAYS 
SYMPTOMS 
 
RESULT 
P 
 
S 
 
MS 
 
MR 
 
1 963 Mohaideen 58/M 10.4.18 25.5.18 46 + + + + G00D 
2 1023 Muthlakshmi 55/F 16.4.18 25.5.18 40 + + + + MODERATE 
3 821 Jesima 43/F 26.3.18 10.5.18 45 + + + + MODERATE 
4 770 Ponuthai 52/F 20.3.18 30.4.18 40 + + + + GOOD 
5 26 Nagurmeeral 52/F 26.12.17 28.1.18 40 + + + + GOOD 
6 89 Papa 59/F 17.1.18 1.3.18 43 + + + + MILD 
7 94 Airathaal 48/F 18.1.18 28.1.18 41 + + + + GOOD 
8 804 Madaswamy 41/M 22.3.18 22.4.18 31 + + + + GOOD 
9 771 Uthaiyakumar 27/M 20.3.18 25.4.18 36 + + + + MODERATE 
10 1072 Koppammal 54/F 19.4.18 25.5.18 36 + + + + FAIR 
11 99 Rani 45/F 7.4.18 6.6.18 62 + + + + MILD 
12 101 Kumarai 39/F 6.1.18 2.2.18 27 + + + + MODERATE 
13 809 Shanthi 41/F 10.1.18 20.2.18 41 + + + + MODERATE 
14 2783 Kathir 33/M 26.7.17 30.8.17 34 + + + + MODERATE 
15 1053 Mariammal 45/F 7.3.18 20.4.18 43 + + + + GOOD 
16 8994 Bhagavathi 48/F 1.9.17 1.11.18 61 + + + + GOOD 
17 2424 Tamilarasi 45/F 20.4.18 20.5.18 30 + + + + MILD 
18 2630 Vani 45/F 28.4.18 1.6.18 34 + + + + MILD 
19 26798 Rahamed 60/F 1.5.18 30.5.18 29 + + + + GOOD 
20 38219 Murugaesan 40/M 1.5.18 
 
6.6.18 36 + + + + GOOD 
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Table 26 (b) Investigation for IP Patients 
S.No IP.No 
Haemotological Investigation     Urine Analysis 
WBC Total 
WBC Differential Count 
(%) E.S.R. mm/hr 
HB 
(gms%) 
BT AT RA 
FACTOR BT AT mgs% mgs% 
BT AT 
BT AT BT AT 
BT AT BS BU BC BS BU BC BT AT Alb Sug Dep Alb Sug Dep P L E P L E 
1/2 
hr 
1 
hr 
1/2 
hr 
1 
hr 
1 963 6200 6200 64 32 4 66 32 2 15 30 15 28 11 12 80 31 108 90 24 106  +  + Nil Nil 1-2 PC Nil Nil NAD 
2 101 8200 8600 72 24 4 72 26 2 27 45 20 42 10.5 11 90 19 13 100 20 158  +  + Nil Nil 1-2 PC Nil Nil NAD 
3 1023 9500 9000 66 34 0 63 37 0 26 40 25 38 9.8 10.5 80 28 199 80 22 195  +  + Nil Nil 1-2 PC Nil Nil NAD 
4 26798 8000 8100 61 33 6 61 35 4 13 44 12 42 9 10.5 109 20 141 105 17 150  +  + Nil Nil 1-2 PC Nil Nil NAD 
5 1030 10000 9900 65 34 1 67 33 - 18 40 22 58 9.9 10.5 90 25 126 90 19 120  +  + Nil Nil 1-2 PC Nil Nil NAD 
6 809 8100 8200 73 20 7 74 22 4 80 120 65 90 9.9 11 88 17 198 92 16 194  +  + Nil Nil 1-2 PC Nil Nil NAD 
7 770 11000 11000 50 36 4 60 37 3 20  44 14 36 11.2 11.4 100 12 121 98 15 121  +  + Nil Nil 1-2 PC Nil Nil NAD 
8 2783 8800 8400 66 29 5 65 30 5 25 41 24 35 10.4 11.5 108 28 140 118 27 133  +  + Nil Nil 1-2 PC Nil Nil NAD 
9 1072 8700 9000 75 24 1 77 24 1 28 40 18 38 8.9 10.6 90 13 137 92 14 135  +  + Nil Nil 1-2 PC Nil Nil NAD 
10 1053 7000 7200 68 30 2 67 30 3 45 76 42 72 9.3 10.4 106 21 144 102 19 145  +  + Nil Nil 1-2 PC Nil Nil NAD 
11 771 7500 7800 70 30 - 66 33 1 10 20 6 14 11.5 11.5 112 19 168 110 17 162  +  + Nil Nil 1-2 PC Nil Nil NAD 
12 8994 9500 9600 62 36 2 63 34 3 8 10 10 20 12 12.5 80 26 164 82 24 156  +  + Nil Nil 1-2 PC Nil Nil NAD 
13 804 7000 7100 69 28 3 72 27 1 20 38 18 38 11 11.4 82 18 130 90 20 128  +  + Nil Nil 1-2 PC Nil Nil NAD 
14 2630 9000 9200 65 30 5 64 31 5 30 54 28 48 11.5 12 109 16 150 107 17 157  +  + Nil Nil 1-2 PC Nil Nil NAD 
15 26 7800 8000 70 26 4 72 25 3 20 60 18 55 9.9 11 96 26 152 88 18 145  +  + Nil Nil 1-2 PC Nil Nil NAD 
16 26798 8600 8400 73 25 2 70 24 6 33 40 31 38 11 11.5 110 20 160 109 22 140  +  + Nil Nil 1-2 PC Nil Nil NAD 
17 89 7000 7200 65 32 3 68 28 4 22 41 20 40 12 13 86 28 152 90 25 138  +  + Nil Nil 1-2 PC Nil Nil NAD 
18 38219 8100 8200 70 26 4 68 26 6 30 60 26 59 12.5 13 94 24 152 100 22 150  +  + Nil Nil 1-2 PC Nil Nil NAD 
19 821 9100 9200 64 34 2 70 30 - 15 38 13 35 11.8 12.2 101 21 160 105 22 146  +  + Nil Nil 1-2 PC Nil Nil NAD 
20 94 8900 8800 63 30 7 62 36 2 18 42 16 34 10 11 101 16 188 96 26 168  +  + Nil Nil 1-2 PC Nil Nil NAD 
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DISCUSSION 
The main aim of the treatment was to study the Therapeutic effect of the drug 
MATHIYOOSHNA RASAYANAM to reduce pain, swelling and restricted joint movements in 
the disease Uthira Vatha Suronitham. The clinical features of Uthiravatha Suronitham can be 
correlated to Rheumatoid Arthritis in modern science. Rheumatoid Arthritis is a chronic 
inflammatory, destructive, and deforming symmetrical poly arthritis associated with symmetrical 
involvement of joints. 
            Uthiravatha Suronitham is a Vatha disease in which, there occur a derangement of Vatha 
thathu and Pitha thathu.  
Among the 40 patients selected 
 According to the Age group 41-50 was42..5%, 31-40was 12.5 and 51-60 were 30%, 61-
70 was 2.5%, 21-30 was 10. 
 In Gender among the 40 patients seleced, the disease (R.A) was found to be higher in 
females (97.5%) and lower in males (2.5%) 
 In Religion among the 40 cases observed, 75% of the cases were hindu, 20% of the cases 
were muslim and 2% of the cases were christians. 
 In Body constitution out of 40 cases all the 100% cases were came under thontha thegi. 
 In Paruvakaalam (season) out of 40 cases, 35% cases were included in munpani kaalam, 
30% cases were in pinpanilkaalam, 15% cases were in koothir kaalam, 12.5% cases were in 
Ilavenil kalam and 7.5% cases in kaar kalam. 
 In nilam out of 40 cases, 70% cases were from marutha nilam and the remaining 30cases 
were neithal nilam30.%vegetarian diet. 
 In occupational distribution out of 40 cases, 62.5% were house wives, 12.5% were 
farmer, 10% were house maids, 7.5% were tailors, 5% were teachers, and 2.5% were clerical. 
 In duration of illness out of 40 cases 25% were 1 year – 2 years, 22.5% were 3 months – 
6 months and 2-5 years, 20% were 6 months – 1 year, 7.5% were 5-10 years, and 2.5% were 
more than 10 years. 
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 In onset of symptoms out of 40 cases, 77.5% of the cases had gradual onset and 22.5% 
had sudden onset. 
 In vatham out of 40 cases, samaanan vyaanan were affected in 100% cases, 
Dhevathathan was affected in 82.5% cases, udhanan was affected in 57.5% cases, praanan was 
affected in 55% cases, koorman, kirukaran were affected in 27.5% cases, naagan was affected in 
25% cases, abaanan was affected in 15% cases. 
 In pitham out of 40 cases, saathagam was affected in 100% cases, Analagam was 
affected in 37.5% cases, Ranjagam was affected in 50% cases, Alosagam was affected in 27.5% 
cases, Prasagam was affected in 2.5% cases. 
 In kabam out of 40 cases santhigam was affected in 100% cases, avalambagam was 
affected in 50% cases, kilethagam was affected in 37.5% cases, tharpagam was affected in 30% 
cases, pothagam was affected in2. 5% cases. 
 In gnanenthriyam out of 40 cases, all 40 (100%) cases had mei affected, 10(25%) cases 
kan was affected, 3(7.5%) cases vai was affected. 
 In kanmenthriyam out of 40 cases kai and kaal (Upper and lower limbs) are affected in 
all (100%) of the case, eruvai was affected in 10% of cases, vai was affected in 7.5% of cases. 
In  udal thathukkal out of 40 cases, saaram , senneer , oon , kozhuppu, enbu ,moolai 
100% were affected. 
In envagai thervugal among the 40 cases, sparisam was affected in 70%, vizhi was 
affected in 50% cases, naa was affected in 35.5% cases, malam was affected in 25% cases niram 
was affected in 2.5% cases. 
While seeing the Naadi among the 40 cases vatha pitha naadi was found in 75% cases 
and pitha vatha naadi was found 25% cases. 
In neikkuri, among the 40 cases, 77.5% of the cases showed vathaneer, 17.5% of the 
cases showed kabaneer, 5% of the cases showed pithaneer. 
According to the clinical features all 100% of cases had pain, swelling of the joints, 
early morning stiffness, tenderness, restricted movements and warmth, 75% cases had 
sleeplessness, 40% cases had fever, 37.5% cases had loss of appetite. 
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According to deformities in my study 17.5% cases had spindle shaped fingers, 17.5% 
cases had ulnar deviation of hand, 5% cases had hallus valgus and1 7.5% cases has swan neck 
deformity. 
Involvement  of joints in my study, 100% had knee joints, 87.5% of the cases had 
proximal interphalangeal joints, ankle joint and metacarpophalangeal joints, 75% had wrist 
joints, 65% had cervical spine, 32.5% had elbows, 25% had hip joints, shoulder joints and 
metatarsophalangeal joints. 
After treatment out of 40 cases 
 In my study, before treatment 100% of cases had pain, swelling of joints, morning 
stiffness, tenderness, restricted movements and warmth.  75% of cases had sleeplessness, 40% of 
cases had low grade fever and 15% cases had loss of appetite. 
 After treatment 15% of cases had relieved and 80% of cases had reduced and 5% of cases 
had no improvement in pain. 
 Over all Results are in my 57.5% cases showed Good improvement, 22.5% cases showed 
Moderate improvement, 15% cases showed mild improvement 5% cases showed no 
improvement. 
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SUMMARY 
Yugi Muni classified vatha diseases into 80 types one among them is uthiravatha 
suronitham.In modern uthiravatha suronitham is compared with Rheumatoid arthritis. It is the 
most common persistent inflammatory arthritis, occurring throughout the world and in all ethnic 
groups with intermittent exacerbations. 
The aim of the study was to evaluate the efficacy of Mathiyooshna Rasayanam and 
Nympathy thylam in Uthiravatha Suronitham. 
Based on the inclusion and exclusion criteria in the approved protocol 40 cases were 
diagnosed clinically Out of the 40 cases, 20 cases were admitted and treated with the trial Drugs 
Mathiyooshna Rasayanam [internal] and Nympathy thylam [external] in the In-patient ward and 
the rest were treated in Outpatient department of Sirappu Maruthuvam in Government Siddha 
Medical College, Palayamkottai. 
Among the 20 Ip patients, 10 IP patients were treated by Steam bath treatment along with 
the trial medicine and remaining 30 cases were treated only with the trial drugs for 48 days. 
In this study, first the patients were well informed about the study and they were asked to 
sign the consent form. After signing the consent form, information sheet and diatery advice 
forms were given to the patients. 
The various Siddha methods of examination of the disease were carried out and the data 
were recorded in the prescribed Proforma for the 40 selected cases. 
Purgation was given by administering Moolakudori ennai 15ml is given in early morning 
to bring the Thirithodam to equilibrium a day prior to treatment and the patient was given 
complete rest on the day of purgation. 
The prognosis of the patients during each visit was entered and monitored for any adverse 
drug reactions or poor patient compliance, investigation reports were recorded before and after 
treatment. 
Bio-chemical analysis revealed that the drug contains Calcium, Ferrous iron, tannic acid, 
reducing  sugar and Unsaturated compounds. 
The pain assessment was done in all the 40 patients participated in the trial using the 
universal pain assessment scale and at the end of the study the results showed, the mean pain 
score before treatment was 3.85  and after treatment it was reduced to  2.33 
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Among the 20 IP patients, 10 IP patients were given Steam bath treatment along with 
their internal medicine. The remaining 10 IP patients didn’t received steam bath treatment. The 
results are compared at the end of the study. The mean pain score of the 10 patients who received 
steam bath treatment before treatment is 4.3  and after treatment it is reduced to  1.7. Hence 
steam bath treatment along with internal medicine is more effective in the treatment of 
rheumatoid arthritis 
From this clinical trial it could be inferred that Mathiyooshna Rasayanam and Nympathy 
thylam possess good therapeutic efficacy in Uthiravatha suronitham. 
Good Improvement  - 23 Patients (57.5%) 
Moderate Improvement - 9 patients (22.5%) 
Mild Improvement  - 6 patients (15%) 
No improvement   - 2 patients (5%) 
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CONCLUSION 
The result of this clinical trial indicate that trial drug is clinically effective in Uthira vatha 
Suronitham.  The toxicity study reveals that the trial drug mathiyooshna rasayanam is safe.  
Mathiyooshna Rasayanam have analgesic and anti inflamatory activity. 
  The main aim of the treatment was to study the Therapeutic effect of the drug 
Mathiyooshna Rasayanam by its action on Pain, swelling, morning stiffness, restricted 
movements etc,.  
In this study it was found that about 77.5% of patients were women and after taking 
internal and external medicine it was found that they felt better and were able to do their day to 
day work without anyothers help. 
Hence the study concludes that, the trial drugs are clinically effective in reducing the 
pain, swelling and morning stiffness, restricted movements in Uthiravatha suronitham patients. 
However further work with large number of patients should be carried out towards finding the 
ideal dose response. 
The treatment was aimed at normalizing the deranged thodams and providing relief from 
symptoms. 
There were no adverse reactions complained during the trial. 
Because of the encouraging clinical outcome, the study may be further carried out with 
the same drug in a large number of cases. 
 
.  
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ANNEXURE -I 
PREPARATION OF TRIAL DRUG 
INGREDIENTS 
Internal medicine: MATHIYOOSHNA RASAYANAM 
S.No Ingredient Botanical name Part used Measurement 
1 Paranki pattai Smilax china Root tube 10palam(350 grams) 
2 Jathipathri Myristica fragrans  Pericarp ¼palam(8.75grams) 
3 Milagu Piper nigrum Unriped fruit ¼palam(8.75grams) 
4 Vaivilangam Embelia ribes Dried fruits ¼palam(8.75grams) 
5 Chukku 
 
Zingiber officinale Dried rhizome ¼palam(8.75grams) 
6 Santhanam Santalum album Wood ¼palam(8.75grams) 
7 Kadukkai Terminalia chebula Pericarp 
 
¼palam(8.75grams) 
8 Thippili Piper longum Fruit ¼palam(8.75grams) 
9 Nelli  paruppu Phyllanthus emblica Dried fruit ¼palam(8.75grams) 
10 Lavanga pattai Cinnamomum verum Bark 
 
¼palam(8.75grams) 
11 Ealakkai  
 
Elettaria 
cardamomum 
Seed ¼palam(8.75grams) 
12 Kirambu  Syzygium 
aromaticum 
Flower buds 
 
¼palam(8.75grams) 
13 Thanri kaai Terminalia bellirica Dried fruit ¼palam(8.75grams) 
14 Sevviyam Piper nigram Root ¼palam(8.75grams) 
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15 Jeeragam Cuminum cyminum Seed ¼palam(8.75grams) 
16 Thippili moolam Piper longum Root ¼palam(8.75grams) 
17 Kandu parangi Clerodendrum 
serratum 
Root ¼palam(8.75grams) 
18 Vetpalai Wrightia tinctoria Seed ¼palam(8.75grams) 
19 Arathai Alpinia galanga Rhizome ¼palam(8.75grams) 
20 Vaaluluvai arisi Clestrus paniculatus Seed ¼palam(8.75grams) 
21 Korai kilangu Cyperus rotundus Root tuber ¼palam(8.75grams) 
22 Nannari Hemidesmus indicus Root ¼palam(8.75grams) 
23 Kostam Costus speciosus Rhizome ¼palam(8.75grams) 
24 Sadaamaanjil Nardostachys 
grandiflora 
Root ¼palam(8.75grams) 
25 Annachipoo Illicium verum Flower ¼palam(8.75grams) 
26 Adhimathuram Glycyrrhiza glabra Root ¼palam(8.75grams) 
27 Kaattu milagu Piper nigrum Seed ¼palam(8.75grams) 
28 Krosani Omam Hyoscyamus niger Seed ¼palam(8.75grams) 
29 Omam Carum copticum Seed ¼palam(8.75grams) 
30 Mullai ver Jasminum 
trichotomum 
Root ¼palam(8.75grams) 
31 Honey   325 ml 
32 Ghee   Equal to all remaining 
parts 
 
Purifications of drugs: 
• Raw drugs will be heated to a golden brown colour and cooled it.  
• In kadukkai seed is removed. 
• Paranki pattai should be dried and pulverized. Then should be boiled by steam of milk. 
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• In chukka outer skin to be removed. 
• All roots to be cleaned thoroughly by water and dried in shadow. 
 
Preparation: 
 Purified dry drug is taken and powdered. Then it is filtered using pure white cloth, honey 
to be added. Add ghee and make like a Pittu. Keep in airtight container 
Method of preparation 
The purified dried raw drugs are powdered and shifted well separately 
Equal quantity of each powdered drugs are then mixed well. Add honey and ghee and mix well 
to make it like a pittu. 
 
External medicine: NYMPATHY THAILAM 
S. 
No: 
Ingredient  Botanical name Part used Measurement 
1. Veppennai (Neem oil) Azadirachta indica Seed oil ¼ padi (325 ml) 
2. Nallennai (Gingilee oil) Sesamum indicum Seed oil ¼ padi (325 ml) 
3. Chadurakalli juice Euphorpia antiquorum Extract ½ padi(650 ml) 
4. Maampattai chaaru Mangifera indica Pattai ½ padi(650 ml) 
5. Maangolunthu chaaru Mangifera indica Leaf ½ padi (650 ml) 
6. Maampoo chaaru Mangifera indica Flower ½ padi (650 ml) 
7. Erukkam ver pattai chaaru Calotropis gigantean Root ½ padi (650 ml) 
8. Etti kottai Strychnos nuxvomica Seed 15 
 
Method of preparation: 
 Grind the Etti kottai to kalkam , mix the kalkam with all other extracts, and heat until 
required consistency formed. Filter it then kept in a dry airtight container.  
95 
 
TRIAL DRUG 
Internal medicine 
 hxr<gqh<hm<jm< < << < << < < !
Sju!
osb<jg<<< !
 dmx<Okx<xq!
 Olgh<h{q!uqzg<gq!
 gill<!ohVg<gq!
G{l<!
“kigl<!hzuigkf<!kiK!fm<ml<!H{<!hqtju!
Olgr<!gcgqvf<kq!uQp<&zf<` !OkgLme<!
Gm<jm!hgf<k!Olx<!ogit<ulel<!Ohil<!hxr<gqh<!
hm<jmbqje!Bs<svqk<Kh<!hiI”!
ohiVt<<<<!
fQI!Oum<jg?!Lmuikl<?!GOx!Ofib<?!fQvqpqU?!gcuqml<?!H{<!-ju!fQr<Gl<!
Chemical constituents 
 7-o-seta-D-gluco pyranoside, engeletin, isoengeletin, kaemiferol, rutin, vanillic acid 
 Lz<jz!OuI<<< !
hbe<hMl<!dXh<H! ;!OuI!
Sju!.!jgh<H?!!ke<jl!.!!ouh<hl<?!!hqvqU!.!giIh<H!
osb<jg<<< !
 HPg<ogiz<zq!
 uQg<gLVg<gq!
 sqXfQI!ohVg<gq!
 VKU{<mig<gq!
G{l<<<<!
Lg<gx<xl<?!kjzOfib<?!dmz<!ouh<hl<?!g{<hmzl<!-ju!fQr<Gl<?!leg<gzg<gk<jk!
Ohig<Gl</!
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 Sg<G<<< !
English Name  : Dried Ginger 
Botanical Name : Zingiber officinale 
Family   : Zingiberaceae 
Part used  : Dried rhizome 
Other names in Tamil : nVg<ge<?!uqm&cb!nlqi<kl<?!fuSX?!dzi<f<k!-R<sq!
Constituents  : Zingerd, adenine, shogaol, isovanillin. 
Organoleptic characters 
 Taste   : Acrid 
 Potency  : Hot 
 Division  : Acrid 
Therapeutic Actions 
 ouh<hL{<mig<gq! .! Stimulant 
! hsqk<kQk<K~{<c! .! Stomachic 
! ngm<Muib<ugx<xq! .! Carminative 
Therapeutic Effect 
! “uikh<!hq{qubq!X~kx<!osuquib<!
! uzqkjz!uzqGjz!uzqbqV!uqpqfQI!
! sQkk<!okiMuiq!Ohkqh<!hzOvi!
! sqglzq!Lglg!Lglqc!ghliI!
! sQks<!Svl<uqiq!Ohks<!SvOfib<!
! okxqhMoleolipq!Gui<Huq!keqOz!
! =Kg<!GkUlq!kQKg<!Gkui!
! okEl<uqkq!bqjzfu!SXG{!LeOu”!
. Okjvbi<!G{uigml<<<<!
!
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 sf<kel<< << << <!
English Name  : Sandal wood 
Botanical Name : Santalum album 
Family   : Santalaceae 
Part used  : Wood 
Constituents  : Teresantalol, Santalic acid, Santalone, Santene. 
Organoleptic characters 
 Taste   : Bitter, astringency 
 Potency  : Cold, hot 
 Division  : Sweet 
Therapeutic Actions 
 dmx<Oxx<xq! ! .! Alterative! !
! sqXfQIh<ohVg<gq! .! Diuretic 
! uqbi<juh<ohVg<gq! .! Diaphoretic!
! ouh<hL{<mig<gq! .! Stimulant!
! nPgz<l{lgx<xq! .! Disinfectant 
! Kui<h<hq! ! .! Astringent 
! Gtqi<s<sqB{<mig<gq! .! Cooling 
Therapeutic Effect 
! “Ogikqz<!sf<keR<!< < << < << < < sQOkiQQQ ]<{r<!ogi{<cVg<Gl<< < < < << < < < << < < < <!
! uikhqk<kl<!Jbl<!leh<hqvjl!< < < << < < << < < < –!YKSvl<<<<!
! Olgl<!keqk<kigl<!ouh<H!osixq!Bl<Ohig<Gl<< < < < < < << < < < < < << < < < < < <!
! Ngf<!keg<GXkq!bil<< < << < << < <”!
Lg<Gx<xl<?! leg<gzg<gl<?! dm<$M?! yPg<G! out<jt?! fiuxm<sq?! fjls<sz<! -ju!
fQr<Gl</!!dmz<!ue<jl!ohXl</!
!
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 gMg<gib<<< <!
English Name  : Ink nuts, chebulic myrobalan 
Botanical Name : Terminalia chebulla 
Family   : Combretaceae 
Part used  : Pericarp 
Other names in Tamil : nl<jl?!Olgl<?!\Quf<kq?!niqkgq?!Okuq?!uiqg<gib<!
Constituents  : Ethyl galate, chebulin, corilagin, chebulegic acid. 
Organoleptic characters 
 Taste   : Astringency(more);  sweet,  sour, acrid, bitter (less). 
 Potency  : Hot 
 Division  : Sweet 
Therapeutic Actions 
 uiklmg<gq! ! .! Antivatha 
! hsqk<kQk<K~{<c! .! Stomachic 
! dmx<Oxx<xq! ! .! Alterative 
Therapeutic Effect 
 “kijm!gPk<kg<gq!kiZ!< << << < Gxqbquqmh<< <<!
! hQjm!sqzqhkLx<!OhkqLml<!Q < <Q < <Q < < .!Njmobm<mik<< << << <!
! K~zlqc!H{<uik!Osi{qgi!lijzbqv{<< << << <!
! hizlqc!Ohiluiqg<gi!biz<< << << <”/!
gMg<gibqeiz<?! ge<el<?! gPk<K?! fi?! N{<Gxq! -u<uqmr<gtqz<! Ofib<gt<?!
gizch<Hx<XOfib<?!nkqK~zl<?!-ch<H{<?!uikOsi{qkuikl<?!gilijz?!kiuvsr<gl!uqmr<gt<!
-ju!Ohil</!
! !
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 kqh<hqzq<<< !
English Name  : Long pipper 
Botanical Name : Piper longum 
Family   : Piperaceae 
Part used  : Fruit 
Other names in Tamil : NkqlVf<K?!juOkgq?!nl<H?!Gmiiq?!svl<!
Constituents  : Piperin, rutin, piperamine, pinene. 
Organoleptic characters 
 Taste   : Sweet 
 Potency  : Hot 
 Division  : Sweet 
Therapeutic Actions 
 ouh<hL{<mig<gq! ! .! Stimulant! !
! ngm<Muib<ugx<xq! ! .! Carminative 
Therapeutic Effect 
! “-Vlz<!Ge<ll<!-jvh<H!gbh<hq{q< < < < << < < < << < < < < !
! =jt!hi{<M!sf<bisl<!nOvisgl<< < < << < < << < < <!
! ohiVlz<!Djk!sqvh<hq{q!&Is<jsOfib<< < < << < < << < < <!
! H,iqg<!<<< GR<sz!Okiml<!hQzqgLl<< < Q << < Q << < Q <!
! uVl!zh<ohVg<!OgiM!lOgikvl<< < << < << < <!
! uikl<!NkqLk<!OkimR<!Svr<Gtqi<< < < < << < < < << < < < <!
! ohVlijzh<Hiq!Olgh<!hqmgLl<< < << < << < <!
! OhVf<!kqh<hqzqh<!Ohvr<Gjvg<gOu< < < < << < < < << < < < < ”!
 
 
! !
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 ofz<zqh<hVh<H< < << < << < < !
English Name  : Indian Gooseberry 
Botanical Name : Phyllanthus emblica 
Family   : Euphorbiaceae 
Part used  : Dried fruit 
Other names in Tamil : Nlzgl<?!kik<kqiq?!Ogivr<gl<?!lqXKhzi?!Nl<hz<!
Constituents  : Emblicanin A & B, glutamic acid, Vitamin C. 
Organoleptic characters 
 Taste   : Sour, Acrid, Sweet 
 Potency  : Cold 
 Division  : Sweet 
Therapeutic Actions 
 Kui<h<hq! .! Astringent 
Therapeutic Effect 
 “ofz<zqg<gib<g<!Gh<hqk<kl<!fQr<G!lke<Htqh<hiz<< < < < < < < Q < < < << < < < < < < Q < < < << < < < < < < Q < < < <!
! osz<ZOl!uiklkqx<!Osi<Kuviz<!< < < << < < << < < < .!osiz<Zjlbl<< << << <!
! YMlqjks<!sqk<kk<kqz<!de<e!neZmOe< < < < << < < < << < < < < !
! %Mhqx!OlgLl<!Ohir<!%X/< << << < !
! !
101 
 
 Wzg<gib<!niqsq< << << < !
English Name  : Cardamom seeds 
Botanical Name : Elettaria cardamomum 
Family   : Zingiberaceae 
Part used  : Seed 
Other names in Tamil : NR<sq?!Ogivr<gl<?!Kc!
Constituents  : Limonene, cineole, terpinolene. 
Organoleptic characters 
 Taste   : Acrid 
 Potency  : Hot 
 Division  : Acrid 
Therapeutic Actions 
 ouh<hL{<mig<gq! .! Stimulant 
! ngm<Muib<ugx<xq! .! Carminative 
! hsqk<kQk<K~{<c! .! Stomachic 
Therapeutic Effect 
 “oki{<jm!uib<gUt<!kiZG!kr<gtqz<< < < < << < < < << < < < <!
! Okie<Xl<!Ofibkq!sivl<he<!Olgk<kiz<< < < < < << < < < < << < < < < <!
! d{<jm!Ohiz<wPr<!gm<c!gqiqs<svl<< < < < < << < < < < << < < < < <!
! dpjz!uif<kq!sqzf<kq!uq< << << < ]R<Svl<< << << <!
! h{<jm!<<< oug<jg!uqkigOfib<!gisLl<< < << < << < <!
! hiPR<!Osilh<!hq{quqf<K!fm<mLl<< < < < << < < < << < < < <!
! n{<m!bQjtue<!hqk<kl<!-jug<ogz<zil<< Q < < < < < << Q < < < < < << Q < < < < < <!
! Nz!lir<glp<!Wz!lVf<kOk///< < << < << < < ”!
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 gqvil<H<<< !
English Name  : Cloves 
Botanical Name : Syzygium aromaticum 
Family   : Myrtaceae 
Part used  : Flower buds 
Other names in Tamil : -zur<gl<?!nR<Sgl<?!kqvtq?!dx<gml<!
Constituents  : Eugenol. eugenitin, eugenin, Kaempferol. 
Organoleptic characters 
 Taste   : Acrid 
 Potency  : Hot 
 Division  : Acrid 
Therapeutic Actions 
 -squgx<xq! ! .! Antispasmodic 
! ngm<Muib<ugx<xq! .! Carminative!
! hsqk<kQk<K~{<c! .! Stomachic 
Therapeutic Effect 
 “hqk<k!lbg<gl<!OhkqobiM!uif<kqBl<Ohil<< < < < < << < < < < << < < < < <!
! Sk<kquqvk<!kg<gMh<Hf<!Okie<XOli!< < < < < << < < < < << < < < < < –!olk<k<<< !
! -zur<gr<!ogi{<muVg<!Ogx<!SgliGl<< < < < < << < < < < << < < < < <!
! lzlr<Og!gm<Mole!uip<k<K/< < < << < < << < < < ”!
! !
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 g{<Mhvr<gq< << << < !
Sju!.!jgh<H?!KuIh<H?!ke<jl!.!ouh<hl<?!hqvqU!.!giIh<H!
osb<jg<<< !
 ouh<hL{<mig<gq!
 kiK!ouh<hgx<xq!
G{l<<<<!
!!!Lg<Gx<xl<?-jvh<hqVlz<?dt<! ouh<hl<?ouxq! Ofib<?Svl<?fim<hk<m! utqOfib<?! Gtq◌்I!
gib<s<sz<?!dmz<!!uzq?!-ju!fQr<Gl<!
oum<hijz<<< !
hbe<hMl<!dXh<H< < << < << < < !nvqsq!
Sju!.!-eqh<H?!ke<jl!.!km<hl<?!hqvqU!.!-eqh<H!
osb<jg<<< !
dvlig<gq!
G{l<<<<!
“oum<hijz!ke<evqsq!uQXhqk<k!uikOliM!
ogim<hiI!gvh<hie<!Gmz<uik.!dh<hqsk<jkg<!
gi{il!OzfiTr<!g{<cg<Gr<!gisqeqbqx<!
h,{iI!Ljzbi!Hgp<”!
ohiVt<;<<< !kQ!utq!Ofib<gt<!?!Gmz<!uiB?!ubqx<X!ohiVlz<!gpqs<sz<!Ohig<Gl<!
 uiZTju!
hbe<hMl<!dXh<H;!uqjk!
Sju!.!jgh<H?!ke<jl!.!ouh<hl<?!hqvqU!.!giIh<H!
osb<jg<<< !
 dmx<Okx<xq?!
 ficBvlig<gq!
 uqbIju!ohVg<gq!
!
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G{l<<<<!
ubqx<X! gMh<H?! jggiz<! Gk<kz<?! Gjms<sz<?gQz<! uiBuqz<! d{<miGl<! Ofig<giM!
fQr<Gl<!
 nvk<jk<<< !
hbe<hMl<!dXh<H! ;! !OuI?!
Sju!.!giIh<H?!uQvqbl<!.!ouh<hl<?!!hqvqU!.!giIh<H!
osb<jg<<< !
 Ogijpbgx<xq!
 ouh<hgx<xq!
 hsqk<kQk<K~{<c!
G{l<<<<!
uikOsi{qkl<?uQg<gl<?!kQs<Svk<kix<!hqxf<k!Jbl<?!-Vlz<??hz<!Ofib<!OhiGl<!
 nkqlKvl<<<<!
hbe<hMl<!dXh<H! ;! !OuI!
Sju!.!-eqh<H?!ke<jl!.!sQkl<?!!hqvqU!.!-eqh<H!
osb<jg<<< !
 uxm<sqbgx<xq!
 Ogijpbgx<xq!
 lzlqtg<gq!
 dvlig<gq!
 dt<tpzix<xq!
G{l<<<<!
wZl<H!hx<xqb!Ofib<!Ohil<?!kQg<Gx<xk<kqe<!ue<ljb!Gjxg<Gl<?!ouxq!Ofib<!uqg<gz<?!
ou{<Ht<tq!!Ohig<Gl<!
 Ogijv!
OuXohbI!;!!Lk<kg<giS!
hbe<hMl<!dXh<H!;!gqpr<G!
osb<jg<<< !
 KuIh<hq!
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 dvlig<gq!
 sqXfQI!ohVg<gq!
 uqbIju!ohVg<gq!
 VKU{<mig<gq!
 HPugx<xq!
G{l<<<<!
Svl<?! gpqs<sz<?! Lh<hq{q?hqk<k! kigl<?! ! ghOvigl<?Gkqr<giz<! uikl<?! uif<kq?!
Lkzqbju!!G{lig<Gl<!
 Ogi]<ml<< << << <!
hbe<hMl<!dXh<H! ;!OuI!
Sju!.!jgh<H?!ke<jl!.!ouh<hl<?!!hqvqU!.!giIh<H!
osb<jg<<< !
 hsqk<kQk<K~{<c!
 Ogijpbgx<xq!
 dvlig<gq!
 ouh<hL{<mig<gq!
 uqbIju!ohVg<gq!
G{l<<<<!
g{<?!kijm?!ubqX?!gPk<K?!kjz?!fi?!uib<?!-u<uqmk<kqz<!d{<miGl<! Ofib<gt<!
G{liGl<??Svl<?!uiB?&zLjt?!-jvh<hqVlz<?!wzq?!hil<H?!fR<S!Ohig<Gl<?!
 gim<MlqtG<<< !
hbe<hMl<!dXh<H!;!uqjk!
Sju!.!giIh<H?!!ke<jl!.!ouh<hl<?!hqvqU!.giIh<H!
osb<jg<<< !
 ouh<hL{<mig<gq!
 ngm<Muib<ugx<xq!
G{l<<<<!
fim<hm<m!gpqs<sz<?!Jbutq!Svl<?Olgl<?!OhiGl<?!hsq!d{<miGl<!!
 ne<eisqh<h,< << << < !
hbe<hMl<!dXh<H! ;!h,!
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Sju!.!-eqh<H?!uqXuqXh<H?!!ke<jl!.ouh<hl<?!hqvqU!.giIh<H!
osb<jg<<< !
 dvlig<gq!
 hsqk<kQk<K~{<c!
 ouh<hL{<mig<gq!
G{l<<<<!
osvqbijl?!lif<kl<?ue<jl!GjxU!Lkzqb!Ofib<gjth<!Ohig<Gl<!
 GOvisieqObill<<<<!
hbe<hMl<!dXh<H! ;!uqjk!
Sju!!.!giIh<H?!sqX!jgh<H?!ke<jl!.!ouh<hl<?!hqvqU!.!giIh<H!
osb<jg<<< !
 dxg<gL{<mig<gq!
 kiKouh<hgx<xq!
 Kbvmg<gq!
 -squgx<xq!
G{l<<<<!
hz<zc! Ofib<?! $kguzq?! lf<kv! -jvh<H?! gPk<K! Ofib<?! fMg<gl<?! K~g<glqe<jl?!
klvg!Kch<H!!Ngqbju!G{liGl<!
 osu<uqbl<< << << <!
-KOu!lqtgqe<!OuI!
G{l<<<<!
“$jz!nVgqse<eq!okiz<zqVlz<!=jthqk<kl<!
Oljzg<!Gvx<gl<lz<!our<gtOfib<!.!&zSvl<!
gu<uqbr<gk<!OkX!geki!uvuqmLR<!
osu<uqbr<!ogit<tuqMf<!OkI”!
ohiVt<;<<< !! !
$jz?! Sjubqe<jl?! Lh<hq{q?! fim<hm<m! Svl<?! fQck<k! -Vlz<?! =jt?! ouxq?!
Gvx<gl<lz<?!oki{<jm!Ofib<?!wZl<jhh<!hx<xq!WXgqe<x!fR<S!Ngqbju!Ohig<Gl</!
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EXTERNAL DRUG 
 li!
hbe<hMl<!dXh<H!: hm<jm!
osb<jg<<< !
 KuIh<hq!
 dvlig<gq!
 wm<cg<ogim<jm!
 osb<jg!
 nPgzgx<xq!
 dvlig<gq!
G{l<<<<!
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ANNEXURE - II 
QUALITATIVE AND QUANTITATIVE ANALYSIS 
BIO-CHEMICAL ANALYSIS OF MATHIYOOSHNA RASAYANAM 
Preparation of the extract:   
  5gms of the drug was weighed accurately and placed in a 250ml clean beaker.  Then 
50ml of distilled water is added and dissolved well.  Then it is boiled well for about 10 minutes.  
It is cooled and filtered in a 100ml volumetric flask and then it is make up to 100ml with distilled 
water.  This fluid is taken for analysis. 
 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  
TEST FOR CALCIUM 
2ml of the above prepared extract is 
taken in a clean test tube. To this 
add 2ml of 4% Ammonium oxalate 
solution 
 white precipitate is 
formed 
presence of calcium 
2. 
TEST FOR SULPHATE 
2ml of the extract is added to 5% 
Barium chloride solution. 
A white precipitate 
is formed 
Presence of sulphate 
3.  
TEST FOR CHLORIDE 
The extract is treated with silver 
nitrate solution 
No white precipitate 
is formed 
Absence of 
chloride 
4. 
TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
No Brisk 
effervessence is 
formed 
Absence of carbonate 
5. 
 
TEST FOR STARCH 
The extract is added with weak 
iodine solution 
 Blue colour is 
formed 
Indicates presence of 
starch 
6.  
TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro 
No blue colour is 
formed 
Absence of ferric iron 
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cyanide. 
7. 
TEST OF FERROUS IRON  
The extract is treated with 
concentrated Nitric acid and 
Ammonium thio cyanate solution 
Blood red colour is 
formed 
Indicates the presence 
of ferrous iron 
8.  
TEST FOR PHOSPHATE 
The extract is treated with 
Ammonium Molybdate and 
concentrated nitric acid 
No yellow 
precipitate is 
formed 
Absence of phosphate 
9.  
TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent 
No Yellow 
precipitate is 
formed 
Absence of Albumin 
10.  
TEST FOR TANNIC ACID 
The extract is treated with ferric 
chloride. 
Blue black 
precipitate is 
formed 
Indicates the presence 
of tannic acid 
11.  
TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract 
It gets decolourised 
 
Indicates the presence 
of   
unsaturationcompound 
12.  
TEST FOR THE REDUCING 
SUGAR 
5ml of Benedict’s qualitative 
solution is taken in a test tube and 
allowed to boil for 2 mts and add 8-
10 drops of the extract and again 
boil it for 2 mts. 
Colour change 
occurs. 
Indicates the presence 
of Reducing sugar 
13.  
TEST FOR AMINO ACID 
One or two drops of the extract is 
placed on a filter paper and dried 
well. After drying, 1% Ninnhydrin 
is sprayed over the same and dried 
it well. 
 Violet colour is 
formed 
Presence of Amino acid 
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14. 
TEST FOR ZINC 
The extract is treated with 
Potassium Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc. 
 
Inference: 
  The given sample of “Mathiyooshna Rasayanam contains calcium, ferrous iron, tannic 
acid, unsaturated compound,  reducing sugar, amino acid,Sulfate. 
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EFFECT OF MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE ON 
CARRAGEENAN-INDUCED LOCALISED INFLAMMATORY PAIN IN RATS 
SUMMARY 
  The study plan was developed based on the guidelines of Vogel1 and also it has reference 
to Chao Ma and Jun-Ming Zhang2 and Walker et al. 3, Winter CA, Risley EA, Nuss GW. 
Carrageenin induced edema in hind paw of the rat as an assay for anti-inflammatory drugs. Proc 
Soc Exp Biol Med. 1962;111:544–7. 
Objective 
  To study the anti-inflammatory effect of MATHIYOOSHNA RASAYANAM were 
prepared WITH HONEY/GHEE in the rat model of Carrageenan-induced localized 
inflammation.  
Methods: 
Test System 
Species : Rat   
Strain : Albino Wister 
Age : 6-8 weeks at the time of dosing 
Total no. of Rats : 24 
Sex : Male 
Weight                   :    150 gm 
 
 The animals were housed in polypropylene cages with stainless steel top grills having 
facilities for holding pellet food and drinking water in bottle with stainless steel sipper tube. Each 
cage contained 6 rats. All rats had free access to potable water and standard pelleted laboratory 
animal diet ad libitum. Paddy husk was used as bedding material. The animals were divided into 
5 groups (6 rats/group). Localized inflammatory pain was induced in all groups of animals by 
intraplantar injection of carrageenan (50 µl of 3% suspension).  
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 One day before the experiment, three basal readings of hind paw in each rat were 
recorded. Group 1 received vehicle orally, Group 2 received a standard drug Diclofenac sodium 
(10 mg/kg i.p), whereas groups 3,4and 5 received MATHIYOOSHNA RASAYANAM. The 
doses of MATHIYOOSHNA RASAYANAM were prepared WITH HONEY/GHEE, whereas 
Diclofenac sodium was dissolved in normal saline. After 30 min, the rats were challenged with 
subcutaneous injection of 0.1 ml of 1% w/v solution of carrageenan into the sub plantar region of 
left paw. The paw was marked with ink at the level of lateral malleolus and immersed in mercury 
up to the mark. The paw volume was measured at 0, 1, 2, 3, 4, 5 and 6th hr after carrageenin 
injection using Digital Plethysmometer. The difference between initial and subsequent reading 
gave the actual edema volume.  
 
DOSAGE SCHEDULE: 
  The required dose for mice/rat will be calculated by using the standard dose calculation 
procedure from recommended clinical dose. 
 
CONVERSION FORMULA: 
Human dose is 6000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
6000 mg x 2(a) x 0.018 (b) = 108 (c) /150 gm of Rat 
108/1000x150 = 16.2 mg  
Experimental Doses Calculated as per the standard procedures are 
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S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
 
1 Vehicle Control -- 1 ml 
 
2 Therapeutic Dose 16.2 mg /kg 
 
1 ml 
3 Middle  Dose 81mg/kg 1 ml 
 
4 High Dose 405mg/kg 1 ml 
 
EXPERIMENTAL DESIGN: 
Group-I:   Served as a negative control (0.1ml of 1% carrageenin) 
Group-II: Served as standard received Diclofenac sodium (10mg/kg, i.p) + 
                  (0.1ml of 1% carrageenin) 
Group-III: Received MATHIYOOSHNA RASAYANAM were prepared WITH HONEY/GHEE  
        (16.2 mg /kg) + (0.1ml of 1% carrageenin) 
 
Group IV: Received MATHIYOOSHNA RASAYANAM were prepared WITH HONEY/GHEE  
                   (81 mg/kg ) + (0.1ml of 1% carrageenin) 
Group V: Received MATHIYOOSHNA RASAYANAM were prepared WITH HONEY/GHEE  
                   (405 mg/kg ) + (0.1ml of 1% carrageenin) 
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TABLE: EFFECT OF MATHIYOOSHNA RASAYANAM were prepared WITH HONEY/GHEE ON CARRAGEENIN-
INDUCED PAW EDEMA IN RATS (BODY WEIGHT) 
 
 
Group 
Control Carrageenin + 
Standard 
Carrageenin + LD Carrageenin + 
M D 
Carrageenin 
+ H D 
 
INITIAL 
BODY 
WEIGHT 
161.3±3.198 
 
171.5±1.708 
 
165.8±1.652 
 
161.8±2.78 
 
152.3±2.25 
 
 
Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one way 
ANOVA  followed by dunnett’s. ns- not significant **P< 0.05 calculated by comparing treated group with 
control group. 
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TABLE: EFFECT OF MATHIYOOSHNA RASAYANAM were prepared WITH HONEY/GHEE ON 
CARRAGEENIN-INDUCED PAW EDEMA IN RATS 
 
 Values are expressed as the mean ± S.D. Statistical significance (p) calculated by one way ANOVA  
followed by dunnett’s. ns- not significant **P< 0.05 calculated by comparing treated group with control group. 
 
 
Group 
Mean paw 
volume 
before 
carrageenan 
injection 
Paw Volume after induction with carrageenin  
 
Increase in paw volume (ml) after carrageenan injection (mean ± 
SEM)/Percent   
inhibition of edema 
0 min 30 min 1h 2h 3h 4h 5h 6h 
 
Control 
Carrageenin 
 
4.588± 
0.4256 
 
7.75± 
0.5439 
 
7.765± 
0.2884 
 
8.315± 
0.2375 
 
8.343± 
0.1365 
 
8.33± 
0.4573 
 
8.028± 
0.2207 
 
7.965± 
0.2984 
 
Carrageenin  
+Standard 
 
3.75± 
0.2779 
 
7.323± 
0.2648 
 
7.653± 
0.1554 
 
7.763± 
0.2521 
 
7.695± 
0.1508 
 
6.42± 
0.1922** 
 
7.018± 
0.1832* 
 
6.023± 
0.5354* 
 
Carrageenin  + 
LD 
 
4.213± 
0.606 
7.898± 
0.34 
 
 
8.125± 
0.4637 
7.878± 
0.2395 
 
8.075± 
0.07665 
 
 
7.455± 
0.4548 
 
6.76± 
0.3905* 
 
6.308± 
0.6038 
Carrageenin  + 
M D 
 
3.788± 
0.0838 
 
7.73± 
0.4115 
 
8.028± 
0.5725 
 
7.735± 
0.1989 
 
7.838± 
0.2671 
6.143± 
0.3342** 
 
 
6.238± 
0.4052** 
6.13± 
0.4716 
 
 
Carrageenin  + 
H D 
3.975± 
0.3172 
7.595± 
0.5804 
8.2± 
0.485 
7.33± 
0.2054 
7.503± 
0.1944 
6.943± 
0.1603 
6.305± 
0.1455 
5.665± 
0.35 
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FIGURE SHOWS EFFECT OF MATHIYOOSHNA RASAYANAM were prepared WITH HONEY/GHEE ON 
CARRAGEENIN-INDUCED PAW EDEMA IN RATS 
   
                                 Only Carrageenin                                             Carrageenin + STD 
   
                           Carrageenin + MR L.D                                             Carrageenin + MR M.D 
 
Carrageenin + MR H.D 
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EFFECT OF MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE ON ACETIC ACID 
INDUCED WRITHING IN MICE1 
1. Kaneria MS, Naik SR, Kohli RK. Anti-inflammatory,antiarthritic and analgesic activity 
of a herbal formulation. Indian J.Experimental Biol. 2007; 45: 279. 
 
       Acetic acid induced writhing method was adopted for evaluation of analgesic activity. 
Writhing is defined as a stretch, tension to one side, extension of hind legs, contraction of the 
abdomen so that the abdomen of mice touches the floor, turning of trunk (twist). Any writhing is 
considered as a positive response. 
 
MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. All the 
animals were obtained from Animal house of the KMCH College of Pharmacy, Coimbatore. The 
animals were housed comfortably in a group of six in a single clean plastic cage with a metal 
frame lid on its top. They were housed under standard environmental conditions of temperature 
(24±1°C) and relative humidity of 30-70 %. A 12:12 h light dark cycle was followed. All 
animals had free access to water and standard pelletized laboratory animal diet ad libitum. All 
the experimental procedures and protocols used in this study were reviewed and approved via the 
Approval No. ----------------------------- by the Institutional Animal Ethical Committee (IAEC) of 
KMCH College of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 
constituted in accordance with the guidelines of the CPCSEA, Government of India. 
DRUGS: 
         Acetic acid (Sigma Chemical Co. Bangalore, India) and Indomethacin were purchased 
from (Ranbaxy, India). All drugs were dissolved in saline. The different doses of 
MATHIYOOSHNA RASAYANAM were prepared WITH HONEY/GHEE. The control group received 
vehicle as control. All drugs were prepared just before use. 
 PREPARATION OF ACETIC ACID: 
         A solution of acetic acid (1% v/v) in distilled water was prepared. 
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DOSAGE SCHEDULE: 
  The required dose for mice/rat will be calculated by using the standard dose calculation 
procedure from recommended clinical dose. 
 
CONVERSION FORMULA: 
Human dose is 6000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 30 gm of mice 
6000 mg x 2(a) x 0.018 (b) = 108 (c) /30 gm of mice 
108/1000x30 = 3.24 mg  
Experimental Doses Calculated as per the standard procedures are 
 
S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
1 Vehicle Control -- 0.5 ml 
2 Therapeutic Dose 3.24 mg /kg 
 
0.5 ml 
3 Middle  Dose   16.2mg/kg 0.5 ml 
4 High Dose 81mg/kg 0.5 ml 
 
EXPERIMENTAL PROCEUDRE: 
 
       GROUP 1 – CONTROL (IP injection of 0.1 ml 1% acetic acid) 
       GROUP 2 -- IP injection of 0.1 ml 1% acetic acid + Indomethacin (5mg/kg, i.p) 
       GROUP 3 -- 0.1 ml 1% acetic acid (ip) + MATHIYOOSHNA RASAYANAM with HONEY/GHEE  
                          3.24MG /KG(PO)                        
                                      
       GROUP 4 -- 0.1 ml 1% acetic acid (ip) + MATHIYOOSHNA RASAYANAM with HONEY/GHEE     
                           16.2mg/Kg(Po) 
 
      GROUP 5 -- 0.1 ml 1% acetic acid (ip) + MATHIYOOSHNA RASAYANAM with HONEY/GHEE 
                              81mg/kg(po) 
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 PROCEDURE: 
            Wister albino mice of either sex were divided into five different groups each containing  
Six animals, the animals were marked individually. Food was withdrawn 12 hours prior to drug 
administration till completion of experiment. The animals were weighed and numbered 
appropriately. The test and standard drugs were given orally. After 60 minutes writhing was 
induced by intra-peritoneal injection of 1% acetic acid in volume of 0.1 ml/10g body weight. The 
writhing episodes were recorded for 30 minutes; stretching movements consisting of arching of 
the back, elongation of body and extension of hind limbs were counted. 
Anti-nociceptive  activity was expressed as the percentage inhibition of abdominal constrictions 
using the ratio:  
             (Control mean – Treated mean) × 100/Control mean 
 
EFFECT OF MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE ON ACETIC ACID 
INDUCED WRITHING IN MICE1 
 
GROUP 
 
No of Writhing (30min) 
 
Inhibition (%) 
 
 
CONTROL 
 
 
45.33±4.807 
 
---- 
 
Indomethacin (5mg/kg, i.p) 
 
 
22.67±1.764 
 
49.98 % 
 
M R 0.028mg/kg(po) 
 
 
35±1.732 
 
 22.78 % 
 
M R 0.014mg/kg(po) 
 
 
30±1.155 
 
33.81 % 
 
MR 0.28mg/kg(po) 
 
 
24.33±1.202 
 
46.32 % 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
121 
 
        ACETIC ACID INDUCED WRITHING IN MICE
CO
NT
RO
L
In
do
m
et
ha
cin
 
(5m
g/k
g, 
i.p
)
 
L.
D
M.
D
H.
D
0
20
40
60
se
c/m
in
 
 
 
EFFECT OF MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE ON HOT 
PLATE METHOD IN MICE1 
 
1. Turner RA. Screening methods in pharmacology. In: Turner, R., Hebborn, P. (eds.). 
Academic press, New York. 1965; 100.  
 
            The paws of mice and rats are very sensitive to heat at temperatures which are not                 
damaging the skin. The responses are jumping, withdrawal of the paws and licking of the paws. 
 MATERIAL AND METHODS 
ANIMALS: 
          Healthy Swiss albino rats of either sex weighing 20-25g were used in this study. All the 
animals were obtained from Animal house of the KMCH College of Pharmacy, Coimbatore. The 
animals were housed comfortably in a group of six in a single clean plastic cage with a metal 
frame lid on its top. They were housed under standard environmental conditions of temperature 
(24±1°C) and relative humidity of 30-70 %. A 12:12 h light dark cycle was followed. All 
animals had free access to water and standard pelletized laboratory animal diet ad libitum. All 
the experimental procedures and protocols used in this study were reviewed and approved via the 
Approval No. ----------------------------- by the Institutional Animal Ethical Committee (IAEC) of 
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KMCH College of Pharmacy, Coimbatore (685/PO/Re/S/2002/CPSCEA Dated 21st August 2002 
constituted in accordance with the guidelines of the CPCSEA, Government of India. 
      The hot plate, which is commercially available, consists of a electrically heated surface. The 
temperature is controlled for 55° to 56 °C. This can be a copper plate or a heated glass surface. 
The animals are placed on the hot plate and the time until either licking or jumping occurs is 
recorded by a stop-watch. 
EXPERIMENTAL PROCEUDRE: 
       GROUP 1 – CONTROL  
       GROUP 2 – Pentazocine (10mg/kg, I.P) 
       GROUP 3 -- MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE  
                                   3.24 mg /kg(po)           
              
       GROUP 4 – MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE     
                                      16.2mg/kg(po) 
 
      GROUP 5 -- MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE     
                                      81mg/kg(po) 
 
PROCEUDRE: 
Mice were screened by placing them on a hot plate maintained at 55±1ºC and recording the 
reaction time in seconds for forepaw licking or jumping. Only mice which reacted within 15sec 
and which did not show large variation when tested on four separate occasions, each 15min 
apart, were taken for the test. The time for forepaw licking or jumping on the heated plate of the 
analgesiometer maintains at 55ºC was taken as the reaction time. Prior to treatment, the reaction 
time of each mouse (licking of the forepaws or jumping response) was done at 0- and 10-min 
interval. The average of the two readings was obtained as the initial reaction time (Tb). The 
reaction time (Ta) following the administration of the ---------------, Pentazocine and distilled 
water was measured at 0.5, 1, 2, and 3h after latency period of 30min. 
 
The following calculation was:  
 
          Percentage analgesic activity = Ta-Tb/Tb × 100 
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EFFECT OF MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE ON HOT PLATE 
METHOD IN MICE 
 
 
GROUP 
 
Reaction time in seconds at time (minutes) (mean ± sem) (mean ± sem) 
 
O mints 60 mints 90 mints 120 mints 180 mints 
 
CONTROL 
 
3.42±0.14 
 
4.44±0.12 
 
4.745±0.145 
 
4.915±0.045 
 
4.39±0.165 
 
 
STANDARD 
 
3.56±0.11 
 
 
5.715±0.065** 
 
6.945±0.055*** 
 
7.77±0.02*** 
 
7.10±0.21*** 
 
 
M R  + LOW 
DOSE 
 
3.24±0.02 
 
7.77±0.12*** 
 
7.82±0.07*** 
 
8.83±0.07*** 
 
8.52±0.07*** 
 
 
M R  + MIDDLE 
DOSE   
 
3.655±0.095 
 
7.56±0.11*** 
 
8.73±0.17*** 
 
7.8±0.2*** 
 
7.3±0.15*** 
 
 
M R + HIGH 
DOSE 
 
3.52±0.26 
 
6.5±0.2*** 
 
7.2±0.05*** 
 
7.3±0.05*** 
 
7.31±0.33*** 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by 
one way ANOVA  followed by dunnett’s ***P< 0.001, **P < 0.01,*P < 0.05 
calculated by comparing treated group with CONTROL group. 
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ACUTE TOXICITY STUDY IN FEMALE WISTER RATS TO EVALUATE TOXICITY 
PROFILE OF MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE   
 
Table 1. Test substance details 
Name of the test substance  
VATHATHIRKU LEGHIYAM  
With Honey/Ghee 
Colour of the test substance - brown 
Nature of the test substance Powder 
 
Table 2. Experimental protocol 
Name of the study Acute toxicity 
Guideline followed OECD 423 method-acute toxic class method 
Animals Healthy young adult female wister rats, 
nulliparous, non-pregnant 
Body weight 150-200 g 
Sex                       female 
Administration of dose and volume 6000 mg/kg in 200g body weight, single 
dose in 1 ml 
Number of groups and animals 
5 groups and 3 animals in each group 
1000,2000,3000,5000and 6000mg/kg 
Route of administration Oral Cavage (po) 
Vechicle Honey/Ghee 
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Table3. Housing and feeding conditions 
Room temperature 22°C  ±  3°C 
Humidity 40-60% 
Light 12 h : 12h (light : dark cycle) 
Feed 
Standard laboratory animal food pellets 
with water ad libitum 
Table 4. Study period and observation parameters 
Initial once observation First 30 minutes and periodically 24 h 
Special attention First 1-4 h after drug administration 
Long term observation Upto 14 days 
Direct observation parameters 
Tremors, convulsions, salivation, diarrhea, 
lethargy, sleep and coma. 
Additional observation parameters 
Skin and fur, eyes and mucous membrane, 
respiratory, circulatory, autonomic and 
central nervous systems, somato motor 
activity and behavior pattern etc. 
  
The time of death, if any, is recorded. (Complete observations: annexure I). After administration 
of the drug, food is withheld for a further 1-2 hours. 
Study procedure 
Acute oral toxicity was performed as per organization for economic co-operation for 
development (OECD) guideline 423 method. The MATHIYOOSHNA RASAYANAM WITH 
HONEY/GHEE   was administered in a single dose by tuberculin syringe. Animals are fasted 3 h 
prior to dosing (food was withheld for 3 h but not water). Following the period of fasting animals 
was weighed and test substance was administered orally at a dose of 1000,2000,3000,5000 and 
6000mg/kg. After the MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE   administration, food 
was withheld 2 h in mice. Animals are observed individually after at least once during the first 
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30 minutes, periodically during the first 24 hrs, with special attention given during the first 4 hrs, 
and daily thereafter, for a total of 14 days.  
REPORT 
Toxicological evaluation of MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE   
Table:5 Effect of MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE  on acute 
toxicity test in female rats 
 
RESULT: 
  From acute toxicity study it was observed that the administration of 
MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE   to Female Wister 
S.N 
 
 
Response 
Head Body Tail 
Before After Before After Before After 
1 Alertness Normal Normal Normal Normal Normal Normal 
2 Grooming Absent Absent Absent Absent Absent Absent 
3 Touch response Absent Absent Absent Absent Absent Absent 
4 Torch response Normal Normal Normal Normal Normal Normal 
5 Pain response Normal Normal Normal Normal Normal Normal 
6 Tremors Absent Absent Absent Absent Absent Absent 
7 Convulsion Absent Absent Absent Absent Absent Absent 
8 Righting reflux Normal Normal Normal Normal Normal Normal 
9 Gripping strength Normal Normal Normal Normal Normal Normal 
10 Pinna reflux Present Present Present Present Present Present 
11 Corneal reflux Present Present Present Present Present Present 
12 Writhing Absent Absent Absent Absent Absent Absent 
13 Pupils Normal Normal Normal Normal Normal Normal 
14 Urination Normal Normal Normal Normal Normal Normal 
15 Salivation Normal Normal Normal Normal Normal Normal 
16 Skin colour Normal Normal Normal Normal Normal Normal 
17 Lacrimation Normal Normal Normal Normal Normal Normal 
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rats did not induce drug-related toxicity and mortality in the animals up to 
6000mg/kg in 200g female Wister rats. So No-Observed-Adverse-Effect- Level 
(NOAEL) of MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE is 6000 mg/kg 
equal to human dose 
DISCUSSION 
MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE   was 
administered single time at the doses of 1000,2000,3000,5000 and 6000mg/kg to female 
Wister rats and observed for consecutive 14 days after administration. Doses were 
selected based on the pilot study and literature review. All animals were observed 
daily once for any abnormal clinical signs. Weekly body weight and food 
consumption were recorded. No mortality was observed during the entire period of 
the study. Data obtained in this study indicated no significance physical and 
behavioral signs of any toxicity due to administration of MATHIYOOSHNA 
RASAYANAM WITH HONEY/GHEE   at the doses of 1000,2000,3000,5000 and 
6000mg/kg to female Wister rats  
At the 14th day, all animals were observed for functional and behavioral 
examination. In functional and behavioral examination, home cage activity, hand 
held activity were observed. Home cage activities like Body position, Respiration, 
Clonic involuntary movement, Tonic involuntary movement, Palpebral closure, 
Approach response, Touch response, Pinna reflex, Sound responses, Tail pinch 
response were observed. Handheld activities like Reactivity, Handling, Palpebral 
closure, Lacrimation, Salivation, Piloercetion, Papillary reflex, abdominal tone, 
Limb tone were observed. Functional and behavioral examination was normal in 
all treated groups. Food consumption of all treated animals was found normal as 
compared to normal group. 
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SUMMARY & CONCLUSION: 
Summary: 
The present study was conducted to know single dose toxicity of 
MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE   on female Wister 
rats. The study was conducted using 15 female Wister rats. The female animals 
were selected for study of 8- 12 weeks old with weight range of within ± 20 % of 
mean body weight at the time of randomisation. The groups were numbered as 
group I, II, III, IV and V and dose with 1000,2000,3000,5000 and 6000mg/kg of LACTIC 
ACID BACTERIA. The drug was administered by oral route single time and observed 
for 14 days. Daily the animals were observed for clinical signs and mortality.  
There were no physical and behavioral changes observed in Female Wister 
rats during 14 days. Mortality was not observed in any treatment groups. 
Conclusion: 
The study shows that MATHIYOOSHNA RASAYANAM WITH 
HONEY/GHEE   did not produce any toxic effect at dose of 1000,2000,3000,5000 
and 6000mg/kg to rats. So No-Observed-Adverse-Effect-Level (NOAEL) of 
MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE   is 6000 mg/kg. 
7.0 ABBREVIATIONS 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o  peros 
ML  Milliliter 
%   percentage 
R&D   Research and Development 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
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MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of 
Experiments on Animals 
 
 
8.0 REFERENCES: 
 
1. OECD. Guideline for Testing of Chemicals 423, Acute oral toxicity (acute toxic class 
method). December 2001. 
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SUB-ACUTE TOXICITY STUDY IN WISTER RATS TO EVALUATE 
TOXICITY PROFILE OF MATHIYOOSHNA RASAYANAM WITH 
HONEY/GHEE  
Objective 
 The objective of this study is to evaluate the toxic effects, if any, as a result of the 
repeated once daily oral administration of MATHIYOOSHNA RASAYANAM WITH 
HONEY/GHEE to Wister Albino rats for a minimum period of 28 consecutive days. This 
study will provide information on any major toxic effects, target organs and a rationale for 
concluding the No-Observed-Adverse-Effect-Level (NOAEL) and/or No Observed Effect 
Level (NOEL) / LOEL (Low Observed Effect Level) and risk assessment in humans. 
1. Test Guidelines  
This study plan is prepared as per the following guidelines: 
Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945. 
OECD – 407 – Repeated dose 28-day Oral Toxicity Study in Rodents, Adopted 3 October, 
2008. 
1.1. Test System Details 
Species : Rat 
Strain  : Wister Albino  
Source    : Sree Venkateshwara Enterprises Pvt Ltd, Bangalore  
Age : 6-8 weeks  
Sex : Male / Female (nulliparous and non-pregnant) 
Body weight   : 160.0to 180.0 g 
1.2.  Acclimatization 
Animals will be allowed to acclimatize to the experimental room conditions for five days 
prior to the commencement of dosing. During the acclimatization period, the animals will 
be observed daily for any apparent adverse clinical signs. Prior to assignment to the study 
and commencement of treatment, a detailed physical health examination will be 
performed on all animals by a veterinarian and animals with any evidence of ill health or 
poor physical condition will not selected for the study. 
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1.3. Randomization and Grouping 
On the starting day of dosing, the animals will be weighed and health examination will be 
performed by veterinarian. Animals will be randomly allocated to different groups 
according to their body weight by using MS-Excel sheet as described in the 
randomization SOP. Animals will be divided into four groups (vehicle control, low, 
intermediate, and high dose). At the initiation of the treatment, the body weight variation 
between the groups did not exceed ±20% of the mean weight of each sex. 
1.4. Animal Identification 
In each cage, animals will be identified with numbers by marking at the base of the ear. 
The cages will be identified with an attached colored cage label showing study number, 
study code, group number, sex, dose, strain, species, cage number, route of 
administration and animal number. 
2. Animal Husbandry 
2.1. Animal Welfare and approval 
The study was approved by the IAEC (SLS) and Committee for the Purpose of Control 
and Supervision of Experiments on Animals (CPCSEA registration number: 
Abc14).Their recommendations regarding animal care and handling will be followed. 
2.2. Environmental Conditions 
The temperature of the experimental room will be maintained at 22±30C and the relative 
humidity between 30-70 %. The photoperiod will be 12 hours light and 12 hours dark 
cycles  
2.3. Housing Conditions 
Two animals will be housed in autoclaved polypropylene rat cages (Size in mm=L x W x 
H: 430 x 290 x 160) using paddy husk as the bedding material. Each cage will be fitted 
with a top grill having provision for keeping rodent pellet feed and an autoclaved 
polypropylene water bottle with stainless steel drinking nozzle. Cages will be placed on 
3-tier racks and cage rotation will be performed every week. Cages will be changed at 
least twice a week. The cages and water bottles will be cleaned and autoclave sterilized. 
2.4. Sanitation 
Each day, the floor of the animal room will be swept and mopped. Cages and bedding 
material will be changed once in three days and water bottles will be changed daily. All 
the experimental procedures will be done in a clean environment. 
2.5. Feed 
The experimental animals will be provided with irradiated rodent pellet feed ad libitum 
supplied from Sai feeds Pvt ltd, Chennai . Feed will be withheld for four hours prior to 
blood collection and necropsy. 
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2.6. Drinking Water 
Animals will be provided with filtered drinking water ad libitum  passed through water 
filter system (Aquaguard™) in autoclaved polypropylene bottles. Water bottles will be 
changed daily. Microbial analysis of water will be carried out once monthly and the 
report is maintained in the study file. 
3. Personnel Safety 
All personnel handling animals undergo regular medical examination. Protective clothing 
like apron, face mask, head cap, and gloves will be used to maintain hygienic conditions. 
4. Materials and Methods  
4.1. Preparation of Dose formulation 
The dose formulation will be prepared under aseptic conditions as per SLS, SOP.  
4.2. Route of Administration and Justification 
Administration will be by oral gavage, as it is one of the possible routes of exposure. 
4.3. Frequency and Duration of Administration  
Once daily for 28 consecutive days 
4.4. Dosing Procedure 
The test item will be administered in once daily by oral gavage using a suitable 
intubation cannula fitted with a graduated syringe. The scheme of dosing and sacrifice 
time points are presented in the below below Table. 
4.5. Experimental Procedures 
All experimental procedures will be performed in accordance with the Study plan and 
Standard Operating Procedures (SOPs) of SLS. 
4.6 DOSAGE SCHEDULE: 
The required dose for mice/rat will be calculated by using the standard dose calculation 
procedure from recommended clinical dose. 
CONVERSION FORMULA: 
Human dose is 6000 mg /kg day 
Total clinical dose (a) x conversion factor (b) 0.018 = (c) per 150 gm of Rat 
6000 mg x 2(a) x 0.018 (b) = 108 (c) /150 gm of Rat 
108/1000x150 = 16.2 mg  
Experimental Doses Calculated as per the standard procedures are 
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S.No 
 
Groups 
 
Dose /kg, weight 
 
Volume of administration 
1 Vehicle Control -- 1 ml 
 
2 Therapeutic Dose 16.2 mg /kg 
 
1 ml 
3 Middle  Dose 81mg/kg 1 ml 
 
4 High Dose 405mg/kg 1 ml 
 
Experimental Design 
 
 
 
Group 
No. Group 
Dose                          
(mg/kg  
b.wt /day) 
No. of Animals 
Male Female 
G1 Vehicle control HONEY/GHEE 5 5 
G2 Low dose of   VATHATHIRKU 
LEGHIYAM WITH HONEY/GHEE 
               
16.2m g /kg 
 
5 5 
G3 
Intermediate dose MATHIYOOSHNA 
RASAYANAM WITH 
HONEY/GHEE   
81mg/kg 5 5 
G4 
High dose  MATHIYOOSHNA 
RASAYANAM WITH 
HONEY/GHEE   
405mg/kg 5 5 
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5. Observations 
Animals will be observed daily throughout the treatment period at regular intervals. During 
the treatment period, animals will be observed twice daily for any clinical signs of toxicity, 
morbidity and mortality. All the surviving animals will be sacrificed at the end of scheduled 
period and subjected to gross necropsy and histopathological evaluations. 
5.1.Clinical Signs 
All the animals will be subjected to cage-side (home-cage) observations twice a day for 
any clinical signs of toxicity, preferably at the same time each day and considering the 
peak period of anticipated effect. In addition to home cage observations, a detailed 
clinical examination will be performed once prior to dosing and weekly thereafter during 
treatment period.  
5.2. Morbidity/ Mortality 
All animals will be examined twice a day for mortality and signs of morbidity.  
5.3. Body Weights 
Body weights will be recorded at the beginning of acclimatization, before randomization, 
there after at weekly intervals and at the time of necropsy. 
5.4. Feed Consumption 
Feed consumption will be calculated on a weekly basis throughout the study period. 
5.5. Hematology and Clinical Biochemistry  
Hematology and clinical biochemistry tests will be performed with terminally collected 
blood samples on day-29 from all animals. Animals will be deprived of feed overnight 
and blood samples will be collected by tapping the ear for visibility of the vein site and 
inserted the needle into the marginal ear vein and collected the blood into micro 
centrifuge tube. Approximately 0.5 ml of blood will be collected in vials containing 1% 
EDTA (20µl) as an anticoagulant for hematological analysis. 
Approximately 2 ml blood will be collected from each animal in micro centrifuge tubes 
containing 15µl of heparin (19 units) and the plasma will be separated by centrifugation 
at 4000 rpm for ten minutes at 4oC. The plasma will be stored at -20 oC ± 2 and used for 
all clinical chemistry analysis. 
5.6. Hematology 
Erythrocyte count (RBC), Total Leucocyte count (WBC), Hemoglobin (Hb), Hematocrit 
(HCT), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), 
Mean Corpuscular Hemoglobin Concentration (MCHC) and Platelet (PLTC). 
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5.7. Clinical Biochemistry  
Glucose, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline 
phosphatase (ALP), Total protein, Albumin, Creatinine, Urea, Cholesterol, Triglycerides, 
Sodium, Potassium, Calcium, and  Chloride. 
5.8 Pathology 
All animals will be euthanized by CO2 asphyxiation and subjected to necropsy under the 
supervision of the veterinary pathologist. Different tissues/organs of thoracic, abdominal 
and cranial cavities will be examined for any gross pathological changes. Tissues from 
vehicle control and high dose groups will be subjected to detailed histopathological 
analysis (Ovaries/ testes,  kidneys, liver, lungs). The organs will be fixed using Bouin’s 
(reproductive organs) and 10% neutral buffered formalin (kidneys, liver, spleen, 
lungs).Processing of tissue will be done by spin tissue processer, embedding of the tissue 
by tissue embedder. The tissues will be initially trimmed to 10-20µ thickness and later 3-
6µ to obtain thinner tissue sections by using rotary microtome. Haematoxylin and Eosin 
staining will be performed for all tissues. 
5.8. Organ Weights 
Absolute weights of adrenal glands, brain, ovaries/testes, epididymis/uterus, heart, 
kidneys, liver, spleen and lungs will be recorded for all the animals after trimming 
adherent tissue immediately after dissection from the animal. Paired organs will be 
weighed together. Relative weights of these organs against fasting animal body weights 
will be calculated and reported. 
6. Data Compilation  
Data will be summarised in a tabular form showing the number of animals, experimental 
design, dose groups, dose volume and concentrations, test item and vehicle control details. 
All findings like clinical signs, mortality and morbidity data, time of death, body weights, 
feed consumption, clinical signs, and necropsy and pathology observations will be recorded 
and given in the final report. One original copy of the final report is issued to the sponsor.  
7. Statistical Analysis 
All the parameters of treated groups of both sex, viz. body weight, feed consumption, organ 
weights (absolute and relative), biochemical parameters, and hematology parameters will be 
analyzed using SPSS software, version 16.0 by using one-way ANOVA test with multiple 
comparison (vehicle controls treated groups) in the study report, and p value < 0.05 is 
considered as statistically significant.  
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MATERIALS AND METHODS 
         ESTIMATION OF HEMATOLOGICAL PARAMETERS: 1 
Collection of blood for hematological studies 
After the treatment period the animals were anaesthetized by ketamine hydrochloride and the blood 
was collected from Retro-orbital sinus by using capillary into a centrifugation tube which contains 
EDTA for haematological parameters The haematological parameters like RBC, WBC and Hb 
percentage, Differential cell count, MCV, MCHC, Hematocrit, MCH, platelet count were estimated by 
the following procedures. 
1. ENUMERATION OF RED BLOOD CELLS: 1    Ramnic 2007) 
Reagents : RBC diluting fluid 
       Procedure: 
         Using a red blood cell pipette of haemocytometer, well mixed blood was drawn up to 0.5 mark and RBC 
diluting fluid was taken up to mark II. The fluid blood mixture was shaken and transferred onto the counting 
chamber. The cells were allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get dried. 
Using 45X or high power objective the RBC’s were counted uniformly in the larger corner squares.   
The cells were expressed as number of cells x1012/l 
2. ENUMERATION OF WBC: 2    John 1972) 
      Reagents: 
 Turk’s fluid: Turk’s fluid was prepared by mixing 2ml of acetic acid with 100 ml of distilled 
water. To this 10 drop of aqueous methylene blue 3 %    w/v) was added. This solution haemolysis the red 
cells due to acidity so that counting of white cells becomes easy. 
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Procedure:     
              Using a white blood cell pipette of haemocytometer, well mixed blood was drawn up to 0.5 mark and WBC 
diluting fluid was taken up to mark II. The fluid blood mixture was shaken and transferred onto the counting 
chamber. The cells were allowed to settle to the bottom of the chamber for 2 min. See the fluid does not get dried. 
 Using 10X or low power objective the WBC’s were counted uniformly in the larger corner squares.  
 The cells were expressed as number of cells/10mm. 
3. DIFFERENTIAL LEUCOCYTE COUNT: 3      John 1972) 
Reagent: 
              Leishmann’s stain: 150mg of powdered leishmann’s stain was dissolved in 133ml of acetone free methanol. 
Procedure: 
 A blood film stained with leishmann’s stain was examined under oil immersion and the different types of 
WBCs were identified. The percentage distribution of these cells was then determined. Smears were made from 
anticoagulant blood specimens and stained with leishmann’s stain. The slides were preserved for counting the 
number of lymphocytes and neutrophils, per 100 cells were noted.  
 From the different Leukocyte count and WBC count, absolute lymphocyte and neutrophil count were 
calculated. 
                                 Number of neutrophils  
 Absolute neutrophil count =   _______________________________   x  TWBC 
                             100  
                                                                  Number of lymphocytes  
 Absolute lymphocyte count =   _______________________________ x TWBC 
                             100 
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DETERMINATION OF BIOCHEMICAL PARAMETERS: 
 
For assessment of biochemical parameters, blood samples were collected from the animals by puncturing the 
retro-orbital plexus and centrifuged. The serum collected after centrifugation was analyzed for various biochemical 
parameters like SGOT, SGPT, ALP,TC.TG,HDL All of the above biochemical parameters were estimated using 
semi autoanalyzer (Photometer 5010 V5+, Germany) with enzymatic kits procured from Piramal Healthcare limited, 
Lab Diagnostic Division, Mumbai, India. 
1. Total Cholesterol (TC)  
 Principle 
Determination of cholesterol is done after enzymatic hydrolysis and oxidation. The colorimetric indicator is 
quinoneimine, which is generated from 4-aminoantipyrine and phenol by hydrogen peroxide under the catalytic 
action of peroxidase (trinder’s reaction). 
Cholesterol ester + H2O       CHE       Cholesterol + Fatty acid 
Cholesterol + O2          CHO      Cholesterol-3-one +H2O2 
2H2O2  + 4- Amino antipyrine + Phenol      POD          Quinonelimine + 4 H2O2 
Method  
 CHOD-PAP: Enzymatic photometric test 
Table 6: Reagents 
Goods buffer (pH 6.7) 50 mmol/ l 
Phenol 5 mmol/l 
4-aminoantipyrine 0.3 mmol/l 
Cholesterol estrase >  200 U/l 
Cholesterol oxidase >  100 U/l 
Peroxidase 3 KU/l 
Standard (5.2 mmol/l) 
 
Assay procedure 
a. 1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b.  Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C   for 5 min. 
d. Read the test sample. 
 
NORMAL RANGE: < 200 mg/dl in serum.      
1. Deeg R, Ziegenhorn J, Kinetic enzymatic method for automated determination of total cholesterol in serum, 
Clin. Chem., 1983, 29:1798-802. 
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2. Triglycerides 
Principle 
Determination of triglycerides (TG) alters enzymatic splitting with lipoprotein lipase. Indicator is quinoneimine 
which is generated from 4-aminoantipyrine and 4- chlorophenol by hydrogen peroxidase under the catalytic action 
of peroxidase. 
Triglycerides              LPL           Glycerol + fatty acid 
Glycerol + ATP              GK            Glycerol-3-phosphate+ ADP 
Glycerol-3-phosphate +O2         GPO         Dihydroxyaceton phosphate + H2O2 
2H2O2  + 4- Amino antipyrine + 4- chlorophenol         POD     Quinonelimine + HCL + 4H2O2 
Method 
 Colorimetric enzymatic test using glycerol-3-phosphate-oxidase (GPO). 
Reagents 
Components and concentrations in the test Goods buffer pH 7.2, 50 mmol/ l 
Table 7: Reagents 
4-chloroPhenol 4 mmol/l 
ATP 2 mmol/l 
Mg2+ 15 mmol/l 
Glycerokinase > 0.4 Kµ/l 
Peroxidase > 2 Kµ/l 
Lipoprotein lipase > 4 Kµ/l 
4-aminoantipyrine 0.5 mmol/l 
Glcerol-3-phosphate- oxidase > 1.5Kµ/l 
Standard (2.3 mmol/l) 
 
Assay procedure 
a.  1 ml (1000 µl) of reagent-1 is taken in a 5 ml test tube. 
b. Added 0.01 ml (10 µl) of serum. 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample. 
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Normal Range: < 200 mg/dl in serum. 
1. Cole T.G, Klotzsch S.G, Mcnarmara J, Measurement of triglyceride concentration, In 
Rifai N, Warnick G.R, Dominiczak M.H, Handbook of lipoprotein testing, 
Washington:AACC, Press, 1997, 115-26. 
3. HDL Cholestrol 
 Principle  
Chylomicrons, VLDL and LDL are precipitated by adding phosphotungstic acid and 
magnesium ions to the sample. Centrifugation leaves only the HDL in the supernatant. The 
cholesterol content in it is determined enzymatically. 
Method 
Phosphotungstic acid precipitation method. 
Table 8: Reagents 
Phosphotungstic acid 0.55 mmol/l 
Magnesium chloride 25 mmol/l 
Assay procedure 
A.  Preparation of supernatant for the HDL-CHL estimation 
    Added 200 µl of serum to the 500 µl of HDL-Cholesterol precipitating reagent (from HDL kit) 
in 1.5 ml centrifuge tube and mixed well. Centrifuged the above solution at 4000 rpm for 10 min. 
B. Preparation of test sample for the estimation of HDL-Cholesterol 
a. Taken 1000 µl of reagent-1 (from cholesterol kit) in a 5 ml test tube. 
b. Added, 100 µl of supernatant from above centrifuged solution 
c. Mixed well and incubated at 37◦C for 15 min. 
d. Read the test sample.  
Normal Range: > 60 mg/dl in serum. 
1. Friedewald W.T, Levy R.T, Frederickson D.S, Estimation of VLDL and LDL cholesterol, 
Clin. Chem., 1972, 18:499-502. 
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4. ESTIMATION OF SERUM GLUTAMATE PYRUVATE TRANSAMINASES 
(SGPT/ ALT) 
1. Determination of aspartate aminotransferase (AST) 
      Aspartate aminotransferase, also known as Glutamate Oxaloacetate Transaminase (GOT) 
catalyses the transamination of L-aspartate and α keto glutarate to form oxaloacetate and L- 
glutamate. Oxaloacetate formed is coupled with 2,4- Dinitrophenyl hydrazine to form hydrazone, 
a brown coloured complex in alkaline medium which can be measured colorimetrically. 
Reagents  
Buffered aspartate  (pH 7.4); 2,4- DNPH reagent;  4N sodium hydroxide;  working pyruvate 
standard; solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with purified water). 
Procedure  
 Rietman and Frankle method was adopted for the estimation of SGOT. (Reitmann S, 
Frankel S, 1957. A colorimetric method for the determination of serum oxaloacetic and glutamic 
pyruvate transminases. American Journal of Clinical Pathology.28: 56-63.The reaction systems 
used for this study included blank, standard, test (for each serum sample) and control (for each 
serum sample). 0.25 ml of buffered aspartate was added into all the test tubes. Then 0.05 ml of 
serum was added to the test group tubes and 0.05 ml of working pyruvate standard into the 
standard tubes. After proper mixing, all the tubes were kept for incubation at 37oC for 60 min, 
after which 0.25 ml each of 2,4- DNPH reagent was added into all the tubes. Then, 0.05 ml of 
distilled water and 0.05 ml of each serum sample was added to the blank and the serum control 
tubes respectively. The mixture was allowed to stand at room temperature for 20 min. After 
incubation, 2.5 ml of solution I was added to all test tubes. Mixed properly and optical density 
was measured in a spectrophotometer at 505 nm within 15 min. 
The enzyme activity was calculated as:-  
AST (GOT) activity in IU/L) = [(Absorbance of test - Absorbance of control)/ (Absorbance of 
standard - Absorbance of blank)] x concentration of the standard         
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2.  Determination of alanine aminotransferase (ALT) 
 Alanine aminotransferase, also known as Glutathione Peroxidase (GPT) catalyses the 
transamination of L-alanine and α keto glutarate to form pyruvate and L- Glutamate. Pyruvate so 
formed is coupled with 2,4 – Dinitrophenyl hydrazine to form a corresponding hydrazone, a 
brown coloured complex in alkaline medium which can be measured colorimetrically. 
Reagents 
Buffered alanine (pH 7.4), 2,4–DNPH, 4N sodium hydroxide, working pyruvate standard, 
solution I (prepared by diluting 1 ml of reagent 3 to 10 ml with purified water). 
Procedure  
 Rietman and Frankle method was dopted for the estimation of SGPT. The reaction 
systems used for this study included blank, standard, test (for each serum sample) and control 
(for each serum sample). 0.25 ml of buffered alanine was added into all the test tubes. This was 
followed by the addition of 0.05 ml of serum into the test group tubes and 0.05 ml of working 
pyruvate standard into the standard tubes. After proper mixing, all the tubes were kept for 
incubation at 37oC for 60 minutes, after which 0.25 ml each of 2,4- DNPH reagent was added 
into all the tubes. Then, 0.05 ml of distilled water and 0.05 ml of each serum sample was added 
to the blank and the serum control tubes respectively. The mixture was allowed to stand at room 
temperature for 20 min. After incubation, 2.5 ml of solution I was added to all test tubes. Mixed 
properly and optical density was read against purified water in a spectrophotometer at 505 nm 
within 15 min. 
The enzyme activity was calculated as:- ALT (GPT) activity in IU/L) = [(Absorbance of test - 
Absorbance of control)/ (Absorbance of standard - Absorbance of blank)] x concentration of the 
standard.        
            
 
143 
 
3. Determination of alkaline phosphatase (ALP) 
Alkaline phoshatase from serum converts phenyl phosphate to inorganic phosphate and phenol at 
pH 10.0. Phenol so formed reacts in alkaline medium with 4-aminoantipyrine in presence of the 
oxidising agent potassium ferricyanide and forms an orange-red coloured complex, which can be 
measured spectrometrically. The color intensity is proportional to the enzyme activity. 
Reagents: 
Buffered substrate 
Chromogen Reagent 
Phenol Standard, 10 mg% 
Procedure: 
  ALP was determined using the method of Kind (Kind PRM, King EJ, 1972. In-vitro 
determination of serum alkaline phosphatase. Journal of Clinical Pathology 7: 321-22\). The 
working solution was prepared by reconstituting one vial of buffered substrate with 2.2 ml of 
water. 0.5 ml of working buffered substrate and 1.5 ml of purified water was dispensed to blank, 
standard, control and test. Mixed well and incubated at 370C for 3 min. 0.05 ml each of serum 
and phenol standard were added to test and standard test tubes respectively. Mixed well and 
incubated for 15 min at 370C. Thereafter, 1 ml of chromogen reagent was added to all the test 
tubes. Then, added 0.05 ml of serum to control. Mixed well after addition of each reagent and the 
O.D of blank, standard, control and test were read against purified water at 510 nm. 
Serum alkaline phosphatase activity in KA units was calculated as follows  
[(O.D. Test-O.D. Control) / (O.D. Standard- O.D. Blank)] x 10 
 
4. Determination of bilirubin  
  In toxic liver, bilirubin levels are elevated. Hyperbilirubinemia can result from impaired 
hepatic uptake of unconjugated bilirubin, such a situation can occur in generalized liver cell 
injury, certain drugs (e.g Rifampin and probenecid) interfere with the rat uptake of bilirubin by 
the liver cell and may produce a mild unconjugated hyperbilirubinemia. Bilirubin level rises in 
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diseases of hepatocytes, obstruction to bilirubin excretion into duodenum, in haemolysis and 
defects of hepatic uptake and conjugation of Bilirubin pigment such as Gilbert’s disease.  
Elevation of total serum bilirubin may occur due to:  
1.Excessive haemolysis or destruction of the red blood cells.Eg:Haemolytic disease of the new 
born. 
2.Liver diseases.Eg.Hepatitis and cirrhosis. 
3.Obstruction of the biliary tract.Eg.Gall stones. 
The method is based on the reaction of Sulfonilic acid with sodium nitrite to form azobilirubin 
which has maximum absorbance at 546nm in the aqueous solution. The intensity of the color 
Produced is directly proportional to the amount of direct or total bilurubin concentration present in the 
sample. 
Reagents 
1. Diazo A-(Reagent-R1) :Ready to use 
2. Diazo B-(Reagent-R2):Ready to use 
3. Bilirubin Activater :Ready to use 
Procedure 
  Kind & King’s method was followed for the estimation of Bilirubin. Five hundred µl of working reagent 
was added to 50 µl of rat serum & incubated for 5 min at 37°C. Absorbance was measured AT 546 NM in semi auto 
analyzer against the standard. 
The Bilirubin content was calculated using the following equation: 
Total bilirubin (mg/dt) = Abs of the sample blank x 15. 
Direct Bilirubin(mg/dt) = Abs of sample blank x 10. 
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5. ESTIMATION OF UREA 
Urea is the nitrogen-containing end product of protein catabolism. States associated with elevated levels of 
urea in blood are referred to as hyper uremia or azotemia.  
Method 
Estimation of urea was done by Urease-GLDH: enzymatic UV test.  
Principle 
Urea + 2H2O     Urease       2NH4 + 2HCO3 
2- Oxoglutarate +NH4+ +NADH      GLDH      L- Glutamate +NAD+ + H2O                                         
Table 14. Reagents 
 
 
 
 
 
 
 
 
 
Procedure 
a. Take 1000 µl of reagent-1 and 250 µl of reagent-2 in 5 ml test tube. 
b. To this, add 10 µl of serum. 
c. Mix well and immediately read the test sample at 340 nm Hg 334 nm Hg 365 nm optical path 1 cm against 
reagent blank (2-point kinetic). 
d. And note down the value. 
Normal range: 10 – 50 mg/dl. 
  
R 1 
TRIS pH 7.8 120  mmol/l 
2-Oxoglutarate 7 mmol/l 
ADP 0.6 mmol/l 
Urease ≥ 6 KU/l 
GLDH ≥ 1 KU/l 
R 2 NADH 0.25 mmol 
R 3 Standard 40 mg/dl 
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6. ESTIMATION OF URIC ACID 
Uric acid and its salts are end products of the purine  metabolism. In gout the most common complication 
of  hyperuricemia, ie. Increased serum levels of uric acid lead to formation of  monosodium urate crystal around the 
joints. 
Method  
Enzymatic photometric test using  TOOS (N ethyl- N (hydroxyl -3- sulfopropyl)-m- toluidin) 
Principle  
Uric acid + H2O + O2       uricase         Allantoin +CO2 +H2O2 
TOOS + 4 aminoantipyrine + 2H2O2      POD       Indamine + 3H2O 
Table 15.reagents 
R1 Phosphate buffer pH 7.0 100mmol/l 
TOOS 1mmol/l 
Ascorbate oxidase ≥1 KU/l 
R2 Phosphate buffer pH 7.0 100mmol/l 
4- amino antipyrine 0.3mmol/l 
K4 (Fe( CN)6) 10µmol/l 
Peroxidase ≥1KU/l 
Uricase ≥50U/l 
Procedure 
a. Take 800µl of  reagents -1 in a2ml centrifuge tube. 
b. To this add 20µl of serum. 
c. Mix well and incubate at 30°c for 5 minutes. 
d. Then add 200µl of reagent2 
e. Mix well incubate for 5min at 37°c 
f. Measure the not down the values. 
Normal range: 1.9-8.2mg/dl 
7. ESTIMATION OF CREATININE:  
Principle: 
Creatinine forms a coloured complex with picrate in alkaline medium.  
The rate of formation of the complex is measured.  
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Reagents: 
Reagent 1    Standard Creatinine (2mg/100ml) 
Reagent 2    Picric acid solution. 
Reagent 3     sodium hydroxide solution  
Procedure: 
 Take 500 µl of reagent -2 and 500 µl of reagent -3 in a 5ml test tube. To this add 100 µl of serum. Mix well 
and immediately read the test sample at Hg 492 nm 1cm light path and note down the values.  
Normal range is 0.6 -1.1 mg/dl. 
 
TABLE: 1   EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MATHIYOOSHNA RASAYANAM WITH 
HONEY/GHEE ON BODY WEIGHT IN Gram (PHYSICAL PARAMETER) 
EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE 
ON BODY WEIGHT IN Gram (PHYSICAL PARAMETER). 
GPs Control Low Dose Middle Dose High Dose 
 
Male Female Male Female Male Female Male Female 
1stwk 
146.7± 
0.8819 
150.3± 
3.283 
154± 
1.155 
150.3± 
1.453 
146± 
1.155 
145.7± 
1.202 
147± 
2.082 
151.7± 
2.963 
2ndwk 153± 
2.082 155±4 
159.3± 
0.8819 
155.3± 
1.453 
151.7± 
1.453 
153.3± 
2.333 
153.3± 
2.186 
158± 
2.887 
3rdwk 
163.3± 
3.712 
165± 
3.512 
166.3± 
1.333 
166.3± 
1.453 
160± 
3.055 
162.3± 
1.764 
161.3± 
1.764 
165.3± 
3.18 
4thwk 
171.7± 
1.453 
 
172.7± 
2.404 
 
174± 
2.646 
 
174.3± 
0.8819 
 
171.3± 
2.186 
 
169.3± 
3.756 
 
176.3± 
0.8819 
 
173.7± 
2.603 
 
 
Values are expressed as the mean ± S.D 
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3rd WK BODY WEIGHT
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 EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MATHIYOOSHNA RASAYANAM WITH 
HONEY/GHEE ON FOOD INTAKE In Gram  
Effect Of Sub Acute Doses (28 Days) 0f MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE ON FOOD 
INTAKE IN gms 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 
60 12 24 15 10 34 28 18 
DAY2 
80 8 58 56 31 38 62 28 
DAY3 
32 34 14 44 52 38 30 66 
Day 4 
22 42 22 34 24 56 18 18 
DAY5 
58 38 26 18 6 34 10 44 
Day 6 
38 58 64 58 68 60 12 32 
DAY7 
34 62 74 61 88 50 14 58 
DAY8 
64 58 62 18 40 32 44 26 
Day 9 
56 56 64 22 60 80 56 48 
DAY10 
74 24 58 45 56 74 62 64 
Day 11 
62 70 56 68 58 44 54 30 
DAY12 
64 62 48 38 62 54 60 56 
DAY13 
74 54 78 38 44 72 56 57 
Day 14 
74 72 56 54 50 38 19 16 
DAY15 
56 56 28 64 71 48 36 82 
Day 16 
80 56 77 54 42 56 78 56 
DAY17 
56 56 74 64 58 56 78 44 
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DAY18 
64 62 54 34 56 45 52 72 
Day 19 
64 64 58 62 56 50 48 88 
DAY20 
56 72 20 34 75 56 16 35 
DAY21 
64 45 64 62 68 34 34 56 
Day 22 
78 56 18 42 58 28 56 64 
DAY23 
58 18 64 34 56 42 46 67 
DAY24 
64 30 34 68 78 80 54 46 
Day 25 
80 34 55 64 44 42 40 88 
DAY26 
46 58 56 56 64 45 64 52 
DAY27 
80 56 32 58 38 36 68 56 
DAY28 
74 62 58 61 34 35 88 24 
 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MATHIYOOSHNA RASAYANAM WITH 
HONEY/GHEE ON WATER INTAKE IN ml 
Effect Of Sub Acute Doses (28 Day) 0f MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE on Water 
Intake in ml 
Groups Control Low Dose Middle Dose High Dose 
 
DAY Male Female Male Female Male Female Male Female 
Day 1 
70 100 70 75 50 70 85 140 
DAY2 
50 85 105 60 140 105 85 60 
DAY3 
70 150 130 60 165 130 85 60 
Day 4 
80 100 70 90 90 70 40 55 
DAY5 
130 70 130 210 75 60 60 70 
Day 6 
65 60 50 70 70 85 90 50 
DAY7 
60 70 70 80 90 55 50 130 
DAY8 
75 50 130 60 70 55 50 70 
Day 9 
130 20 110 40 130 85 80 55 
DAY10 
70 50 65 130 60 70 40 130 
Day 11 
60 60 80 60 70 30 55 70 
DAY12 
45 80 70 60 60 40 75 40 
DAY13 
55 50 50 60 30 60 40 65 
Day 14 
85 65 40 40 20 70 65 60 
DAY15 
65 80 60 65 60 70 20 60 
Day 16 
30 70 45 60 60 40 50 65 
DAY17 
30 60 80 60 20 55 40 70 
153 
 
DAY18 
40 90 60 80 170 140 65 60 
Day 19 
20 95 70 115 185 140 125 120 
DAY20 
50 75 50 70 90 65 60 95 
DAY21 
130 90 50 95 85 70 60 85 
Day 22 
105 70 60 90 60 140 40 60 
DAY23 
65 80 95 70 50 60 95 60 
DAY24 
60 70 50 60 70 110 90 75 
Day 25 
110 85 60 70 60 130 60 125 
DAY26 
60 50 70 110 40 70 110 90 
DAY27 
70 40 110 60 140 70 90 50 
DAY28 
60 85 75 60 125 65 50 110 
Values are expressed as the mean ± S.D 
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EFFECT OF SUB-ACUTE DOSES (28 DAYS) OF MATHIYOOSHNA RASAYANAM WITH 
HONEY/GHEE ON ORGAN WEIGHT in gm 
 
 
Values arae expressed as mean ± SEM Statistical significance (p) calculated by one way 
ANOVA followed by dunnett’s (n=6); nsp>0.05, *p<0.05, **p<0.01, ***p<0.001, calculated by 
comparing treated groups with control group.  
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GROUP CONTROL 
 
Low Dose 
 
Middle Dose 
 
High Dose 
LIVER  WEIGHT 7.124±0.6045 4.894±0.6955 5.145±0.91 5.955±0.133 
KIDNEY 
WEIGHT 
L 1.152±0.07 0.738±0.05 0.696±0.022 0.98±0.032 
R 1.434±0.2445 0.737±0.045 0.6965±0.0175 0.921±0.005 
HEART WEIGHT 0.9325±0.0535 0.8555±0.0105 0.85±0.022 0.975±0.053 
LUNGS  WEIGHT 2.605±0.217 1.107±0.281 1.54±0.116 2.06±0.373 
TESTIS WEIGH 2.346±0.021 2.233±0.093 1.831±0.147 1.762±0.2165 
UTERUS 0.724±0.068 0.6225±0.0705 0.548±0.114 0.615±0.053 
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE 
ON HAEMATOLOGICAL PARAMETERS 
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Effect Of Sub Acute Doses (28 Day) 0f MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE On 
HAEMATOLOGICAL PARAMETERS 
Groups Control Low Dose Middle Dose High Dose 
Rbc (X103/µl)  
 
5.33±0.6071 
 
6.403±0.2043 
 
5.96±0.1537 
 
6.213±0.2559 
 
Wbc(X106/µl)  
 
11.17±0.6196 
 
11.87±0.5807 
 
13.73±0.4497** 
 
13.3±0.255* 
 
Hb (g/dl) 16.4±0.912 
 
16.43±1.209 
 
13.5±0.216 
 
14.43±0.6933 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE 
ON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
 
Groups Control Low Dose Middle Dose High Dose 
Total 
Bilirubin(mg/dl) 
 
0.6233±0.07219 
 
 
0.8633±0.1126 
 
 
0.79±0.03464 
 
 
1.013±0.0318* 
 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.      
    
TOTAL BILRUBIN
CO
NT
RO
L
LO
W 
DO
SE
MI
DE
L D
OS
E
HIG
E D
OS
E
0.0
0.5
1.0
1.5
m
g/
dl
 
 
 
 
 
 
160 
 
EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE 
ON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
 
Groups Control Low Dose Middle Dose High Dose 
SGOT (U/L) 85.95±5.34 
 
133.2±21.91 
 
77.9±8.603 
 
81.35±1.761 
 
SGPT (U/L) 69.79±9.073 
 
45.4±2.194 
 
48.15±12.62 
 
38.15±2.281 
 
ALP (U/L) 308.2±14.17 
 
321.8±9.093 
 
247.8±6.091 
 
267.3±1.097 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p) calculated by one 
way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 
calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE 
ON BIOCHEMICAL PARAMETER (LIVER PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
 
SGOT (U/L) 
 
85.95±9.25 
 
133.2±37.95 
 
77.9±14.9 
 
81.35±3.05 
 
SGPT (U/L) 69.79±15.72 
 
45.4±3.8 
 
48.15±21.85 
 
38.15±3.95 
 
ALP (U/L) 308.2±24.55 
 
321.8±15.75 
 
247.8±10.55 
 
267.3±1.9 
 
 
Values are expressed as the mean ± S.D; Statistical significance (p) calculated by one 
way ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 
calculate by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE 
ON BIOCHEMICAL PARAMETER (KIDNEY PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Urea (mg/dl) 26.03±0.5831 
 
33.45±0.1443 
 
39.08±0.6813 
 
26.74±0.6524 
 
Uric acid (mg/dl) 1.615±0.07794 
 
1.2±0.02309** 
 
1.31±0.04041** 
 
1.64±0.05774 
 
Creatinine 
(mg/dl) 
0.33±0.02887 
 
0.275±0.002887 
 
0.23±0.01155 
 
0.29±0.05196 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
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EFFECT OF SUB ACUTE DOSES (28 DAY) 0F MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE 
ON BIOCHEMICAL PARAMETER (LIPID PROFILE) 
Groups Control Low Dose Middle Dose High Dose 
Total cholesterol 
(mg/dl) 
34.3±2.078 
 
44.83±0.4333* 
 
44.93±4.648* 
 
41.2±0.6351 
 
Triglycerides 
(mg/dl) 
99.3±1.225 
 
72.03±1.776*** 
 
68.4±1.042*** 
 
78.9±2.164*** 
 
HDL-
Cholesterol 
(mg/dl) 
10.61±0.3955 
 
6.75±1.21* 
 
7.133±0.895* 
 
5.133±0.2603** 
 
Values are expressed as the mean ± S.D; Statistical significance (p)calculated by one way 
ANOVA  followed by dunnett’s ns- no significant  *P< 0.001,  **P < 0.01, ***P < 0.05 calculate 
by comparing treated group with CONTROL group.         
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RESULTS: 
    CLINICAL SIGNS: 
All animals in this study were free of toxic clinical signs throughout the dosing   period 
of 28 days. 
 Mortality: 
All animals in control and in all the treated dose groups survived throughout the dosing 
period of 28 days. 
 Body weight: 
Results of body weight determination of animals Table-1 from control and different dose 
groups exhibited comparable body weight gain throughout the dosing period of 28 days. 
Food consumption: 
During dosing and the post-dosing recovery period, the quantity of food consumed by 
animals from different dose groups was found to be comparable with that by control animals. 
Organ Weight: 
Group Mean Relative Organ Weights (% of body weight) are recorded in Table No.4 
Comparison of organ weights of treated animals with respective control animals on day 29 was 
found to be comparable similarly. 
Hematological investigations: 
The results of hematological investigations (Table 4) conducted on day 29 revealed 
following significant changes in the values of different parameters investigated when compared 
with those of respective controls; however, the increase or decrease in the values obtained was 
within normal biological and laboratory limits or the effect was not dose dependent. 
Biochemical Investigations: 
Results of Biochemical investigations conducted on days 29 and recorded in Table 2 
revealed the following significant changes in the values of hepatic serum enzymes studied. When 
compared with those of respective control. However, the increase or decrease in the values 
obtained was within normal biological and laboratory limits. 
Histopathology: 
In histopathological examination, revealed normal architecture in comparison with 
control and treated animal. 
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 DISCUSSION: 
1)  All the animals from control and all the treated dose groups up to 500 mg/kg survived 
throughout the dosing period of 28 days. 
2)  No signs of toxicity were observed in animals from different dose groups during the dosing 
period of 28 days. 
3)  Animals from all the treated dose groups exhibited comparable body weight gain with that of 
controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be comparable throughout the 
dosing period of 28 days 
5)   Haematological analysis conducted at the end of the dosing period on day 29, revealed no 
abnormalities attributable to the treatment. 
6) Biochemical analysis conducted at the end of the dosing period on day 29 no abnormalities 
attributable to the treatment. 
7) Organ weight data of animals sacrificed at the end of the dosing period was found to be 
comparable with that of respective controls. 
8) Histopathological examination revealed normal architecture in comparison with control and 
treated animal. 
 SUMMARY AND CONCLUSION:  
In conclusion MATHIYOOSHNA RASAYANAM WITH HONEY/GHEE can be 
considered safe, as it did not cause either any lethality or adverse changes with general behavior 
of rats and also there were no observable detrimental effects (100 to 300 mg/kg body weight) 
over a period of 28 days. Our results have demonstrated that the MATHIYOOSHNA 
RASAYANAM WITH HONEY/GHEE is relatively safe when administered orally in rats. 
9.0 ABBRVIATION 
No.   Number 
Mg  Milligram 
Kg   Kilogram 
LD50  Lethal Dose 50 
p.o.  peros 
mL  Milliliter 
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%   percentage 
R&D   Research and Development 
EDTA  Ethylene Diamine Tetra Acetic Acid 
M   Male 
g%   Gram percentage 
g  Gram 
NOAEL  No-Observed-Adverse-Effect-Level 
MLD   Minimum Lethal Dose 
MTD   Maximum Tolerated Dose 
OECD  Organisation of Economic Co-operation and Development 
CPCSEA  Committee for the Purpose of Control and Supervision of Experiments on 
Animals 
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HISTOPATHOLOGY   -  TOXICITY STUDY 
SPECIMEN     : A) Liver.    Group –    :  Mathiyooshna rasayanam 
 
                                                       
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
 Section from liver shows lobular architecture with interface hepatitis. Individual Hepatocytes shows 
reactive atypia. Portal triad shows no significant pathology. Central vein and Sinusoids show dilatation. 
10x shows lobular architecture with central vein 
congestion 
10x shows lobular architecture 
10x shows normal lobular architecture 40x normal hepatocytesshows 
40x shows interface hepatitis 40x shows mild periportal inflammation (2) 
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SPECIMEN    :  B) spleen. 
Group – :  Mathiyooshna rasayanam 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
Section studied from spleen shows normal white pulp and red pulp. Red pulp shows pigment laden 
macrophages and congested vessels. White pulp shows lymphocytic infiltrates forming germinal centre. 
The pencillar artery shows normal morphology. Megakaryocytes 
10x shows normal red and white pulp 10x shows normal spleen 
40 xshows normal lymphocytic infiltrates with 
megakaryocytes 
40x shows megakaryocytes 
40x shows normal morphology of white pulp 40x shows red pulp with lymphocytic infiltration 
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SPECIMEN  :  C)  Kidney. 
Group – :  Mathiyooshna rasayanam 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE: 
 
Section from kidney shows both cortex and medulla. Glomeruli and tubules shows no significant 
pathology. Interstitium shows no significant pathology. Blood vessels show congestion. There is no 
evidence of toxic changes. 
  
10x shows mild interstitial lymphocytic infiltration 10x shows normal kidney cortex and medulla 
40x hsows normal interstitium 
40x shows blood vessels congestion 
40x shows mild inflammation 
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SPECIMEN  :  D) Testis 
Group – :  Mathiyooshna rasayanam 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MICROSCOPIC APPEARANCE:  
Section from testes with seminiferous tubules showing maturation arrest with lacking of 
spermatogenesis.  
10x shows focal maturation arrest 40x show smaturation arrest 
40x shows normal semini ferous tubules 40x shows normal spermatogenesis 
40x shows normal spermatogenesis 
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Name   : 
Ref. No. : [H0 332A/18] 
 
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
              TOXICITY STUDY            
 
 
SPECIMEN                   :  Liver 
    
Group –                   : Dr.Aysha- M.R. 
 
GROSS APPEARANCE: 
 
                     Received a specimen of liver measuring 3.5x2.3x1.2cms.                     
  
(PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section from liver shows normal lobular architecture with mild interface hepatitis. Individual 
Hepatocytes shows no significant pathology. Portal triad shows mild periportal inflammation. Central 
vein shows dilated and congested. Sinusoids show dilatation. 
 
 
        
                                                                                                                             
Dr.C.R.Ajeethkumar.M.D. (Path). 
             
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
Checked 
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Name   : 
Ref. No. : [H0 332B/17] 
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
         Toxicity study                
 
SPECIMEN                   :  B) Spleen. 
    
Group –                   : Dr.Aysha- M.R. 
 
GROSS APPEARANCE:  
 
                     Received a specimen of spleen measuring 2.6x0.9x0.4cms. 
 
 (PE): Two bits – One block. 
 
MICROSCOPIC APPEARANCE:  
 
                     Section studied from spleen shows normal white pulp and red pulp. Red pulp shows pigment 
laden macrophages and congested vessels. White pulp shows lymphocytic infiltrates forming germinal 
centre. The pencillar artery shows normal morphology. Megakaryocytes are also seen. There is no 
evidence of toxic changes. 
 
 
 
    
                                                                                      
                                                                                Dr.C.R.Ajeeth kumar. M.D. (Path), 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path), Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
Checked 
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Name   :   
Ref. No. : [Ho 332C/18]                      
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : Kidney. 
 
Group –                        : Dr.Aysha- M.R. 
 
GROSS APPEARANCE    : 
 
Received specimen of kidneys each measuring 1.2x0.6x0.5cms and 1.2x0.5x0.5cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from kidney shows both cortex and medulla. Glomeruli and tubules show no 
significant pathology. Interstitium shows mild lymphocytic infiltrates. Blood vessels show congestion. 
There is no evidence of toxic changes. 
 
 
                           Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
Checked 
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Name   :   
Ref. No. : [Ho 332D/18]                      
 
Rec.On :  25/03/2018 
Rep.On :  18/04/2018 
 
HISTOPATHOLOGY 
                                 Toxicity study 
SPECIMEN                          : Testis. 
 
Group –                        : Dr.Aysha- M.R.   
 
GROSS APPEARANCE    : 
 
Received specimen of both testis measuring each 1.0x0.7x0.5cms and 1.0x0.6x0.5cms. 
 
PE : Two bits – One block.                                                            
 
MICROSCOPIC APPEARANCE:  
 
                     Section from testes with focal seminiferous tubules shows maturation arrest with lacking of 
spermatogenesis. No evidence of granuloma/ malignancy 
 
Dr. C.R.Ajeeth kumar.M.D. (Path). 
 
 
 
 
Consultant pathologists: 
Dr.S.Kalyani.M.D. (Path),   Dr. C.R.Ajeeth kumar.M.D. (Path), 
 
 
 
 
  
176 
 
 
 
ANNEXURE –V 
ASSESSMENT FORMS 
 
FORM I  : Screening and Selection Proforma 
FORM I A  : History Proforma on Enrollment 
FORM II  : Clinical assessment on enrollment 
FORM II A  : Clinical assessment during and after trial 
FORM III  : Laboratory Investigation on enrollment and conclusion of trial 
FORM IV  : Consent Form 
FORM IV B  : Withdrawal form 
FORM IV C  : Patient information sheet 
FORM IV D  : Dietary Advice form 
FORM IV E  : Adverse Reaction form 
FORM IV F  : Discharge proforma 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
 
A PHASE II CLINICAL STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA FORMULATION “MATHIYOOSHNA RASAYANAM” INTERNAL &                              
“NYMPATHY THYLAM” EXTERNAL IN “UTHIRA VATHA SURONITHAM”                              
(RHEUMATOID ARTHRITIS). 
 
FORM I – SCREENING & SELECTION PROFORMA 
1. OP / IP NO    : ___________ 
2. NAME   : ___________ 
3. RELIGION    : H / C / M / O 
4. AGE / GENDER  : ___________ 
5. OCCUPATION  : ___________ 
6. INCOME   : ___________ 
7. CONTACT NO  : ___________ 
8. INCLUSION CRITERIA :  
INCLUSION CRITERIA : 
• Age : 18-60 years 
• Sex : Both Male and Female 
• Symmetrical joint involvement 
• Arthritis of 3 or more joints 
• Rheumatoid factor positive or negative 
• Morning stiffness 
• Swelling especially in the inter Phalangeal joint. 
• Patients who are willing for admission and stay in ipd for 48 days or willing to attend 
OPD 
• Patient who are willing to undergo radiological investigation and give blood and urine 
samples for laboratory investigation. 
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• Patient willing to sign the informed consent stating than he/she will consciously stick to 
the treatment during 48 days but can opt out of the trial of his/her own conscious 
discretion. 
 
EXCLUSION CRITERIA : 
• Hypertension and other cardial ailments. 
• Diabetes  mellitus 
• Narcotics 
• Alcoholics and smokers 
• Pregnancy and lactation 
• History of trauma 
• Neurological disorder 
• Tuberculosis 
• Any other serious illness 
• Psoriatic arthritis 
• Gouty arthritis 
 
ADMITTED TO TRIAL: 
    YES  NO 
If Yes Serial Number : 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
A PILOT STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
FORMULATION “MATHIYOOSHNA RASAYANAM” INTERNAL & “NYMPATHY 
THYLAM” EXTERNAL IN “UTHIRA VATHA SURONITHAM” (RHEUMATOID 
ARTHRITIS). 
 
FORM I A – HISTORY PROFORMA 
1. SL.NO     : ___________ 
2. OP / IP NO     : ___________ 
3. NAME    : ___________ 
4. RELIGION     : H / C / M / O 
5. AGE / GENDER   : ___________ 
6. OCCUPATION   : ___________ 
7. INCOME    : ___________ 
8. CONTACT NUMBER  : ___________ 
9. MARITAL STATUS   : Married / Unmarried 
10. COMPLAINTS & DURATION : 
 
11. PERSONAL HISTORY: 
PERSONAL HABITS YES NO IF YES SPECIFY DURATION 
Smoking    
Tobacco Chewing    
Alcohol    
Narcotic Drug Addiction    
12. DRUG HISTORY: 
 Whether the Patient has underwent any allopathic Treatment  
1. Yes    2. No. 
 If yes specify the nature of the drug and treatment duration _____ 
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13. FAMILY HISTORY: 
 Whether this problem runs in family? 
1. Yes  2. No 
If yes, mention the relationship of affected person(s) 
1. ___________ 
2. ___________ 
14. DIETARY HABITS : 
 
   1. Pure vegetarian 
   2. Non-Vegetarian 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
 
A PILOT STUDY TO EVALUATE THE THERAPEUTIC EFFICACY OF SIDDHA 
FORMULATION “MATHIYOOSHNA RASAYANAM” INTERNAL & “NYMPATHY 
THYLAM” EXTERNAL IN “UTHIRA VATHA SURONITHAM” (RHEUMATOID 
ARTHRITIS). 
 
FORM II AND II-A  CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS 
 
1. OP / IP No     :  
2. BED No    :  
3. SL. NO    : 
4. NAME    : 
5. AGE     : 
6. GENDER    : 
7. OCCUPATION   : 
8. SOCIAL STATUS   : 
9. DATE OF ADMISSION  : 
10. DATE OF DISCHARGE  : 
11. POSTAL ADDRESS   : 
12. COMPLAINTS & DURATION : 
13. HISTORY OF PRESENT ILLNESS : 
14. PAST HISTORY   : 
15. FAMILY HISTORY   : 
 
16. MENSTRUAL HISTORY (If Applicable): 
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17. HABITS: 
1. Smoker    : 
2. Alcoholic    : 
3. Tobbaco chewer   :  
4. Betel nut chewer   : 
5. Non-Vegetarian   : 
6. Drug addiction   : 
18. GENERAL EXAMINATION: 
1. Body weight (Kg)   : 
2. Height (Cm)   :  
3. Body Temperature (F)  :  
4. Blood Pressure (mmHg)  : 
5. Pulse Rate (/min)   : 
6. Heart Rate (/min)   : 
7. Respiratory Rate (/min)  :  
8. Pallor    :  
9. Jaundice    : 
10. Clubbing    : 
11. Cyanosis    : 
12. Pedal Oedema   :  
13. Lymphadenopathy  :  
14. Jugular venous pulsation  : 
19. CLINICAL EXAMINATION: 
I. INSPECTION: 
1. Attitude    : 
2. Muscular spasm   : 
3. Muscle wasting – Proximal :  
4. Muscle wasting – Distal  : 
5. Minor Joint Swelling  : 
6. Major Joint Swelling  : 
7. Nodules    : 
8. Deformity    : 
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II. PALPATION: 
1. Swelling    : 
2. Tenderness   :  
3. Joint Stiffness   : 
4. Muscle wasting   : 
5. Local heat    : 
6. Local Lymphadenopathy  : 
7. Pitting Oedema   : 
8. Nodules    : 
III. MOVEMENTS: 
Restriction of joint movements 
1. Neck              :            Full            Partial    
2. Shoulder  : 
3. Elbow joint  : 
4. Knee joint  : 
5. Ankle joint  : 
6. Hip joint  : 
7. Minor joints  : 
IV. PAIN: 
1. Onset :   Sudden : Gradual : 
2. Early morning stiffness :  Present  : absent  : 
3. Nature of pain:  Mild  : Moderate :     Severe: 
4. Aggravating factor –Movements  : 
5. Relieving factor – rest   : 
6. Stiffness     : 
7. Tenderness    :  
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V. CLINICAL ASSESSMENT :  
1. Arthritis of three or more Joints  : 
2. Arthritis of hand joints   : 
3. Morning Stiffness    : 
4. Fever     : 
5. Anorexia     : 
6. Anaemia     : 
7. Spindle appearance of fingers  : 
8. Restricted movements   : 
9. Rheumatoid Nodules   : 
10. Numbness     : 
20. EXAMINATION OF OTHER SYSTEMS:  
1. CVS    : 
2. RS     : 
3. CNS    : 
4. ABDOMEN   : 
5. GENITO – URINARY  : 
 
EXAMINATION – SIDDHA ASPECTS 
1. NILAM: 
 1. Kurinji 2. Mullai 3. Marutham 4. Neithal 5. Paalai 
2. KAALAM: 
 1. Kaar Kaalam 2. Koothir Kaalam 3. Munpani Kaalam 
 4. Pinpani Kaalam 5. Elavenir Kaalam 6. Mudhuvenir Kaalam 
3. YAAKKAI:  
 1. Vatham   2. Pitham   3. Kabam 
 4. Vathapitham  5. Pithavatham  6. Kabavatham 
 7. Vathakabam  8. Pithakabam   9. Kabapitham 
4. GUNAM:  
 1. Sathuvam   2. Rasatham   3. Thamasam 
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5. KANMENDHIRIUM / KANMAVIDAYAM 
 1. Kai   : 
 2. Kaal   : 
 3. Vaai   : 
 4. Eruvaai  : 
5. Karuvaai  : 
6. UYIR THATHUKKAL: 
I. VATHAM: 
1. Piraanan  : 
2. Abaanan  : 
3. Viyaanan  : 
4. Uthaanan  : 
5. Samaanan  : 
6. Naagan  : 
7. Koorman  : 
8. Kirukaran  : 
9. Devathathan : 
10. Dhananjeyan : 
II. PITHAM : 
1. Analagam  : 
2. Ranjagam  : 
3. Saathagam  : 
4. Aalosagam : 
5. Praasagam  : 
III. KABAM: 
1. Avalambagam : 
2. Kilethagam : 
3. Pothagam  : 
4. Tharpagam : 
5. Santhigam  : 
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7. UDAL THAATHUKKAL: 
1. Saaram  : 
2. Senneer  : 
3. Oon  : 
4. Kozhuppu  : 
5. Enbu  : 
6. Moolai  : 
7. Sukkilam / Suronitham: 
8. ENVAGAI THERVUGAL: 
1. Naadi  : 
2. Sparisam  : 
3. Naa  :  
4. Niram  : 
5. Mozhi  : 
6. Vizhi  : 
7. Malam :  
i. Niram:  ii. Thanmai: iii. Irugal: iv.Ilagal: 
8. Moothiram : 
 
I. NEERKURI: 
 a. Niram : 
 b. Manam : 
 c. Edai  : 
 d. Nurai : 
 e. Enjal : 
II. NEIKURI: 
 Vatha Neer  :  Pittha Neer   :    Kaba Neer : 
   
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
 
A PHASE II CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA FORMULATION “MATHIYOOSHNA RASAYANAM” INTERNAL & 
“NYMPATHY THYLAM” EXTERNAL IN “UTHIRA VATHA SURONITHAM” 
(RHEUMATOID ARTHRITIS). 
 
FORM III – LABORATORY INVESTIGATION 
1. BLOOD: 
1. TC   : (Cells / Cumm) 
2. DC (%)  : N : L : M : E : 
3. ESR (mm)  : ½ hr : 1 hr : 
4. Hb   : 
5. Blood Sugar : a) Fasting : b) Post Prandial : 
6. Renal function tests: 
Blood Urea:  Serum creatinine: 
7. Lipid profile : 
HDL:   LDL:  VLDL: 
Total Cholesterol : TGL : 
8. Liver Function tests: 
Serum Bilirubin :  Total  Direct  Indirect 
 
SPECIFIC INVESTIGATIONS 
 RA factor   : 
 ASO titre   : 
 C-Reactive Protein  : 
 SGOT    : 
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SGPT    : 
 Serum albumin & globulin : 
 Total protein   : 
II. URINE: 
1. Albumin   : 
2. Sugar   : 
3. Epithelial cells  : 
4. Pus cells   : 
5. Red blood cells  : 
6. Casts / Crystals  : 
III. MOTION: 
1. Ova   : 
2. Cyst   : 
3. Occult blood  : 
4. Pus cells   : 
IV. X-RAY FINDINGS 
 
 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
A PHASE II CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA FORMULATION “MATHIYOOSHNA RASAYANAM” INTERNAL & 
“NYMPATHY THYLAM” EXTERNAL IN “UTHIRA VATHA SURONITHAM” 
(RHEUMATOID ARTHRITIS). 
    
FORM IV A – CONSENT FORM 
 
CERTIFICATE BY INVESTIGATOR 
 I certify that I have disclosed all the details about the study in the terms readily 
understood by the patient. 
Signature ______________ 
Date      ______________ 
Name    ______________ 
CONSENT BY PATIENT 
 I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
 I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so. 
 I exercising my free power of choice, hereby give my consent to be included as a subject 
in the clinical trial of “MATHIYOOSHNA RASAYANAM” (Internal drug) and “NYMPATHY 
THYLAM” (External drug) for the treatment of “UTHIRA VATHA SURONITHAM” 
(RHEUMATOID ARTHRITIS)”. 
 
Place :        Signature  :  
Date :         Name  : 
        Witness Signature: 
        Name  :  
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murpdH rpj;j kUj;Jtf; fy;Yhhp ; ; ; ;; ; ; ;; ; ; ; kw;Wk; kUj;Jtkid; ; ;; ; ;; ; ;  
ghisaq;Nfhl;il; ;; ;; ;  
gl;lNkw;gbg;G rpwg;G kUj;Jtj;Jiw; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;  
 
‘kjpA+\; z urhadk;; ;; ;; ;” kw;Wk; ‘; ;; ;; ; epk;ghjp ijyk;; ;; ;; ;” ,tw;wpd; ghpfhpg;Gj; jpwidf; ; ; ; ; ;; ; ; ; ;; ; ; ; ;
fz;lwpAk; kUj;Jt Ma;T xg;Gjy; gbtk; Ma;thsuhy; rhd;wspf;fg;gl;lJ.; ; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ; ;; ; ; ; ; ; ; ; ; ; ; ; ;  
 
ehd; ,e;j Ma;itf; Fwpj;j midj;J tpguq;fisAk; Nehahspf;F GhpAk; 
tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd;. 
 
Njjp  :        ifnahg;gk;: 
,lk; :         ngaH: 
Nehahspapd; xg;Gjy;; ; ;; ; ;; ; ; 
 vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk; kUe;jpd; jd;ik kw;Wk; 
kUj;Jt topKiwiag; gw;wpAk; njhlHe;J vdJ cly; ,af;fj;ij fz;fhzpf;fTk;> 
mjidg; ghJfhf;fTk; gad;gLk; kUj;Jt Ma;Tf;$l ghpNrhjidfs; gw;wpAk; jpUg;jp 
mspf;Fk; tifapy; Ma;T kUj;Jtuhy; tpsf;fpf; $wg;gl;lJ. 
 ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; vg;nghOJ 
Ntz;LkhdhYk; ,e;j Ma;tpypUe;J vd;id tpLtpj;Jf; nfhs;Sk; chpikia 
njhpe;jpUf;fpd;Nwd;. 
 ehd; vd;Dila Rje;jpukhfj; NjHT nra;Ak; chpikiaf; nfhz;L cjpu thj 
RNuhzpjk;;;; vd;Dk; Neha;f;fhd kjpA+\;z urhadk;;; ; kw;Wk; epk;ghjp;;;  ijyk; 
Mfpatw;wpd; ghpfhpg;Gj; jpwidf; fz;lwpAk; kUj;Jt Ma;tpw;F vd;id cl;gLj;j 
xg;Gjy; mspf;fpNwd;. 
 
Njjp :       ifnahg;gk;: 
,lk; :       ngaH :  
     
       rhl;rpf;fhuH ifnahg;gk;: 
       ngaH : 
  
191 
 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III SIRAPPU MARUTHUVAM 
 A PHASE II CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA FORMULATION “MATHIYOOSHNA RASAYANAM” INTERNAL & 
“NYMPATHY THYLAM” EXTERNAL IN “UTHIRA VATHA SURONITHAM”                                
(RHEUMATOID ARTHRITIS). 
FORM IV B – WITHDRAWAL FORM 
1. SL.NO    : ___________ 
2. OP / IP NO    : ___________ 
3. NAME   : ___________ 
4. RELIGION    : H / C / M / O 
5. AGE / GENDER  : ___________ 
6. OCCUPATION  : ___________ 
7. SOCIAL STATUS  : ___________ 
8. CONTACT NO  : ___________ 
9. DATE OF TRIAL COMMENCEMENT  : ___________ 
10. DATE OF WITHDRAWAL FROM TRIAL : ___________ 
11. REASONS FOR WITHDRAWAL   : ___________ 
 Long absence at reporting   :  Yes / No 
 Irregular treatment    :  Yes / No 
 Shift of locality    :  Yes / No 
 Increase in severity of symptoms  :  Yes / No 
 Development of severe adverse drug reactions:  Yes / No 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL 
POST GRADUATE DEPARTMENT 
PALAYAMKOTTAI, TIRUNELVELI – 627002 
BRANCH – III (SIRAPPU MARUTHUVAM) 
 
A PHASE II CLINICAL TRIAL TO EVALUATE THE THERAPEUTIC EFFICACY OF 
SIDDHA FORMULATION “MATHIYOOSHNA RASAYANAM” INTERNAL & 
“NYMPATHY THYLAM” EXTERNAL IN “UTHIRA VATHA SURONITHAM”                           
(RHEUMATOID ARTHRITIS). 
FORM IV C – DRUG COMPILANCE FORM 
Name of the Drug : JATHIPALATHI  CHOORANAM 
Drugs issued  : (Mg / Gram) 
Drugs returned : (Mg / Gram) 
 
S. NO DATE DRUG TAKEN TIME 
MORNING / TIME EVENING / TIME 
Day 1    
Day 2    
Day 3    
Day 4     
Day 5    
Day 6    
Day 7    
Day 13    
Day 14    
Day 15    
Day 16    
Day 17    
Day 18    
Day 19    
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Day 25    
Day 26    
Day 27    
Day 28    
Day 29    
Day 30    
Day 31    
Day 37    
Day 38    
Day 39    
Day 40    
Day 41    
Day 42    
Day 43    
Day 44    
Day 45    
Day 46    
Day 47    
Day 48     
 
 
Date  :  
Station: 
Signature of the Investigator : 
Signature of the Lecturer :    Signature of the HOD  
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INGREDIENTS OF MATHIYOOSHNA RASAYANAM 
 Sathipathiri 
Omam Thippili 
Lavangapattai Parangipattai 
Valuzhuvai 
   
Thippilimoolam Annachipoo 
Elam Nellivattral 
Vaividangam Kadukkai 
  
Nannari Kaatu Milagu 
Arathai Seeragam 
Kurosani omam Milagu 
  
Vetpalai arisi Kostam 
Chukku Athimathuram 
Cheviyam Kanduparangi 
  
Koraikilangu Santhanam 
Sadamanjil Kirambu 
Thandrikai 
   
Sathurakalli Erukku 
Yetti Maa 
Veppaennai Nallennai 
INGREDIENTS OF MATHIYOOSHNA RASAYANAM 
  
MATHIYOOSHNA RASAYANAM (Internal) 
 
 
 
 
 
 
 
 
 
 
 
NYMPATHY THYLAM (External) 
  

 
